



08/27/97

**PATENT APPLICATION TRANSMITTAL LETTER**

**PATENT GROUP**  
**FOLEY, HOAG & ELIOT LLP**  
**ONE POST OFFICE SQUARE**  
**BOSTON, MA 02109-2170**

Atty Docket No. **APV-007.01**

4/\$

To the Assistant Commissioner for Patents:

Transmitted herewith for filing under 35 U.S.C. 111 and 37 CFR 1.53 is the patent application of:

Stuart L. SCHREIBER; Peter J. BELSHAW; and Gerald CRABTREE

entitled Gene Therapy by Cell Specific Targeting

Enclosed are:

- (X) 80 pages of written description, claims and abstract.
- (X) 4 sheets of drawings.
- ( ) an assignment of the invention to \_\_\_\_\_.
- ( ) executed declaration of the inventors.
- ( ) a certified copy of a \_\_\_\_\_ application.
- ( ) a verified statement to establish small entity status under 37 CFR 1.9 and 1.27.
- (X) other: unexecuted Declaration, Petition and Power of Attorney.

**CLAIMS AS FILED**

	# FILED	# EXTRA	Rate	FEE	Rate (Small Entity)	FEE
BASIC FEE			\$770		\$385	
TOTAL CLAIMS	-20 =		x \$22		x \$11	
INDEPENDENT CLAIMS	-3 =	*	x \$80		x \$40	
MULTIPLE DEPENDENT CLAIMS			\$260		\$130	
* NUMBER EXTRA MUST BE ZERO OR LARGER			TOTAL			\$

- ( ) A check in the amount of \$ \_\_\_\_\_ to cover the filing fee is enclosed.
- ( ) The Commissioner is hereby authorized to charge and credit Deposit Account No. 06-1448 as described below. A duplicate copy of this sheet is enclosed.
  - ( ) Charge the amount of \$ \_\_\_\_\_ as filing fee.
  - ( ) Credit any overpayment.
  - ( ) Charge any additional filing fees required under 37 CFR 1.16 and 1.17.

**Certificate of Express Mail**

**Express Mail Label: EM 528 937 135 US**

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, postage prepaid, "Post Office to Addressee", in an envelope addressed to the Assistant Commissioner for Patents, Box Patent Application, Washington, D.C. 20231 on this date of August 27, 1997.

August 27, 1997

Date of Deposit

Matthew P. Vincent  
 Matthew P. Vincent

Matthew P. Vincent  
 Matthew P. Vincent, Ph.D.  
 Reg. No. 36,709  
 Attorney for Applicants

**Declaration, Petition and Power of Attorney For Patent Application**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled:

***GENE THERAPY BY CELL SPECIFIC TARGETING***

the specification of which is filed herewith in the U.S. Patent and Trademark Office.

I do not know and do not believe that the subject matter of this application was ever known or used in the United States before my invention thereof or patented or described in any printed publication in any country before my invention thereof or more than one year prior to the date of this application, and that said subject matter has not been patented or made the subject of an issued inventor's certificate in any country foreign to the United States on an application filed by me or my legal representatives or assigns more than twelve months prior to the date of this application; that I acknowledge my duty to disclose information of which I am aware which is material to the examination of this application, that no application for patent or inventor's certificate on the subject matter of this application has been filed by me or my representatives or assigns in any country foreign to the United States, except those identified below, and that I have reviewed and understand the contents of the specification, including the claims as amended by any amendment referred to herein.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

### PRIORITY CLAIM

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

Check one: ☒ no such applications have been filed.  
☐ such applications have been filed as follows

#### EARLIEST FOREIGN APPLICATION(S), IF ANY FILED WITHIN 12 MONTHS (6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

Country	Application Number	Date of Filing (month,day,year)	Priority Claimed Under 35 USC 119
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No

#### (6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION


CLAIM FOR BENEFIT OF EARLIER U.S./PCT APPLICATION(S)

I hereby claim the benefit under Title 35, United States Code, §120 or §119(e) of any United States application(s) and/or provisional application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application. As to subject matter of this application which is common to my earlier United States application, if any, described below, I do not believe that the same was ever known or used in the United States before my invention thereof or patented or described in any printed publication in any country before my invention thereof or more than one year prior to said earlier application, or in public use or on sale in the United States more than one year prior to said earlier application, that the said common subject matter has not been patented or made the subject of an inventor's certificate issued before the date of said earlier application in any country foreign to the United States on an application, filed by me or my legal representatives or assigns more than twelve months prior to said application and that no application for patent or inventor's certificate on said subject matter has been filed by me or my representatives or assigns in any country foreign to the United States except those identified herein.

<u>60/024,484</u> (Application Serial No.)	<u>27 August 1996</u> (Filing Date)	<u>PENDING</u> (Status) (patented, pending, aband.)
<u>                    </u> (Application Serial No.)	<u>                    </u> (Filing Date)	<u>                    </u> (Status) (patented, pending, aband.)
<u>                    </u> (Application Serial No.)	<u>                    </u> (Filing Date)	<u>                    </u> (Status) (patented, pending, aband.)



**POWER OF ATTORNEY:** As a named inventor, I hereby appoint the following attorneys and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Donald W. Muirhead	Reg. No. 33,978	Charles H. Cella	Reg. No. 38,099
Beth E. Arnold	Reg. No. 35,430	John C. Gorecki	Reg. No. 38,741
Matthew P. Vincent	Reg. No. 36,709	Edward J. Kelly	Reg. No. 38,936
		Sayoko Blodgett-Ford	Reg. No. 40,516

Send Correspondence to: Patent Group  
Foley, Hoag & Eliot LLP  
One Post Office Square  
Boston, MA 02109

Direct Telephone Calls to: Matthew P. Vincent, Ph.D. (617) 832-1000

Wherefore I petition that letters patent be granted to me for the invention or discovery described and claimed in the attached specification and claims, and hereby subscribe my name to said specification and claims and to the foregoing declaration, power of attorney, and this petition.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Stuart L. SCHREIBER	
Inventor's signature	Date
Residence 434 Marlborough Street, Boston, MA 02115	
Citizenship USA	
Post Office Address (if different)	

<b>Full name of second inventor</b> Peter J. BELSHAW	
<b>Inventor's signature</b>	<b>Date</b>
<b>Residence</b> 41 Lewis Street, No. 1, Somerville, MA 02143	
<b>Citizenship</b> USA	
<b>Post Office Address (if different)</b>	

<b>Full name of third inventor</b> Gerald CRABTREE	
<b>Inventor's signature</b>	<b>Date</b>
<b>Residence</b> 7 Durham Road, Woodside, CA 94062	
<b>Citizenship</b> USA	
<b>Post Office Address (if different)</b>	

## GENE THERAPY BY CELL SPECIFIC TARGETING

### BACKGROUND OF THE INVENTION

5 Tolerance to self major histocompatibility (MHC) antigens occurs during T cell maturation in the thymus. During ontogeny, exposure of the immune system to MHC antigens results in the loss of reactivity to those antigens, thus leaving the animal specifically tolerant into adult life. Inducing tolerance in adult animals has been accomplished by high-dose cytoreductive therapy and bone marrow transplantation.

10 Bone marrow transplantation has been found to be effective in the control of certain malignant lymphohematopoietic diseases where conventional chemotherapy has failed or would be expected to fail. There are attendant disadvantages to bone marrow transplantation. Often there is an allogeneic antitumor effect independent of the chemoradiotherapy of the preparative regimen. This adoptive immunotherapy effect is, in large measure, accompanied by graft-versus-host (GVH) disease.

15 Historically, GVH disease has been a major cause of serious morbidity and death after bone marrow transplantation. Graft-versus-host disease and its treatment are accompanied by profound immunodeficiency and immune dysregulation, which places the patient at risk for life-threatening infections and other complications. GVH disease has accounted for approximately two thirds of the deaths after allogeneic bone marrow transplantation.

20 Removing T lymphocytes in allogeneic bone marrow inocula to prevent GVH disease is associated with increased rates of engraftment failure. While these drawbacks are generally considered acceptable for the treatment of otherwise lethal malignant diseases, they would severely limit the application of MHC mismatched bone marrow transplantation as a preparative regimen for organ transplantation, in which nonspecific immunosuppressive agents, while not without major complications, are effective.

25 Since GVH disease is immunologically mediated, efforts to prevent its development have involved the use of immunosuppressive therapy. Of the many agents studied, methotrexate, glucocorticoids, and cyclosporin have been found to be useful. It is a continuing goal to develop better treatments for patients in need of a bone marrow transplant or other diseases that can be specifically cell targeted.

### SUMMARY OF THE INVENTION

One one embodiment of the present invention provides a method for selectively inhibiting proliferation of a hematopoietic cell by contacting a cell which ectopically expresses a mutated macrolide binding protein (MBP) with a macrolide which selectively induces macrolide-dependent inhibition of proliferation of cells expressing the mutated  
5 MBP compared to cells expressing a wild-type form of the MBP. In such embodiments, the mutated MBP has an altered macrolide-binding specificity relative to the wild-type form MBP, e.g., which provides the specificity for macrolide-dependent inhibition.

In another embodiment, the invention provides a method for selectively inhibiting proliferation of a hematopoietic cell comprising: (i) causing, in the cell, the ectopic  
10 expression of an MBP gene encoding a mutated macrolide binding protein (MBP) having an altered macrolide-binding specificity relative to a wild-type form of the MBP, which mutated MBP retains the ability to cause macrolide-dependent inhibition of proliferation; and (ii) contacting the cell with a macrolide which selectively binds to the altered MBP  
15 relative to the wild-type MBP and selectively induces macrolide-dependent inhibition of proliferation of cells expressing the mutated MBP relative to cells not expressing only the wild-type MBP.

In yet another embodiment, there is provided a method for selectively inhibiting proliferation of a transplanted hematopoietic cell by the steps of (i) transplanting, into an animal, hematopoietic cells which ectopically expresses a MBP gene encoding a mutated  
20 macrolide binding protein (MBP), the mutated MBP having an altered macrolide-binding specificity relative to the wild-type form MBP; and (ii) administering to the animal an amount of a macrolide sufficient to inhibit proliferation of the transplanted cells, which macrolide selectively induces macrolide-dependent inhibition of proliferation of cells expressing the mutated MBP compared to cells expressing a wild-type form of the MBP.

In still another embodiment, there is provides a method for treating graft-versus-host disease in an animal by selectively inhibiting proliferation of hematopoietic cells contained a transplanted tissue. Such methods are particularly useful in the transplantation of bone marrow or hematopoeitic stem cells. The method generally comprises transducing, e.g., before implantation, at least a sub-population of  
25 hematopoietic cells of the transplanted tissue with a gene for ectopic expression of a mutated macrolide binding protein (MBP), the mutated MBP having an altered macrolide-binding specificity relative to the wild-type form MBP. Prior to, concurrent with and/or subsequent to transplanting the tissue, the animal (or cells in culture) are treat with an amount of a macrolide sufficient to inhibit proliferation of the hematopoeitic transplanted  
30 cells, which macrolide selectively induces macrolide-dependent inhibition of proliferation of the transplanted cells expressing the mutated MBP compared to endogenous cells of the animal.

In another embodiment, the invention provides a method for promoting engraftment and hematopoietic activity of a hematopoietic stem cell, comprising: (a) transducing the stem cells to be engrafted with a nucleic acid encoding a modified macrolide binding protein specific for a modified macrolide, e.g., to produce a transformed  
5 hematopoietic stem cell; (b) introducing the transformed hematopoietic stem cell into a recipient mammal, such that the modified cellular receptor cyclophilin is expressed; and (c) administering to the animal an effective amount of the modified cyclosporin.

In the subject methods described herein, such as those enumerated above, the MBP  
10 can be a FRAP, an FK506-binding protein, a cyclophilin or a calcineurin. Preferably, the mutated MBP has a dissociation constant,  $K_d$ , for a modified macrolide which is at least one order of magnitude less than the  $K_d$  of the wild-type MBP, though mutated MBP with dissociation constants at least two, three, four, five and even ten orders of magnitude less than the  $K_d$  of the wild-type MBP are contemplated.

The the mutated MBP gene can be provided in a cell as part of an expression  
15 vector, such as a viral expression construct. In certain embodiments, the mutated MBP gene is introduced into the genome of the cell by homologous recombination or other integration techniques.

In preferred embodiments, the macrolide is an analog of rapamycin, FK506 or cyclosporin.  
20 Preferred cells for use in the subject methods are mammalian cells, more preferably primate cells, and even more preferably human cells.

Preferred animals for treatment by the subject methods are mammals, more preferably primates, and even more preferably humans.

In those instances where the engineered cells are transplanted into an animal, the  
25 cells are preferably from an autologous source.

For treatment, the subject method can be used where the treated animal is in an immunosuppressed state, e.g., as a result of radiation or chemotherapy.

Another aspect of the present invention provides expression constructs encoding a mutated macrolide binding protein (MBP) selected from the group consisting of FRAP,  
30 FKBP, cyclophilin and calcineurin, wherein the mutated MBP has an altered macrolide-binding specificity relative to the wild-type form MBP and, in the presence of a macrolide which binds the mutated MBP, induces macrolide-dependent inhibition of proliferation of a cell expressing the mutated MBP.

The present invention also provides hematopoietic cells, particularly stem cells  
35 and/or T cells, which have been engineered with such expression constructs

Yet another aspect of the present invention relates to kits for selectively inhibiting proliferation of a hematopoietic cell. The subject kits can include (i) an expression construct for ectopically expressing an MBP gene encoding a mutated macrolide binding protein (MBP) having an altered macrolide-binding specificity relative to a wild-type form of the MBP, which mutated MBP retains the ability to cause macrolide-dependent inhibition of proliferation; and (ii) a macrolide which selectively binds to the altered MBP relative to the wild-type MBP and selectively induces macrolide-dependent inhibition of proliferation of cells expressing the mutated MBP relative to cells not expressing only the wild-type MBP.

## BRIEF DESCRIPTION OF THE FIGURES

*Figure 1* is a graph showing the cellular assay for calcineurin-mediated NFAT-signalling.

*Figure 2* is a schematic depiction of the interaction between cyclosporin A (CsA) and cyclophilin (Cph) and between a modified CsA (CsA<sup>t</sup>-), containing an additional methyl group, and a modified Cph (Cph<sup>t</sup>-) containing mutations of F113G, S99T which create a "hole" to accommodate the methyl group of CsA<sup>t</sup>.

*Figure 3* represents the amount of thymidine incorporated as a percent of maximal stimulation of normal peripheral lymphocytes after 48 hours incubation with anti CD3 plus CD28 and exposure to the indicated concentrations (nM) of CsA or CsA<sup>t</sup>.

*Figure 4* represents the percent inhibition of NF-AT dependent transcription in Jurkat cells transfected with Cph<sup>t</sup>- or Cph and treated with various concentrations of CsA<sup>t</sup>.

## DETAILED DESCRIPTION OF THE INVENTION

### I. General

The invention pertains to methods for regulating a biological activity of a cell, preferably in a tissue-type or cell-type specific manner. In general, the present invention provides a method for rendering a cell selectively sensitive to a macrolide analog. The present invention is based, *inter alia*, on the observation that, by compensatory mutation, macrolide-dependent protein-protein interactions, e.g., mediated by macrolides, can be recapitulated in systems where the macrolide has been altered (as a "modified ligand") to no longer interact efficiently with a ligand-binding domain (LBD) of one of the proteins ("target protein") found in macrolide-dependent complexes. In particular, compensatory mutations can be made to the ligand binding domain of a target protein which is not

otherwise able to efficiently bind to the modified ligand, and in doing so render the modified target protein able to bind to the modified ligand.

According to the invention, a biological activity of a cell which is contingent on the presence or absence of macrolide-dependent protein complexes can be regulated by treatment with the modified ligand and concomitant expression of a target protein engineered to bind to the modified form of the ligand. Upon expression of the genetically engineered target protein, the modified ligand can selectively bind to or otherwise interact with the engineered protein so as to recruit and/or stabilize the formation of a macrolide-dependent protein complex. In preferred embodiments, the modified ligand will not similarly interact with or induce formation of similar complexes in wild-type cells. Thus, the invention provides the ability to selectively regulate biological events mediated by the protein target. Treatment of wild-type cells (i.e., cells which do not express the modified protein) with the modified ligand will have essentially no impact on the biological activity in those cells, whereas treatment of cells expressing the modified protein with the modified ligand will induce the biological activity.

To provide further guidance, the following three examples illustrate certain aspects of the invention:

(A) The macrolide rapamycin mediates the formation of complexes including an FK506-binding protein (FKBP), such as FKBP12 (SEQ ID NO. 1), and a FRAP (tor1) protein (SEQ ID No. 2). The formation of the rapamycin-dependent complexes correlates with cell-cycle arrest in G1 phase, and is understood to be part of the mechanism by which rapamycin obtains its immunosuppressive, antiproliferative and antineoplastic activities. As described below, there are a variety of rapamycin analogs which bind FRAP and/or FKBP12 with a much reduced affinity (e.g., with  $K_d$  values which are orders of magnitude greater than rapamycin). By compensatory mutation to, for example, the ligand-binding domain of FRAP, formation of rapamycin-dependent FRAP/FKBP complexes by certain of those analogs can be reestablished. Accordingly, a cell can be rendered sensitive to such rapamycin analogs by ectopic expression of a gene encoding a compensatory mutant of FRAP. Similarly, where the modification of rapamycin results in loss of efficient interaction with an FKBP, compensatory mutations to that protein can be used to provide FRAP/FKBP complexes dependent on the presence of the modified rapamycin.

(B) The macrolide FK506 can bring about certain biological events, like cell-cycle arrest, by a mechanism which apparently includes induction of FK506-

dependent complexes of an FKBP and the calcineurin protein (SEQ ID No. 3). Various analogs of FK506 can be made which disrupt the ability of the analog to interaction one or both of the FKBP and calcineurin proteins, or at least disrupt the formation of macrolide-dependent complexes. As above, compensatory mutants can be provided which restore the ability of the analog to induce such biological responses as inhibition of proliferation.

(C) Yet another example of a macrolide-dependent system which can be usurped for use in the present invention involves the cyclosporin-dependent complexes including a cyclophilin and a calcineurin. As above, pairs of cyclosporin analogs and compensatory mutants of one or both of the cyclophilin and/or calcineurin proteins can be used to render cell populations selectively sensitive to treatment with the analog.

Thus, in a generic sense, the present invention provides a method for selectively inhibiting proliferation of a cell by (i) contacting the cell with a macrolide which does not efficiently bind to a native macrolide binding protein (MBP) of the cell, under conditions wherein (ii) the cell ectopically expresses a mutated form of the MBP which causes inhibition of proliferation in a manner dependent on the presence of the macrolide. For example, the MBP can be engineered with compensatory mutations sufficient to decrease the dissociation constant ( $k_d$ ) for binding to the macrolide, e.g., relative to the native MBP, preferably by at least 1, 2, 3 or even 5 or more orders of magnitude.

In a preferred embodiment of the invention, tissue specificity for controlling the effect of treatment with the macrolide is achieved by selective transduction of a gene encoding the modified MBP, and/or by operably linking that gene to a transcriptional regulatory sequence having the desired cell-type or tissue-type specificity for expression. In other embodiments, tissue specificity is provided by tissue-specific delivery of the macrolide.

Exemplary biological activity that can be regulated according to the method of the invention can be cellular proliferation, differentiation, and/or cell death and/or regulation of gene expression, so long as the biological activity is regulated or otherwise mediated by the ligand-crosslinked protein complex. In a preferred embodiment, the biological activity is T cell activation.

Exemplary target proteins which can be engineered in the practice of the subject invention include those intracellular proteins which form protein complexes in a macrolide-dependent fashion, and include cyclophilins, calcineurins, FK506 binding proteins (FKBPs) and FRAP (Tor1), which have mutated ligand binding domains for interacting with such macrolides as altered forms of cyclosporins, FK506 or rapamycin,



e.g., which effect the formation of cyclophilin-calcineurin, FKBP-calcineurin and FKBP-FRAP complexes.

## II. Definitions

5 For convenience, the meaning of certain terms and phrases employed in the specification, examples, and appended claims are provided below.

As used herein, the term "cellular composition" refers to a preparation of cells, which preparation may include, in addition to the cells, non-cellular components such as cell culture media, e.g. proteins, amino acids, nucleic acids, nucleotides, co-enzyme, anti-oxidants, metals and the like. Furthermore, the cellular composition can have components which do not affect the growth or viability of the cellular component, but which are used to provide the cells in a particular format, e.g., as polymeric matrix for encapsulation or a pharmaceutical preparation.

15 The term "lineage committed cell" refers to a stem cell that is no longer pluripotent but has become restricted to a specific lineage, e.g., a myeloid, lymphoid, erythroid lineage. the lineage committed cell subsequently differentiates to specialized cell types, e.g., erythrocytes, T and B lymphocytes.

20 The term "stem cell" refers to an undifferentiated cell which is capable of self-renewal, i.e., proliferation to give rise to more stem cells, and may give rise to lineage committed progenitors which are capable of differentiation and expansion into a specific lineage. In a preferred embodiment, the term "stem cell" refers to a generalized mother cell whose descendants (progeny) specialize, often in different directions, by differentiation, e.g., by acquiring completely individual characters, as occurs in progressive diversification of embryonic cells and tissues. As used herein, the term "stem cells" refers generally to both embryonic and hematopoietic stem cells from mammalian origin, e.g., human.

30 A stem cell composition is characterized by being able to be maintained in culture for extended periods of time, being capable of selection and transfer to secondary and higher order culture, and being capable of differentiating into various lymphoid or myeloid lineages, particularly B and T lymphocytes, monocytes, macrophages, neutrophils, erythrocytes and the like.

As used herein, the term "embryonic stem cell" means a pluripotent, blastocyst-derived cell that retains the developmental potential to differentiate into all somatic and

germ cell lineages (for review, *see* Robertson, E. J. (1986) *Trends in Genetics* 2: 9-13). This cell type is also referred to as an "ES cell".

As used herein, the term "hematopoietic stem cell" (HSC) means a population of cells capable of both self-renewal and differentiation into all defined hematopoietic lineages, i.e., myeloid, lymphoid or erythroid lineages; and limiting number of cells are capable of repopulating the hematopoietic system of a recipient who has undergone myeloablative treatment. HSCs can ultimately differentiate into "hematopoietic cells", including without limitation, common lymphoid progenitor cells, T cells (e.g., helper, cytotoxic, and suppressor cells), B cells, plasma cells, natural killer cells, common myeloid progenitor cells, monocytes, macrophages, mast cells, leukocytes, basophils, neutrophils, eosinophils, megakaryocytes, platelets, and erythroids. HSCs are identifiable by the presence of cell surface antigens of primitive phenotypes, e.g., CD34<sup>+</sup>Thy-1<sup>+</sup>Lin<sup>-</sup>, and negative staining for lineage-specific antigens.

As used herein, the term "gene" or "recombinant gene" refers to a nucleic acid molecule comprising an open reading frame and including at least one exon and (optionally) an intron sequence. The term "intron" refers to a DNA sequence present in a given gene which is not translated into protein and is generally found between exons.

As used herein, the term "nucleic acid" refers to polynucleotides such as deoxyribonucleic acid (DNA), and, where appropriate, ribonucleic acid (RNA). The term should also be understood to include, as equivalents, derivatives, variants and analogs of either RNA or DNA made from nucleotide analogs, and, as applicable to the embodiment being described, single (sense or antisense) and double-stranded polynucleotides.

The term "operably linked" when referring to a transcriptional regulatory sequence and a coding sequence is intended to mean that the regulatory sequence is associated with the coding sequence in such a manner as to facilitate transcription of the coding sequence in an activator-dependent fashion.

As used herein, "heterologous DNA" or "heterologous nucleic acid" include DNA that does not occur naturally as part of the genome in which it is present or which is found in a location or locations in the genome that differs from that in which it occurs in nature. Heterologous DNA is not endogenous to the cell into which it is introduced, but has been obtained from another cell. Generally, although not necessarily, such DNA encodes RNA and proteins that are not normally produced by the cell in which it is expressed. Heterologous DNA may also be referred to as foreign DNA. Any DNA that one of skill in the art would recognize or consider as heterologous or foreign to the cell in which is expressed is herein encompassed by heterologous DNA.

"Transcriptional regulatory sequence", also termed herein "regulatory element", "regulatory sequence" or "regulatory element", are generic terms used throughout the specification to refer to DNA sequences, such as initiation signals, enhancers, and promoters, which induce or control transcription of protein coding sequences with which they are operably linked. The term "enhancer", also referred to herein as "enhancer element", is intended to include regulatory elements capable of increasing, stimulating, or enhancing transcription from a basic promoter. The term "silencer", also referred to herein as "silencer element" is intended to include regulatory elements capable of decreasing, inhibiting, or repressing transcription from a basic promoter. Regulatory elements can also be present in genes other than in 5' flanking sequences. Thus, it is possible that regulatory elements of a gene are located in introns, exons, coding regions, and 3' flanking sequences.

The terms "basic promoter" or "minimal promoter", as used herein, are intended to refer to the minimal transcriptional regulatory sequence that is capable of initiating transcription of a selected DNA sequence to which it is operably linked. This term is intended to represent a promoter element providing basal transcription. A basic promoter frequently consists of a TATA box or TATA-like box and is bound by an RNA polymerase and by numerous transcription factors, such as GTFs and TATA box Binding Proteins (TBPs).

The term "tissue specific regulatory element" refers to promoters and other regulatory elements which effect expression of an operably linked DNA sequence preferentially in specific cell-types or tissue-types. Gene expression occurs preferentially in a specific cell if expression in this cell type is significantly higher than expression in other cell types.

The terms "promoter" and "regulatory element" also encompass so-called "leaky" promoters and "regulatory elements", which regulate expression of a selected DNA primarily in one tissue, but cause expression in other tissues as well. The terms "promoter" and "regulatory element" also encompass non-tissue specific promoters and regulatory elements, i.e., promoters and regulatory elements which are active in most cell types. Furthermore, a promoter or regulatory element can be a constitutive promoter or regulatory element, i.e., a promoter or regulatory element which constitutively regulates transcription, as opposed to a promoter or regulatory element which is inducible, i.e., a promoter or regulatory element which is active primarily in response to a stimulus. A stimulus can be, e.g., a molecule, such as a hormone, a cytokine, a heavy metal, phorbol esters, cyclic AMP (cAMP), or retinoic acid.

As used herein, the terms "transfection" and "transduction" mean the introduction of a nucleic acid, e.g., an expression vector, into a recipient cell by nucleic acid-mediated gene transfer. The term "transduction" is generally used herein when the transfection with a nucleic acid is by viral delivery of the nucleic acid. "Transformation", as used  
5 herein, refers to a process in which a cell's genotype is changed as a result of the cellular uptake of exogenous DNA or RNA, and, for example, the transformed cell expresses a recombinant form of a polypeptide or, in the case of anti-sense expression from the transferred gene, the expression of a naturally-occurring form of the recombinant protein is disrupted.

10 As used herein, the term "transgene" refers to a nucleic acid sequence which has been introduced into a cell. Daughter cells deriving from a cell in which a transgene has been introduced are also said to contain the transgene (unless it has been deleted). A transgene can encode, e.g., a polypeptide, partly or entirely heterologous, i.e., foreign, to the transgenic animal or cell into which it is introduced, or, is homologous to an  
15 endogenous gene of the transgenic animal or cell into which it is introduced, but which is designed to be inserted, or is inserted, into the animal's genome in such a way as to alter the genome of the cell into which it is inserted (e.g., it is inserted at a location which differs from that of the natural gene). Alternatively, a transgene can also be present in an episome. A transgene can include one or more transcriptional regulatory sequences and  
20 any other nucleic acid, (e.g. intron), that may be necessary for optimal expression of a selected coding sequence.

By "gene product" it is meant a molecule that is produced as a result of transcription of a gene. Gene products include RNA molecules transcribed from a gene, as well as proteins translated from such transcripts.

25 The terms "protein", "polypeptide" and "peptide" are used interchangeably herein when referring to a gene product, e.g., as may be encoded by a coding sequence.

The terms "mutated" and "non-native" are used interchangeably herein and refer to genes and genes products which are not native (do not naturally occur) in the particular cell in which they are present, e.g., the term refers to a state relative to the cell's genotype.  
30 Thus, mutant (or non-native) MBPs are proteins which have altered sequences relative to the host cell, and which may have been generated by, for example, mutagenesis, or which could be MBPs found naturally in other cells.

The term "interact" as used herein is meant to include detectable interactions between molecules, such as can be detected using, for example, a yeast two hybrid assay  
35 or by immunoprecipitation. The term interact is also meant to include "binding"

interactions between molecules. Interactions may be, for example, protein-protein, protein-nucleic acid, protein-small molecule or small molecule-nucleic acid in nature.

The term "ligand binding domain" (or "LBD") refers to any protein, though generally a fragment thereof or derivative thereof, which binds a preselected ligand.

- 5           The term "wild-type ligand binding domain" refers to a ligand binding domain as it is naturally occurring in a normal cell.

10           The term "modified ligand binding domain" refers to any ligand binding domain which has been modified, or altered to decrease binding of the naturally occurring ligand to the modified LBD. The modified LBD is preferably capable of interacting specifically with a modified ligand, which is not capable of interacting significantly with the naturally occurring ligand binding domain. A modification of a ligand may consist of the addition, deletion or substitution of at least one atom or chemical moiety of the ligand. If the ligand is a proteinous compound, the modification can be an addition, deletion, or substitution of one or more amino acids or the modification of at least one amino acid.

- 15           The term "ligand" refers to any molecule which is capable of interacting with a receptor. A ligand can be naturally occurring, or the ligand can be partially or wholly synthetic. Preferred ligands include macrolides, e.g, cyclosporin A, FK506, and rapamycin and analogs thereof.

- 20           The term "modified ligand" refers to a ligand which has been modified such that it does not significantly interact with the naturally occurring receptor of the ligand in its non modified form.

25           As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of preferred vector is an episome, i.e., a nucleic acid capable of extra-chromosomal replication. Preferred vectors are those capable of autonomous replication and/or expression of nucleic acids to which they are linked. Vectors capable of directing the expression of genes to which they are operatively linked are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of "plasmids" which refer generally to circular double stranded DNA loops which, in their vector form are not bound to the chromosome. In the present specification, "plasmid" and "vector" are used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors which serve equivalent functions and which become known in the art subsequently hereto.

“Derived from” as that phrase is used herein indicates a peptide or nucleotide sequence selected from within a given sequence. A peptide or nucleotide sequence derived from a named sequence may contain a small number of modifications relative to the parent sequence, in most cases representing deletion, replacement or insertion of less than about 15%, preferably less than about 10%, and in many cases less than about 5%, of amino acid residues or base pairs present in the parent sequence. In the case of DNAs, one DNA molecule is also considered to be derived from another if the two are capable of selectively hybridizing to one another.

As used herein, the term "animal" refers to mammals, preferably mammals such as humans. Likewise, a "patient" or "subject" to be treated by the method of the invention can mean either a human or non-human animal.

A "disease of a hematopoietic cell" refers to any condition characterized by impairment of any normal function of a hematopoietic cell. The diseases of hematopoietic cells that can be treated utilizing the cells of the present invention include, without limitation, genetic disorders (e.g., Adenosine Deaminase Deficiency, Fanconis' Anemia, and hemoglobinopathies such as Sick Cell Anemia, Thalassemias, and Hemoglobin C Disease), as well as diseases acquired by infectious or non-infectious means (e.g., Acquired Immune Deficiency Syndrome and leukemias).

A “discordant species combination”, as used herein, refers to two species in which hyperacute rejection occurs when vascular organs are grafted. Generally, discordant species are from different orders, while non-discordant species are from the same order.

### III. Exemplary Modified Macrolides and Macrolide-binding proteins

The modified target proteins are those forms of a protein which, relative to a naturally occurring form of the protein, have been altered at the amino acid level to increase the binding affinity of the target protein or a complex including the target protein for a modified macrolide ligand. Generally, such alterations will be made to a ligand binding domain of the target protein.

A wide range of techniques are known in the art for generating the modified target proteins of the present invention. In one embodiment, crystallographic or other structural data pertaining to the interaction of the normal ligand with the native protein can be consulted to predict compensatory mutations to the protein to restore binding to the modified ligand. In other embodiments, combinatorial mutagenesis can be used to isolate mutated forms of the target protein by their binding affinity for the modified ligand. The

mutations introduced into the target protein can involve changes in amino acid residues known to be at the binding site, or by random or semi-random mutagenesis.

There are a host of methods available in the art for screening gene products of variegated gene libraries made by combinatorial mutagenesis, especially for identifying individual gene products having a certain binding property. Such techniques will be generally adaptable for rapid screening of gene libraries generated by the combinatorial mutagenesis of, for example, the macrolide binding domain of any of an FKBP, cyclophilin, calcineurin and/or FRAP protein. The most widely used techniques for screening large gene libraries typically comprises cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates relatively easy isolation of the vector encoding the gene whose product was detected. Each of the illustrative assays described below are amenable to high through-put analysis as necessary to screen large numbers of degenerate ligand binding domain sequences created by combinatorial mutagenesis techniques.

In one screening assay, the candidate ligand binding domains are displayed on the surface of a cell or viral particle, preferably in truncated form, and the ability of particular cells or viral particles to bind as appropriate, e.g., FK506, cyclosporin or rapamycin (or a protein complex thereof) via the displayed ligand binding domain is detected in a "panning assay". For instance, the degenerate LBD gene library can be cloned into the gene for a surface membrane protein of a bacterial cell, and the resulting fusion protein detected by panning protocols (see, for example, Ladner *et al.*, WO 88/06630; Fuchs *et al.* (1991) *Bio/Technology* 9:1370-1371; and Goward *et al.* (1992) *TIBS* 18:136-140). In a similar fashion, fluorescently labeled molecules which bind the LBD, such as fluorescently labeled forms of the altered macrolide alone or in preformed protein complexes, can be used to score for ligand binding domains which are capable of interacting with the modified ligand. Cells can be visually inspected and separated under a fluorescence microscope, or, where the morphology of the cell permits, separated by a fluorescence-activated cell sorter.

In an alternate embodiment, the gene library is expressed as a fusion protein on the surface of a viral particle. For instance, in the filamentous phage system, foreign peptide sequences can be expressed on the surface of infectious phage, thereby conferring two significant benefits. First, since these phage can be applied to affinity matrices at very high concentrations, a large number of phage can be screened at one time. Second, since each infectious phage displays the combinatorial gene product on its surface, if a particular phage is recovered from an affinity matrix in low yield, the phage can be amplified by another round of infection. The group of almost identical *E.coli* filamentous phages M13,

fd, and fl are most often used in phage display libraries, as either of the phage gIII or gVIII coat proteins can be used to generate fusion proteins without disrupting the ultimate packaging of the viral particle (Ladner *et al.* PCT publication WO 90/02909; Garrard *et al.*, PCT publication WO 92/09690; Marks *et al.* (1992) *J. Biol. Chem.* 267:16007-16010; 5 Griffiths *et al.* (1993) *EMBO J* 12:725-734; Clackson *et al.* (1991) *Nature* 352:624-628; and Barbas *et al.* (1992) *PNAS* 89:4457-4461).

In an illustrative embodiment, the recombinant phage antibody system (RPAS, Pharmacia Catalog number 27-9400-01) can be easily modified for use in expressing and screening LBD combinatorial libraries. For instance, the pCANTAB 5 phagemid of the 10 RPAS kit contains the gene which encodes the phage gIII coat protein. A combinatorial library of coding sequences for macrolide binding domains can be cloned into the phagemid adjacent to the gIII signal sequence such that it will be expressed as a gIII fusion protein. After ligation, the phagemid is used to transform competent *E. coli* TG1 cells. Transformed cells are subsequently infected with M13KO7 helper phage to rescue the 15 phagemid and its candidate LBD gene insert. The resulting recombinant phage contain phagemid DNA encoding a specific candidate protein, and display one or more copies of the corresponding fusion coat protein. The phage-displayed candidate LBD which are capable of binding to the modified macrolide, or a complex thereof, are selected or enriched by panning. For instance, a phage library of mutant LBDs derived from FKBP12 20 can be panned on a polymer-immobilized form of the modified FK506, and unbound phage washed away from the insoluble matrix. The bound phage is then isolated, and if the recombinant phage express at least one copy of the wild type gIII coat protein, they will retain their ability to infect *E. coli*. Thus, successive rounds of reinfection of *E. coli*, and panning will greatly enrich for variant LBDs retaining the ability to bind to the 25 modified FK506 in each round.

In light of the present disclosure, a variety of forms of mutagenesis generally applicable will be apparent to those skilled in the art, and most will be amenable to the aforementioned combinatorial mutagenesis approach. For example, modified ligand binding domains which can bind to the modified ligand can be generated and screened 30 using, for example, alanine scanning mutagenesis and the like (Ruf *et al.* (1994) *Biochemistry* 33:1565-1572; Wang *et al.* (1994) *J Biol Chem* 269:3095-3099; Balint *et al.* (1993) *Gene* 137:109-118; Grodberg *et al.* (1993) *Eur J Biochem* 218:597-601; Nagashima *et al.* (1993) *J Biol Chem* 268:2888-2892; Lowman *et al.* (1991) *Biochemistry* 30:10832-10838; and Cunningham *et al.* (1989) *Science* 244:1081-1085), by linker scanning 35 mutagenesis (Gustin *et al.* (1993) *Virology* 193:653-660; Brown *et al.* (1992) *Mol Cell Biol* 12:2644-2652; McKnight *et al.* (1982) *Science* 232:316); or by saturation mutagenesis (Meyers *et al.* (1986) *Science* 232:613).



Where mutagenesis of a fragment of the full length target protein is carried out, the coding sequence for an isolated modified form of that fragment is reengineered back into the context of the full length gene, or a portion sufficient to induce the desired biological activity, such as by techniques used to generate fusion proteins.

5 In preferred embodiments, the modified ligand binding domain binds to the modified ligand with a dissociation constant approaching that observed for interaction of the wild-type macrolide receptor and unmodified ligand. In preferred embodiments, the target protein is modified to contain ligand-binding domains which bind to a preselected modified macrolide with a  $K_d$  value below about  $10^{-6}M$ , more preferably below about  $10^{-7}$   
10  $M$ , even more preferably below about  $10^{-8}M$ , and in some embodiments below about  $10^{-9}M$ . Other modified macrolide binding domains useful in the present invention, including mutants thereof, are described in the art. See, for example, WO96/41865, WO96/13613, WO96/06111, WO96/06110, WO96/06097, WO96/12796, WO95/05389, WO95/02684, WO94/18317, each of which is expressly incorporated by reference herein.

15 In selecting a modified ligand, e.g., a modified macrolide, for use in the subject method, there are a number of readily observable or measurable criteria which can be (optionally) considered: (A) the ligand is physiologically acceptable (i.e., lacks undue toxicity towards the cell or animal for which it is to be used), (B) it has a reasonable therapeutic dosage range, (C) desirably (for applications in whole animals), it can be taken  
20 orally (is stable in the gastrointestinal system and absorbed into the vascular system), (D) it can cross the cellular and other membranes, as necessary, and (E) binds to a modified ligand binding domain with reasonable affinity for the desired application. A first desirable criterion is that the compound is relatively physiologically inert, but for its activating capability with the modified protein complexes. The less the ligand binds to  
25 native macrolide binding proteins, and the lower the proportion of total ligand which binds to such proteins, the better the response will normally be. Particularly, the ligand should not have a strong biological effect on native proteins.

Preferred ligands include modified forms of cyclosporin A, FK506, FK520, or rapamycin.

30 Illustrative of this situation, one can modify the groups at position 9 or 10 of FK506 or FK520 (see Van Duyne *et al* (1991) *Science* 252, 839), so as to increase their steric requirement, by replacing the hydroxyl with a group having greater steric requirements, or by modifying the carbonyl at position 10, replacing the carbonyl with a group having greater steric requirements or functionalizing the carbonyl, e.g. forming an  
35 N-substituted Schiff's base or imine, to enhance the bulk at that position. Various functionalities which can be conveniently introduced at those sites are alkyl groups to form

ethers, acylamido groups, N-alkylated amines, where a 2-hydroxyethylimine can also form a 1,3-oxazoline, or the like. Generally, the substituents will be from about 1 to 6, usually 1 to 4, and more usually 1 to 3 carbon atoms, with from 1 to 3, usually 1 to 2 heteroatoms, which will usually be oxygen, sulfur, nitrogen, or the like. By using different derivatives of the basic structure, one can create different ligands with different conformational requirements for binding. By mutagenizing FK506 ligand binding domains, such as from FKBP12, one can have create a library of potential binding domains which will have different affinities for these modified forms of FK506 or FK520.

For instances, Substituents at C9 and C10 of FK506, which can be and have been accessed by synthesis, clash with a distinct set of FKBP12 sidechain residues. Thus, one class of mutant receptors for such ligands should contain distinct modifications, one creating a compensatory hole for the C10 substituent and one for the C9 substituent. As described in U.S. Patent Application Serial No. 08/388,653 by Crabtree et al., carbon 10 was selectively modified to have either an N-acetyl or N-formyl group projecting from the carbon (vs. a hydroxyl group in FK506). The binding properties of these derivatives clearly reveal that these C10 bumps effectively abrogate binding to the native FKBP12. U.S. Patent Application Serial No. 08/388,653 by Crabtree et al. depicts schemes for the synthesis of FK506-type moieties containing additional C9 bumps.

This invention thus encompasses use of a class of FK-506-type compounds comprising an FK-506-type moiety which contains, at one or both of C9 and C10, a functional group comprising -OR, -R, -(CO)OR, -NH(CO)H or -NH(CO)R, where R is substituted or unsubstituted, alkyl or arylalkyl which may be straightchain, branched or cyclic, including substituted or unsubstituted peroxides, and carbonates. "FK506-type moieties" include FK506, FK520 and synthetic or naturally occurring variants, analogs and derivatives thereof (including rapamycin) which retain at least the (substituted or unsubstituted) C2 through C15 portion of the ring structure of FK-506 and are capable of binding with a natural or modified FKBP, preferably with a K<sub>d</sub> value below about 10<sup>-6</sup>M.

Another preferred modified ligand includes FK506 molecules having an electrophilic addition "bump" at the C9 position of FK506, generating 9-S-methoxy-FK506 that does not bind endogenous FKBP, but does bind to FKBP12F36V.

To accomodate a substituent at positions 9 or 10 of FK506 or FK520, one can modify FKBP12's Phe36 to Ala and/or Asp37 to Gly or Ala. In particular, mutant FKBP12 moieties which contain Val, Ala, Gly, Met or other small amino acids in place of one or more of Tyr26, Phe36, Asp37, Tyr82 and Phe99 are of particular interest as receptor domains for FK506-type and FK-520-type ligands containing modifications at C9 and/or C10.

Site-directed mutagenesis may be conducted using the megaprimer mutagenesis protocol (see e.g., Sakar and Sommer, *BioTechniques* 8 4 (1990): 404-407). cDNA sequencing is performed with the Sequenase kit. Expression of mutant FKBP12s may be carried out in the plasmid pHN1<sup>+</sup> in the *E. coli* strain XA90 since many FKBP12 mutants have been expressed in this system efficiently. Mutant proteins may be conveniently purified by fractionation over DE52 anion exchange resin followed by size exclusion on Sepharose as described elsewhere. See e.g. Aldape et al, *J Biol Chem* 267 23 (1992): 16029-32 and Park et al, *J Biol Chem* 267 5 (1992): 3316-3324. Binding constants may be readily determined by one of two methods. If the mutant FKBP12s maintain sufficient rotamase activity, the standard rotamase assay may be utilized. See e.g., Galat et al, *Biochemistry* 31 (1992): 2427-2434. Otherwise, the mutant FKBP12s may be subjected to a binding assay using LH20 resin and radiolabeled T2-dihydroFK506 and T2-dihydroCsA that we have used previously with FKBP12s and cyclophilins. Bierer et al, *Proc. Natl. Acad. Sci. U.S.A.* 87 4 (1993): 555-69.

The invention further provides modified cyclosporin A that cannot bind to its cellular receptor cyclophilin (CypA). As described in the Examples, this rationally modified cyclosporin A is called *alpha*-cyclopentyl, sarcosine11-CsA (CpSar11-CsA). In addition, the inventors designed and synthesized a cellular receptor cyclophilin (Cyp) with compensatory mutations in its cyclosporin A binding pocket that can form tight complexes with CpSar11-CsA. The rationally designed CpSar11-CsA and its genetically engineered Cyp receptor provide a method to inhibit calcineurin conditionally and tissue specifically through selective expression of this modified cyclophilin receptor.

In another embodiment, modified CsA derivatives for use in the subject invention are CsA analogs in which (a) NMeVal11 is replaced with NMePhe (which may be substituted or unsubstituted) or NMeThr (which may be unsubstituted or substituted on the threonine betahydroxyl group) or (b) the *pro-S* methyl group of NMeVal11 is replaced with a bulky group of at least 2 carbon atoms, preferably three or more, which may be straight, branched and/or contain a cyclic moiety, and may be alkyl (ethyl, or preferably propyl, butyl, including t-butyl, and so forth), aryl, or arylalkyl. These compounds include those CsA analogs which contain NMeLeu, NMelle, NMePhe or specifically the unnatural NMe[betaMePhe], in place of MeVal11. The "(b)" CsA compounds are of formula 2 where R represents a functional group as discussed above.

A two step strategy may be used to prepare the modified [MeVal<sup>11</sup>]CsA derivatives starting from CsA. In the first step the residue MeVal11 is removed from the macrocycle. In the second step a selected amino acid is introduced at the (former) MeVal11 site and the linear peptide is cyclized. The synthesis of this compound is further described, e.g., in U.S. Applications Serial No. 08/388,653. Mutant cyclophilins that bind such CsA variants

by accomodating the extra bulk on the ligand can be prepared and identified, e.g., through the structure-based site-directed and random mutagenesis/screening protocols, e.g., as described in the FK1012 studies.

Similar considerations apply to the generation of mutant FRAP-derived domains which bind preferentially to rapamycin analogs (rapalogs) containing modifications (i.e., are 'bumped') relative to rapamycin in the FRAP-binding effector domain. For example, one may obtain preferential binding using rapalogs bearing substituents other than -OMe at the C7 position with FRBs based on the human FRAP FRB peptide sequence but bearing amino acid substitutions for one or more of the residues Tyr2038, Phe2039, Thr2098, Gln2099, Trp2101 and Asp2102. Exemplary mutations include Y2038H, Y2038L, Y2038V, Y2038A, F2039H, F2039L, F2039A, F2039V, D2102A, T2098A, T2098N, and T2098S. Rapalogs bearing substituents other than -OH at C28 and/or substituents other than =O at C30 may be used to obtain preferential binding to FRAP proteins bearing an amino acid substitution for Glu2032. Exemplary mutations include E2032A and E2032S. Proteins comprising an FRB containing one or more amino acid replacements at the foregoing positions, libraries of proteins or peptides randomized at those positions (i.e., containing various substituted amino acids at those residues), libraries randomizing the entire protein domain, or combinations of these sets of mutants are made using the procedures described above to identify mutant FRAPs that bind preferentially to bumped rapalogs.

Further guidance for identifying compensatory mutations to macrolide-binding domains are provided below:

#### *Selection of Compensatory Mutations in FKBP12 for Bump-FK506s Using the Yeast Two-Hybrid System*

One approach to obtaining variants of receptor proteins or domains, including of FKBP12, is the powerful yeast "two-hybrid" or "interaction trap" system. The two-hybrid system has been used to detect proteins that interact with each other. A "bait" fusion protein consisting of a target protein fused to a transcriptional activation domain is co-expressed with a cDNA library of potential "hooks" fused to a DNA-binding domain. A protein-protein (bait-hook) interaction is detected by the appearance of a reporter gene product whose synthesis requires the joining of the DNA-binding and activation domains. The yeast two-hybrid system mentioned here was originally developed by Elledge and co-workers. Durfee et al, *Genes & Development* 7 4 (1993): 555-69 and Harper et al, *Cell* 75 4 (1993): 805-816.

Since the two-hybrid system per se cannot provide insights into receptor-ligand interactions involving small molecule, organic ligands, we have developed a new, FK1012-inducible transcriptional activation system (discussed below). Using that system one may extend the two hybrid system so that small molecules (e.g., FK506s or FK1012s or FK506-type molecules of this invention) can be investigated. One first generates a cDNA library of mutant FKBP12s (the hooks) with mutations that are regionally localized to sites that surround C9 and C10 of FK506. For the bait, two different strategies may be pursued. The first uses the ability of FK506 to bind to FKBP12 and create a composite surface that binds to calcineurin. The sequence-specific transcriptional activator is thus comprised of: DNA-binding domain-mutant FKBP12---bump-FK506---calcineurin A-activation domain (where --- refers to a noncovalent binding interaction). The second strategy uses the ability of FK1012s to bind two FKBP12s simultaneously. A HED version of an FK1012 may be used to screen for the following ensemble: DNA-binding domain-mutant FKBP12---bump-FK506-normal FK506---wildtype FKBP12-activation domain.

1. *Calcineurin-Gal4 activation domain fusion as a bait:* A derivative of pSE1107 that contains the Gal4 activation domain and calcineurin A subunit fusion construct has been constructed. Its ability to act as a bait in the proposed manner has been verified by studies using the two-hybrid system to map out calcineurin's FKBP-FK506 binding site.

2. *hFKBP12-Gal4 activation domain fusion as a bait:* hFKBP12 cDNA may be excised as an EcoRI-HindIII fragment that covers the entire open reading frame, blunt-ended and ligated to the blunt-ended Xho I site of pSE1107 to generate the full-length hFKBP-Gal4 activation domain protein fusion.

3. *Mutant hFKBP12 cDNA libraries* hFKBP12 may be digested with EcoRI and HindIII, blunted and cloned into pAS1 (Durfee et al, *supra*) that has been cut with NcoI and blunted. This plasmid is further digested with NdeI to eliminate the NdeI fragment between the NdeI site in the polylinker sequence of pAS1 and the 5' end of hFKBP12 and religated. This generated the hFKBP12-Gal4 DNA binding domain protein fusion. hFKBP was reamplified. Mutant hFKBP12 cDNA fragments were then prepared using the primers listed below that contain randomized mutant sequences of hFKBP at defined positions by the polymerase chain reaction, and were inserted into the Gal4 DNA binding domain-hFKBP(NdeI/BamHI) construct.

4. *Yeast strain* *S. cerevisiae* Y153 carries two selectable marker genes (*his3* - galactosidase) that are integrated into the genome and are driven by Gal4 promoters. (Durfee, *supra*.)

#### 5 *Using Calcineurin-Gal4 Activation Domain as Bait*

The FKBP12-FK506 complex binds with high affinity to calcineurin, a type 2B protein phosphatase. Since we use C9- or C10-bumped ligands to serve as a bridge in the two-hybrid system, only those FKBP12s from the cDNA library that contain a compensatory mutation generate a transcriptional activator. For convenience, one may prepare at least three distinct libraries (using primers 11207-11209, Primer Table) that will each contain 8,000 mutant FKBP12s. Randomized sites were chosen by inspecting the FKBP12-FK506 structure, which suggested clusters of residues whose mutation might allow binding of the offending C9 or C10 substituents on bumped FK506s. The libraries are then individually screened using both C9- and C10-bumped FK506s. The interaction between a bumped-FK506 and a compensatory hFKBP12 mutant can be detected by the ability of host yeast to grow on *his* drop-out medium and by the expression of  $\beta$ -galactosidase gene. Since this selection is dependent on the presence of the bumped-FK506, false positives can be eliminated by subtractive screening with replica plates that are supplemented with or without the bumped-FK506 ligands.

#### *Using hFKBP12-Gal4 Activation Domain as Bait*

Using the calcineurin A-Gal4 activation domain to screen hFKBP12 mutant cDNA libraries is a simple way to identify compensatory mutations on FKBP12. However, mutations that allow bumped-FK506s to bind hFKBP12 may disrupt the interaction between the mutant FKBP12---bumped-FK506 complex and calcineurin. If the initial screening with calcineurin as a bait fails, the wildtype hFKBP12-Gal4 activation domain will instead be used. An FK1012 HED reagent consisting of: native-FK506---bumped-FK506 (Figure 16) may be synthesized and used as a hook. The FK506 moiety of the FK1012 can bind the FKBP12-Gal4 activation domain. An interaction between the bumped-FK506 moiety of the FK1012 and a compensatory mutant of FKBP12 will allow host yeast to grow on *his* drop-out medium and to express  $\beta$ -galactosidase. In this way, the selection is based solely on the ability of hFKBP12 mutant to interact with the bumped-FK506. The same subtractive screening strategy can be used to eliminate false positives.

In addition to the in vitro binding assays discussed earlier, an in vivo assay may be used to determine the binding affinity of the bumped-FK506s to the compensatory hFKBP12 mutants. In the yeast two-hybrid system, -gal activity is determined by the degree of interaction between the "bait" and the "prey". Thus, the affinity between the bumped-FK506 and the compensatory FKBP12 mutants can be estimated by the corresponding -galactosidase activities produced by host yeasts at different HED (native-FK506-bumped-FK506) concentrations.

Using the same strategy, additional randomized mutant FKBP12 cDNA libraries may be created in other bump-contact residues with low-affinity compensatory FKBP12 mutants as templates and may be screened similarly.

#### *Phage Display Screening for High-Affinity Compensatory FKBP Mutations*

Some high-affinity hFKBP12 mutants for bump-FK506 may contain several combined point mutations at discrete regions of the protein. The size of the library that contains appropriate combined mutations can be too large for the yeast two-hybrid system's capacity (e.g.,  $>10^8$  mutations). The use of bacteriophage as a vehicle for exposing whole functional proteins should greatly enhance the capability for screening a large numbers of mutations. See e.g. Bass et al, *Proteins: Structure, Function & Genetics* 8 4 (1990): 309-14; McCafferty et al, *Nature* 348 6301 (1990): 552-4; and Hoogenboom, *Nucl Acids Res* 19 15 (1991): 4133-7. If the desired high-affinity compensatory mutants is not be identified with the yeast two-hybrid system, a large number of combined mutations can be created on hFKBP12 with a phage vector as a carrier. The mutant hFKBP12 fusion phages can be screened with bumped-FK506-Sepharose as an affinity matrix, which can be synthesized in analogy to our original FK506-based affinity matrices. Fretz et al, *J Am Chem Soc* 113 4 (1991): 1409-1411. Repeated rounds of binding and phage amplification should lead to the identification of high-affinity compensatory mutants.

Illustrative publications providing additional information concerning synthetic techniques and modifications relevant to FK506 and related compounds include: GB 2 244 991 A; EP 0 455 427 A1; WO 91/17754; EP 0 465 426 A1, US 5,023,263, WO 92/00278, and PCT/US93/01617.

#### IV. Nucleic Acids Encoding Modified Macrolide-binding proteins

The invention provides nucleic acids encoding the modified macrolide-binding proteins. In general, nucleic acids encoding wild-type forms of the receptors can be obtained according to methods known in the art. For example, a nucleic acid encoding a

receptor can be obtained, e.g, by reverse transcription polymerase chain reaction (RT-PCR) amplification of RNA or PCR amplification of DNA using primers hybridizing to the ends of the nucleic acid desired to be amplified according to methods well known in the art. The nucleotide sequence of the nucleic acids encoding receptors can be found in the literature or in GenBank, which is publicly accessible on the internet. The template RNA for use in the RT-PCR can be obtained from any cell expressing the transcription factor or DNA binding domain or ligand binding domain. Template DNA can be obtained from any cell, even cells which do not express the desired factor. However, when using DNA as a template, it is preferable to avoid including introns in the construct.

The DNA can be amplified from template RNA or DNA from any species including vertebrates, such as mammals. For gene therapy, the receptor is preferably isolated from a species corresponding to the species of the recipient of the receptor. For example, for gene therapy in humans, the receptor is preferably of human origin. RNA and DNA can be extracted from cells according to methods known in the art.

Further manipulation of the wild-type sequence, e.g., to produce the compensatory mutants, can be carried out by standard molecular biology techniques.

In a preferred embodiment, a DNA encoding the modified target protein is operably linked to a promoter or regulatory element having the desired tissue specificity. Various tissue specific promoters and regulatory elements are known in the art and their nucleic acid sequences are publicly available in GenBank, freely accessible on the internet. Examples of tissue-specific promoters which can be used include the albumin promoter (liver-specific; Pinkert et al. (1987) *Genes Dev.* 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) *Adv. Immunol.* 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) *EMBO J.* 8:729-733) and immunoglobulins (Banerji et al. (1983) *Cell* 33:729-740; Queen and Baltimore (1983) *Cell* 33:741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle (1989) *Proc. Natl. Acad. Sci. U.S.A.* 86:5473-5477), pancreas-specific promoters (Edlund et al. (1985) *Science* 230:912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, for example the murine box promoters Kessel and Gruss (1990) *Science* 249:374-379) and the alpha-fetoprotein promoter (Campes and Tilghman (1989) *Genes Dev.* 3:537-546). Particularly preferred promoters include T cell specific promoters, such as promoters of T cell receptor genes, CD4 promoter (GenBank Accession No. U01066), and MHC class II promoters (e.g., GenBank Accession No. M81180).



Other regulatory elements of interest for practicing the invention include inducible promoters, which can also be tissue specific. For example, certain regulatory elements are responsive to hormones, such as steroid hormones (e.g., glucocorticoid hormone, MMTV promoter), metal ions (e.g., metallothionein promoter), phorbol esters (TRE elements), or calcium ionophores. Yet other inducible promoters include the growth hormone promoter; promoters which would be inducible by the helper virus such as adenovirus early gene promoter inducible by adenovirus E1A protein, or the adenovirus major late promoter; herpesvirus promoter inducible by herpesvirus proteins such as VP16 or 1CP4; promoters inducible by a vaccinia or pox virus RNA polymerases; or bacteriophage promoters such as T7, T3 and SP6, which are inducible by T7, T3, or SP6 RNA polymerases, respectively.

Other systems permitting an inducible expression of the target protein include tetracyclin-responsive promoters. Tight control of gene expression in eucaryotic cells has been achieved by use of tetracycline-responsive promoters. Such systems include the "off-switch" systems, in which the presence of tetracyclin inhibits expression, or the "reversible" Tet system, in which a mutant of the *E. coli* TetR is used, such that the presence of tetracyclin induces expression. These systems are disclosed, e.g., in Gossen and Bujard (*Proc. Natl. Acad. Sci. U.S.A.* (1992) 89:5547) and in U.S. Patents 5,464,758; 5,650,298; and 5,589,362 by Bujard et al. Accordingly, a gene encoding a target protein of the invention can be operably linked to an element responsive to the tetracyclin receptor or mutant form thereof, such that expression of a target gene of the invention is either induced or repressed in the presence of tetracyclin, depending on the system used.

In other embodiments, constitutive promoters may be desirable. There are many strong constitutive promoters that will be suitable for use in the invention, including the adenovirus major later promoter, the cytomegalovirus immediate early promoter, the beta actin promoter, or the beta globin promoter. Many others are known in the art.

For expression of a modified target protein in a cell, a nucleic acid encoding the modified target protein which is operably linked to a promoter is preferably inserted into a vector or plasmid, generally referred to herein as "construct". The constructs can be prepared in conventional ways, where the genes and regulatory regions may be isolated, as appropriate, ligated, cloned in an appropriate cloning host, analyzed by restriction or sequencing, or other convenient means. Particularly, using PCR, individual fragments including all or portions of a functional unit may be isolated, where one or more mutations may be introduced using "primer repair", ligation, *in vitro* mutagenesis, etc. as appropriate. The construct(s) once completed and demonstrated to have the appropriate sequences may then be introduced into the host cell by any convenient means. The constructs may be integrated and packaged into non-replicating, defective viral genomes like Adenovirus, Adeno-associated virus (AAV), or Herpes simplex virus (HSV) or others, including

retroviral vectors, for infection or transduction into cells. The constructs may include viral sequences for transfection, if desired. Alternatively, the construct may be introduced by fusion, electroporation, biolistics, transfection, lipofection, or the like. The host cells will usually be grown and expanded in culture before introduction of the construct(s), followed  
5 by the appropriate treatment for introduction of the construct(s) and integration of the construct(s). The cells will then be expanded and screened by virtue of a marker present in the construct. Various markers which may be used successfully include *hprt*, neomycin resistance, thymidine kinase, hygromycin resistance, *etc.*

In some instances, one may have a target site for homologous recombination,  
10 where it is desired that a an expression construct for the modified target protein be integrated at a particular locus. For example, it can knock-out an endogenous gene for the target protein and replace it (at the same locus or elsewhere) with the gene encoded for by the construct using materials and methods as are known in the art for homologous recombination. Alternatively, instead of providing a gene encoding a modified target  
15 protein, one may modify the endogenous gene encoding the wild-type target protein by, e.g., homologous recombination, such that it encodes the modified form of the protein. See, for example, Thomas and Capecchi, *Cell* (1987) 51, 503-512; Mansour, *et al.*, *Nature* (1988) 336, 348-352; and Joyner, *et al.*, *Nature* (1989) 338, 153-156.

Vectors containing useful elements such as bacterial or yeast origins of replication,  
20 selectable and/or amplifiable markers, promoter/enhancer elements for expression in procaryotes or eucaryotes, *etc.* which may be used to prepare stocks of construct DNAs and for carrying out transfections are well known in the art, and many are commercially available.

The expression constructs of the present invention may be provided in any biologically effective carrier, e.g. any formulation or composition capable of effectively transfecting cells *ex vivo* or *in vivo* with the expression construct. Efficient DNA transfer methods have been developed for hematopoietic cells (see, for example, Keating et al. (1990) *Exp Hematol* 18:99-102; and Dick et al. (1986) *Trends Genet* 2:165; and U.S. patents 5,654,185, 5,498,537 and 5,399,346). Approaches include insertion of the subject gene in viral vectors including recombinant retroviruses, adenovirus, adeno-associated virus, and herpes simplex virus-1, or eukaryotic plasmids. Viral vectors can be used to transfect cells directly; plasmid DNA can be delivered with the help of, for example, cationic liposomes (lipofectin) or derivatized (e.g. antibody conjugated), polylysine conjugates, gramicidin S, artificial viral envelopes or other such intracellular carriers, as well as direct injection of the gene construct or CaPO<sub>4</sub> precipitation carried out. It will be appreciated that because transduction of appropriate target cells represents the critical first step in gene therapy, choice of the particular gene delivery system will depend on such factors as the phenotype, e.g., the degree of commitment the stem cell has undergone, if any. Another factor in the selection of the appropriate transfection formulation is the consideration raised by *ex vivo* transfection versus *in vivo* transfection, with the latter requiring consideration of the route of administration, e.g. locally or systemically.

A preferred approach for both *ex vivo* or *in vivo* introduction of the subject target protein gene construct into a cell is by use of a viral vector containing the target protein gene. Infection of cells with a viral vector has the advantage that a large proportion of the targeted cells can receive the nucleic acid. Additionally, molecules encoded within the viral vector, e.g., by a cDNA contained in the viral vector, are expressed efficiently in cells which have taken up viral vector nucleic acid.

Retrovirus vectors are generally understood to be one of the recombinant gene delivery system of choice for the transfer of exogenous genes into stem cells, particularly into humans cells. (see e.g., Hawley R. G., *et al* (1994) *Gene Therapy* 1: 136-38)). These vectors provide efficient delivery of genes into cells, and the transferred nucleic acids are stably integrated into the chromosomal DNA of the host. A major prerequisite for the use of retroviruses is to ensure the safety of their use, particularly with regard to the possibility of the spread of wild-type virus in the cell population. The development of specialized cell lines (termed "packaging cells") which produce only replication-defective retroviruses has increased the utility of retroviruses as a gene delivery system, and defective retroviruses are well characterized for use in gene transfer for gene therapy purposes (for a review, see Miller, A.D. (1990) *Blood* 76:271). Thus, recombinant retrovirus can be constructed in which part of the retroviral coding sequence (*gag*, *pol*, *env*) has been replaced by the target

protein gene, rendering the retrovirus replication defective. The replication defective retrovirus is then packaged into virions which can be used to infect a target cell through the use of a helper virus by standard techniques. Protocols for producing recombinant retroviruses and for infecting cells *ex vivo* or *in vivo* with such viruses can be found in

5 Ausubel et al., *supra*, Sections 9.10-9.14 and other standard laboratory manuals. Examples of suitable retroviruses include pLJ, pZIP, pWE and pEM which are well known to those skilled in the art. Examples of suitable packaging virus lines for preparing both ecotropic and amphotropic retroviral systems include YCrip, YCre, Y2 and YAm.

Retroviruses have been used to introduce a variety of genes into many different

10 cell types, including embryonic stem cells, bone marrow cells, lymphocytes, hepatocytes, and neuronal cells by both *ex vivo* and *in vivo* protocols (see for example Eglitis, et al. (1985) *Science* 230:1395-1398; Danos and Mulligan (1988) *Proc. Natl. Acad. Sci. USA* 85:6460-6464; Wilson et al. (1988) *Proc. Natl. Acad. Sci. USA* 85:3014-3018; Armentano et al. (1990) *Proc. Natl. Acad. Sci. USA* 87:6141-6145; Huber et al. (1991) *Proc. Natl.*

15 *Acad. Sci. USA* 88:8039-8043; Ferry et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:8377-8381; Chowdhury et al. (1991) *Science* 254:1802-1805; van Beusechem et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:7640-7644; Kay et al. (1992) *Human Gene Therapy* 3:641-647; Dai et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:10892-10895; Hwu et al. (1993) *J. Immunol.* 150:4104-4115; U.S. Patent No. 4,868,116; U.S. Patent No. 4,980,286; PCT

20 Application WO 89/07136; PCT Application WO 89/02468; PCT Application WO 89/05345; and PCT Application WO 92/07573).

Exemplary retroviral vectors have been described that yield a high titre virus capable of efficiently transducing and expressing genes in undifferentiated embryonic and hematopoietic cells (Hawley et al (1994) *Gene Therapy* 1: 136-38). These vectors contain

25 a selectable marker (*neo*, *hph* or *pac*) under the transcriptional control of an internal murine *pgk* promoter and unique restriction sites for insertion of genes downstream of a variant LTR from the retroviral mutant PCMV (PCC4 embryonal carcinoma cell-passaged myeloproliferative sarcoma virus). A variant of the above-described retroviral vectors, the Murine Stem Cell Virus (MSCV), is illustrated in the examples set out below.

In an exemplary embodiment, the target protein gene is inserted in to the MSCVneo vector (Hawley et al, *supra*) under the control of the viral LTR promoter and also carrying the neomycin phosphotransferase gene as a selectable marker to confer resistance to G418. Helper-free MSCVneo-target protein virus producing packaging cells (Markowitz et al. (1988) *J Virol* 62:1120-1124) can be made by infection of tunicamycin-

35 treated cells with supernatant from transient transfectants according to the methods of

Hawley et al. (1991) *Leukemia Res* 15:659-673. The cells are maintained in, e.g., Dulbecco's modified Eagle medium (DMEM) supplemented with G418. Helper-free MSCVneo-target protein viral stocks can be produced by pooling populations of packaging cells with high titre (e.g.,  $>10^6$  CFU/ml). The retroviral infection may be performed by either including into the culture medium, supernatants (e.g., 5 to 20% vol/vol) produced by the pooled retroviral packaging cell lines, or by culturing the stem cells directly over the infected retroviral packaging lines themselves, or by both. See, for example, U.S. Patents 5,399,493 and 5,399,346 and PCT publication WO 93/07281.

Returning to the general discussion of retroviral vectors, it is noted that the art demonstrates that it is possible to limit the infective spectrum of retroviruses, and consequently of retroviral-based vectors, by modifying the viral packaging proteins on the surface of the viral particle (see, for example PCT publications WO93/25234, WO94/06920, and WO94/11524). For instance, strategies for the modification of the infection spectrum of retroviral vectors include: coupling antibodies specific for stem cell surface antigens to the viral *env* protein (Roux et al. (1989) *PNAS* 86:9079-9083; Julan et al. (1992) *J. Gen Virol* 73:3251-3255; and Goud et al. (1983) *Virology* 163:251-254); or coupling cell surface ligands to the viral *env* proteins (Neda et al. (1991) *J Biol Chem* 266:14143-14146). Coupling can be in the form of the chemical cross-linking with a protein or other variety (e.g. lactose to convert the *env* protein to an asialoglycoprotein), as well as by generating fusion proteins (e.g. single-chain antibody/*env* fusion proteins). This technique, while useful to limit or otherwise direct the infection to certain tissue types, and can also be used to convert an ecotropic vector in to an amphotropic vector.

To further illustrate, the target protein gene construct can be generated using a retroviral vector which further provides a fusion protein including the viral envelope protein and the vesicular stomatitis virus (VSV-G) glycoprotein (Burns et al. (1993) *Proc. Natl. Acad. Sci. USA* 90:8033-37; PCT Patent Application WO 92/14829; and WO 96/09400). Unlike typical amphotropic *env* proteins, the VSV-G protein is thought to mediate viral infection by fusing with a phospholipid component of cell membranes rather than by recognition of a cell surface protein. Since infection is not dependent on a specific receptor, VSV-G pseudotyped vectors have a broad host range. CD34+/Thy-1+ mobilized peripheral blood cells have previously been demonstrated to be transduced with high efficiency by a VSV-G pseudotyped retroviral vector (see Kerr et al. PCT publication WO 96/09400). Genetic modification of the stem cells with a target protein gene construct can be accomplished at any point during their maintenance by transduction with VSV-G pseudotyped virion containing the expression construct.

Moreover, use of retroviral gene delivery can be further enhanced by the use of tissue- or cell-specific transcriptional regulatory sequences which control expression of the recombinant target protein gene.

Another viral gene delivery system useful in the present invention utilizes  
5 adenovirus-derived vectors. It has been reported, for example, that adenoviral vectors can be used to transduce human CD34+ hematopoietic cells with high efficiencies. See, for example, Watanabe et al. (1996) *Blood* 87 5032; and Blood Weekly February 10, 1997. The genome of an adenovirus can be manipulated such that it encodes the modified target protein, but is inactivate in terms of its ability to replicate in a normal lytic viral life cycle  
10 (see, for example, Berkner et al. (1988) *BioTechniques* 6:616; Rosenfeld et al. (1991) *Science* 252:431-434; and Rosenfeld et al. (1992) *Cell* 68:143-155). Suitable adenoviral vectors derived from the adenovirus strain Ad type 5 dl324 or other strains of adenovirus (e.g., Ad2, Ad3, Ad7 etc.) are well known to those skilled in the art. Recombinant adenoviruses are relatively stable and amenable to purification and concentration, and as  
15 above, can be modified so as to affect the spectrum of infectivity with respect to stem cell populations.

Additionally, introduced adenoviral DNA (and foreign DNA contained therein) is not integrated into the genome of a host cell but remains episomal, thereby avoiding potential problems that can occur as a result of insertional mutagenesis in situations where  
20 introduced DNA becomes integrated into the host genome (e.g., retroviral DNA). Moreover, the carrying capacity of the adenoviral genome for foreign DNA is large (up to 8 kilobases) relative to other gene delivery vectors (Berkner et al., *supra*; Haj-Ahmand and Graham (1986) *J. Virol.* 57:267). Most replication-defective adenoviral vectors currently in use and therefore favored by the present invention are deleted for all or parts  
25 of the viral E1 and E3 genes but retain as much as 80% of the adenoviral genetic material (see, e.g., Jones et al. (1979) *Cell* 16:683; Berkner et al., *supra*; and Graham et al. in Methods in Molecular Biology, E.J. Murray, Ed. (Humane, Clifton, NJ, 1991) vol. 7. pp. 109-127). Expression of the inserted target protein gene can be under control of, for example, the E1A promoter, the major late promoter (MLP) and associated leader  
30 sequences, the E3 promoter, or exogenously added promoter sequences.

Yet another viral vector system useful for delivery of the subject target protein genes is the adeno-associated virus (AAV). Adeno-associated viral vectors have been shown to be effective at transducing other genes into pluripotent hematopoietic stem cells  
35 *in vitro* (see PCT Application WO 96/08560). Adeno-associated virus is a naturally occurring defective virus that requires another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle. (For a review

see Muzyczka et al. *Curr. Topics in Micro and Immunol.* (1992) 158:97-129). It is also one of the few viruses that may integrate its DNA into non-dividing cells, and exhibits a high frequency of stable integration (see for example Flotte et al. (1992) *Am. J. Respir. Cell. Mol. Biol.* 7:349-356; Samulski et al. (1989) *J. Virol.* 63:3822-3828; and  
5 McLaughlin et al. (1989) *J. Virol.* 62:1963-1973). Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate. Space for exogenous DNA is limited to about 4.5 kb. An AAV vector such as that described in Tratschin et al. (1985) *Mol. Cell. Biol.* 5:3251-3260 can be used to a recombinant target protein gene into stem cells. A variety of nucleic acids have been introduced into different cell types using AAV vectors  
10 (see for example Hermonat et al. (1984) *Proc. Natl. Acad. Sci. USA* 81:6466-6470; Tratschin et al. (1985) *Mol. Cell. Biol.* 4:2072-2081, Wondisford et al. (1988) *Mol. Endocrinol.* 2:32-39, Tratschin et al. (1984) *J. Virol.* 51:611-619; and Flotte et al. (1993) *J. Biol. Chem.* 268:3781-3790).

In addition to viral transfer methods, such as those illustrated above, non-viral  
15 methods can also be employed to cause expression of a heterologous target protein gene in transfected stem cells. Most nonviral methods of gene transfer rely on normal mechanisms used by mammalian cells for the uptake and intracellular transport of macromolecules. In preferred embodiments, non-viral gene delivery systems of the present invention rely on endocytic pathways for the uptake of the target protein gene construct by the targeted cell.  
20 Exemplary gene delivery systems of this type include liposomal derived systems, poly-lysine conjugates, and artificial viral envelopes.

In a representative embodiment, an expression construct including a target protein gene can be entrapped in liposomes bearing positive charges on their surface (e.g., lipofectins) and (optionally) which are tagged with antibodies against cell surface antigens  
25 of the targeted cell population (Mizuno et al. (1992) *No Shinkei Geka* 20:547-551; PCT publication WO91/06309; Japanese patent application 1047381; and European patent publication EP-A43075).

In yet another illustrative embodiment, the gene delivery system comprises an antibody or cell surface ligand which is cross-linked with a gene binding agent such as  
30 polylysine (see, for example, PCT publications W093/04701, W092/22635, W092/20316, W092/19749, and W092/06180). It will also be appreciated that effective delivery of the subject nucleic acid constructs via receptor-mediated endocytosis can be improved using agents which enhance escape of the gene from the endosomal structures. For instance, whole adenovirus or fusogenic peptides of the influenza HA gene product can be used as  
35 part of the delivery system to induce efficient disruption of DNA-containing endosomes

(Mulligan et al. (1993) *Science* 260:926; Wagner et al. (1992) *PNAS* 89:7934; and Christiano et al. (1993) *PNAS* 90:2122).

For example, the target protein gene construct can be used to transfect hematopoietic stem cells using a soluble polynucleotide carrier comprising a ligand to a stem cell receptor (e.g., steel factor) conjugated to a polycation, e.g. polylysine. To further illustrate, the gene delivery system can be targeted specifically to c-kit-expressing cells, e.g. human hematopoietic progenitor cells. The c-kit protein is a tyrosine kinase receptor for steel factor and is expressed on pluripotential stem cells capable of reconstituting all hematopoietic lineages. Furthermore, c-kit expression is restricted to stem/progenitor cells, and is not expressed on their committed progeny except for expression in mast cells. In an illustrative embodiment, the expression vector for the target protein gene is condensed by electrostatic forces with polylysine (PL) which has been covalently linked to streptavidin and PL which has been covalently linked to adenovirus (in order to achieve endosomal lysis). To the vector-PL conjugate is added a biotinylated steel factor which becomes associated with the vector-PL conjugate through the streptavidin-biotin interaction. Using such constructs, hematopoietic stem cells can be targeted for transfection with the target protein gene construct. See, for example, U.S. Patent 5,166,320, and Schwarzenberger et al., *Blood* (1996) 87(2): 472-78). One advantage to the PL-vector construct described above is the ability to carry out transient transfection of stem cell populations, while committed hematopoietic cells will be refractory to the transfection process because of a lack of c-kit. Another advantage to this approach derives from the fact that DNA uptake relies on highly efficient receptor-mediated endocytosis, a physiological pathway for macromolecular uptake not associated with cellular toxicity. However, in other embodiments, the carrier is conjugated with a ligand (or other binding molecule) specific for certain cell lineages, such as T-cells.

The subject target protein gene constructs can be efficiently introduced into stem cells by DNA transfection or by virus-mediated transduction as extensively described above. *In vitro* culturing systems known in the art for stem cells provide an accessible model for genetic manipulations. Possible method of transduction include, but are not limited to, direct co-culture of cells with viral producer cells (see, e.g., Bregni et al. (1992) *Blood* 80: 1418-22). Alternatively, supernatants from virally infected cells can be isolated and applied to cultures of cells under conditions appropriate for infection of the stem cells. See e.g., Xu et al. (1994) *Exp. Hemat.* 22: 223-30; and Hughes et al. (1992). *J. Clin. Invest.* 89:1817. The resulting transduced cells may then be grown under conditions similar to those for unmodified stem cells, whereby the modified stem cells may be expanded and caused to differentiate.



The invention also encompasses genetically engineered cells containing and/or expressing any of the constructs described herein, particularly a construct encoding a receptor, including prokaryotic and eucaryotic cells and in particular, yeast, worm, insect, mouse or other rodent, and other mammalian cells, including human cells, of various types and lineages, whether frozen or in active growth, whether in culture or in a whole organism containing them. Several examples of such engineered cells are provided in the Examples which follow.

At present it is especially preferred that the cells be mammalian cells, particularly primate, more particularly human, but can be associated with any animal of interest, particularly domesticated animals, such as equine, bovine, murine, ovine, canine, feline, *etc.* Among these species, various types of cells can be involved, such as hematopoietic, neural, mesenchymal, cutaneous, mucosal, stromal, muscle, spleen, reticuloendothelial, epithelial, endothelial, hepatic, kidney, gastrointestinal, pulmonary, *etc.* Of particular interest are hematopoietic cells, which include any of the nucleated cells which may be involved with the lymphoid or myelomonocytic lineages. Of particular interest are members of the T- and B-cell lineages, macrophages and monocytes, myoblasts and fibroblasts. Also of particular interest are stem and progenitor cells, such as hematopoietic neural, stromal, muscle, hepatic, pulmonary, gastrointestinal, *etc.*

The cells can be autologous cells, syngeneic cells, allogenic cells and even in some cases, xenogeneic cells. The cells may be modified by changing the major histocompatibility complex ("MHC") profile, by inactivating b<sub>2</sub>-microglobulin to prevent the formation of functional Class I MHC molecules, inactivation of Class II molecules, providing for expression of one or more MHC molecules, enhancing or inactivating cytotoxic capabilities by enhancing or inhibiting the expression of genes associated with the cytotoxic activity, or the like.

In some instances specific clones or oligoclonal cells may be of interest, where the cells have a particular specificity, such as T cells and B cells having a specific antigen specificity or homing target site specificity.

Likewise, this invention encompasses any non-human organism containing such genetically engineered cells. To illustrate this aspect of the invention, an example is provided of a mouse containing engineered cells expressing, in a ligand-dependent manner, an introduced target gene linked to a nucleotide sequence recognized by a transcriptional activator of the invention.

#### IV. Sources of Cells

Those skilled in the art will appreciate that the subject method can be carried out either in *in vivo* or *ex vivo* (e.g., in cell culture) embodiments. The *in vivo* delivery of a hematopoietic gene construct can be carried out using any of a variety of gene therapy techniques. For *ex vivo* applications, the stem cell to be genetically modified must first be isolated in cell culture. A variety of protocols for isolating embryonic and/or hematopoietic stem cells are well known in the art. Exemplary stem cell cultures for use in the subject method are described below.

##### 10 A. *Isolation of Hematopoietic Stem Cells*

Hematopoietic stem cells (HSCs) can be isolated from a mammalian source including, but not limited to, bone marrow (both adult and fetal), mobilized peripheral blood (MPB), umbilical cord blood and/or fetal liver. In a preferred embodiment, the HSCs are obtained from the subject into which the stem cells are to be transplanted after *in vitro* culturing and transduction of the hematopoietic gene construct.

The source of cells for the present invention can be, in addition to humans, non-human mammals. A variety of protocols are known in the art for isolating both embryonic stem cells and hematopoietic stem cells from non-human animals. See, for example, the Wheeler U.S. Patent 5,523,226 entitled "Transgenic swine compositions and methods" and the Emery et al. PCT publication WO 95/13363 entitled "Hematopoietic Stem Cells From Swine Cord Blood And Uses Thereof". The preferred non-human animals include vertebrates such as rodents, non-human primates, sheep, dog, cow and pigs. The term "non-human mammal" refers to all members of the class *Mammalia* except humans.

Where the intended use of the resulting hematopoietic cell is for implantation in human patients, the cells derived from transgenic animals can be used as a source for "humanized" hematopoietic cells, e.g., for xenogenic grafting into human subjects. For example, as described by the Sachs et al. PCT publication WO 96/06165 entitled "Genetically Engineered Swine Cells", the art provides for implantation of swine donor cells which have been engineered to increase desirable interactions between the donor cells and molecules and cells of a recipient, e.g., to promote the engraftment or function of the donor stem cells in the recipient environment. To illustrate, the cells can be engineered to express a human adhesion molecule, e.g., an adhesion molecule involved in engraftment and/or maintenance of hematopoietic cells. Examples of human adhesion molecules include VLA-4, c-kit, LFA-1, CD11a, Mac-1, CR3, CD11b, p150, p95, CD11c, CD49a,

LPAM-1, CD49d, CD44, CD38, and CD34. The transgenic cells can also be engineered to minimize unwanted interactions between the donor cells and molecules and cells of the recipient which, e.g., promote the rejection of donor graft cells or which inhibit the function of the donor graft cells. For example, the donors cells can be derived from a  
5 transgenic animal expressing one or more human MHC polypeptides.

Bone marrow cells can be obtained from a source of bone marrow, including but not limited to, ilium (e.g. from the hip bone via the iliac crest), tibia, femora, spine, or other bone cavities. Other sources of stem cells include, but are not limited to, embryonic yolk sac, fetal liver, and fetal spleen.

10 For isolation of bone marrow, an appropriate solution can be used to flush the bone, e.g., a salt solution supplemented with fetal calf serum (FCS) or other naturally occurring factors, in conjunction with an acceptable buffer at low concentration, generally from about 5-25 mM. Convenient buffers include HEPES, phosphate buffers and lactate buffers. Otherwise bone marrow can be aspirated from the bone in accordance with  
15 conventional techniques.

Methods for mobilizing stem cells into the peripheral blood are known in the art and generally involve treatment with chemotherapeutic drugs, cytokines (e.g. GM-CSF, G-CSF or IL3), or combinations thereof. Typically, apheresis for total white cells begins when the total white cell count reaches 500-200 cells/l and the platelet count reaches  
20 50,000/l.

Various techniques can be employed to separate the cells by initially removing lineage committed cells. Monoclonal antibodies are particularly useful for identifying markers associated with particular cell lineages and/or stages of differentiation. The antibodies can be attached to a solid support to allow for crude separation. The separation  
25 techniques employed should maximize the retention of viability of the fraction to be collected. Various techniques of different efficacy can be employed to obtain "relatively crude" separations. Such separations are where up to 10%, usually not more than about 5%, preferably not more than about 1%, of the total cells present not having the marker can remain with the cell population to be retained. The particular technique employed will  
30 depend upon efficiency of separation, associated cytotoxicity, ease and speed of performance, and necessity for sophisticated equipment and/or technical skill.

The use of separation techniques include, but are not limited to, those based on differences in physical (density gradient centrifugation and counter-flow centrifugal elutriation), cell surface (lectin and antibody affinity), and vital staining properties  
35 (mitochondria-binding dye rho123 and DNA-binding dye Hoechst 33342). Procedures for

separation can include, but are not limited to, magnetic separation, using antibody-coated magnetic beads, affinity chromatography, cytotoxic agents joined to a monoclonal antibody or used in conjunction with a monoclonal antibody, including, but not limited to, complement and cytotoxins, and "panning" with antibody attached to a solid matrix, e.g., plate, elutriation or any other convenient technique. Techniques providing accurate separation include, but are not limited to, FACS, which can have varying degrees of sophistication, e.g., a plurality of color channels, low angle and obtuse light scattering detecting channels, impedance channels, etc.

A large proportion of the differentiated cells can be removed by initially using a relatively crude separation, where major cell population lineages of the hematopoietic system, such as lymphocytic and myelomonocytic, are removed, as well as minor populations, such as megakaryocytic, mast cells, eosinophils and basophils. Usually, at least about 70 to 90 percent of the hematopoietic cells will be removed. If desired, a prior separation can be employed to remove erythrocytes, by employing Ficoll-Hypaque separation.

The gross separation can be achieved using methods known in the art including, but not limited to, magnetic beads, cytotoxic agents, affinity chromatography or panning. Antibodies which find use include antibodies to lineage specific markers which allow for removal of most, if not all, mature cells, while being absent on stem cells.

Concomitantly or subsequent to a gross separation, which provides for positive selection, a negative selection can be carried out, where antibodies to lineage-specific markers present on dedicated cells are employed. For the most part, these markers include, but are not limited to, CD2-, CD3-, CD7-, CD8-, CD10-, CD14-, CD15-, CD16-, CD19-, CD20-, CD33- and glycophorin A; preferably including, but not limited to, at least CD2-, CD14-, CD15-, CD16-, CD19- and glycophorin A; and normally including at least CD14- and CD15-. As used herein, Lin refers to a cell population lacking at least one lineage-specific marker. The hematopoietic cell composition substantially depleted of dedicated cells can then be further separated using a marker for Thy-1, whereby a substantially homogeneous stem cell population is achieved. Exemplary of this stem cell population is a population which is CD34+Thy-1+Lin-, which provides an enriched stem cell composition. Other markers that have been reported to subdivide CD34+ cells, further enriching for stem cells include, but are not limited to, CD38-, rhodamine lo, c-kit receptor, HLA DR lo-, CD71, and CD45 RA-. In fetal tissues and umbilical cord, stem cells are highly enriched in the CD34 hiLin- populations as described by Giusto et al. (1993) Blood 84: 421-32.

The purified stem cells have low side scatter and low to medium forward scatter profiles by FACS analysis. Cytospin preparations show the enriched stem cells to have a size between mature lymphoid cells and mature granulocytes. Cells can be selected based on light-scatter properties as well as their expression of various cell surface antigens.

5 While it is believed that the particular order of separation is not critical to this invention, the order indicated is preferred. Preferably, cells are initially separated by a coarse separation, followed by a fine separation, with positive selection of a marker associated with stem cells and negative selection for markers associated with lineage committed cells.

10 Compositions highly enriched in stem cells can be achieved in this manner. The desired stem cells are exemplified by a population with the CD34+Thy-1+Lin- phenotype and being able to provide for cell regeneration and development of members of all of the various hematopoietic lineages.

15 It should be noted that negative selection lineage selection for lineage specific markers provide a greater enrichment in stem cells obtained from bone marrow than from MPB. The majority of CD34 cells that are mobilized into the peripheral blood do not express lineage-specific markers and, therefore, Lin selection does not significantly enrich over CD34 selection in the peripheral blood as it does in bone marrow. Selection for Thy-1+ does enrich for stem cells in both mobilized peripheral blood and bone marrow.

20 Fetal or neonatal blood are also sources for the hematopoietic stem and progenitor cells of the present invention.

Fetal blood can be obtained by any method known in the art. For example, fetal blood can be taken from the fetal circulation at the placental root with the use of a needle guided by ultrasound (Daffos et al., (1985) *Am. J. Obstet Gynecol* 153:655-660; Daffos et al., (1983) *Am. J. Obstet. Gynecol.* 146:985), by placentocentesis (Valenti, C., (1973) *Am. J. Obstet. Gynecol.* 115:851; Cao et al., (1982) *J. Med. Genet.* 19:81), by fetoscopy (Rodeck, C.H., (1984) in Prenatal Diagnosis, Rodeck, C.H. and Nicolaides, K.H., eds., Royal College of Obstetricians and Gynaecologists, London), etc.

30 In a preferred embodiment of the invention, neonatal hematopoietic stem and progenitor cells can be obtained from umbilical cord blood and/or placental blood. The use of cord or placental blood as a source of hematopoietic cells provides numerous advantages. Cord blood can be obtained easily and without trauma to the donor. In contrast, at present, the collection of bone marrow cells is a traumatic experience which is costly in terms of time and money spent for hospitalization. Cord blood cells can be used  
35 for autologous transplantation, when and if needed, and the usual hematological and

immunological problems associated with the use of allogeneic cells, matched only partially at the major histocompatibility complex or matched fully at the major, but only partially at the minor complexes, are alleviated.

Collections should be made under sterile conditions. Immediately upon collection,  
5 the neonatal or fetal blood should be mixed with an anticoagulant. Such an anticoagulant can be any known in the art, including but not limited to CPD (citrate-phosphate-dextrose), ACD (acid citrate-dextrose), Alsever's solution, De Gowin's Solution, Edglugate-Mg, Rous-Turner Solution, other glucose mixtures, heparin, ethyl biscoumacetate, etc. (See Hurn, B.A.L., 1968, Storage of Blood, Academic Press, New  
10 York, pp. 26-160).

### *B. Isolation of Embryonic Stem Cells*

The present system is based on the ability of ES cells to differentiate and generate hematopoietic cells in culture and *in vivo*. Previous studies have demonstrated that ES  
15 cells will differentiate in culture and generate multiple hematopoietic lineages. However, in most of these studies, the extent of hematopoietic development has been limited and variable, and the exact kinetics of hematopoietic differentiation has been unpredictable or poorly defined. Utilizing the subject method, hematopoietic stem cells can be generated by ectopic expression of a hematopoietic gene such as *LH-2*. The advantages of such a  
20 system are several-fold. First, one has access to the cells at all stages of differentiation, making it possible to manipulate the system as it develops. Second, an *in vitro* system based on ES cells will enable one to study the function of a broad spectrum of genes through inactivation by homologous recombination without encountering the problems inherent to an *in vivo* system; namely, embryonic lethalties.

Embryonic stem cells are generated and maintained using methods well known to the skilled artisan such as those described by Doetschman et al. (1985) *J. Embryol. Exp. Morphol.* 87:27-45). Any line of ES cells can be used, however, the line chosen is typically selected for the ability of the cells to differentiate into embryoid bodies (EB) followed by their commitment into hematopoietic lineages, e.g. erythroid, lymphoid,  
30 myeloid. Thus, any ES cell line from human or non-human origin that is believed to have this capability is suitable for use herein. As an example of one mouse strain that is typically used for production of ES cells, is the 129J strain, e.g. cell line CCE utilized in the Examples below. Still another preferred murine cell line is the cell line J1. Other ES cell lines include D3 (American Type Culture Collection, catalog no. CKL 1934) and the  
35 WW6 cell line (see Ioffe et al. (1995) *PNAS* 92:7357-7361).

ES cells are cultured using methods well known to the skilled artisan, such as those set forth by Robertson in: *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, E.J. Robertson, ed. IRL Press, Washington, D.C. [1987]); by Bradley et al. (1986) *Current Topics in Devel. Biol.* 20:357-371); and by Hogan et al. (Manipulating the Mouse Embryo: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY [1986]). As an illustration, ES cells can be grown and passaged *in vitro* with or without feeder layers, e.g., embryonic fibroblasts, in the presence of growth factors selected from steel factor (membrane -associated or soluble forms), leukemia inhibitory factor (LIF) and fibroblast growth factor (FGF). See e.g., US Pat No. 5,453,357. Growth and differentiation enhancing concentrations of these factors can range from 0.5-500 ng/ml, preferably, 10-20 ng/ml. Differentiation of ES cells into embryoid bodies (EBs) and multiple cell-types, e.g., hematopoietic, endothelial, muscle and neuronal lineages, can be achieved by a number of standard methods known in the art (reviewed in G. Keller, *Current Opinion*: 862-69; see also, G. Keller et al. *MCB* 13(1) 473-86).

The technique most frequently used to differentiate ES cells is simply to remove the cells from contact with the feeder cells, or from the presence of LIF, and culture them in liquid or methyl cellulose containing media in bacterial grade petri dishes. Under these conditions, ES cells are unable to adhere to the surface of the dish, and the formation of EBs is enhanced. A modification of this method to maximize ES cell differentiation into hematopoietic lineages involves the culturing of these cells on stromal cells, which provides a supportive environment for hematopoietic cells as they develop within the EBs. Stromal cell culturing methods are extensively described below in *Expansion and Differentiation of Genetically Modified Cells*. Once EBs are formed, they can be dissociated into a single cell suspension. The generated EBs can be assayed at various stages of development for the presence of specific cell populations. For example, hematopoietic lineages can be examined by plating EB-derived cells in methyl cellulose in the presence of growth factors for determining hematopoietic precursor populations. A specific illustration of precursor cell assay is provided in the Examples below. In brief, single cell suspension of EBs can be assayed for precursor content in colony forming cell-culture (CFC-c) assay as described in Keller et al., *supra*. This procedure will be hereinafter referred to as the precursor assays. Alternatively, EB-derived cells can be analyzed for the presence of specific cell-surface antigens (e.g., immunoglobulin can be used to stain B lymphocytes) by immunocytochemical methods or by FACS analysis. The most stringent test for the differentiation potential of these cells involves the ability of dissociated EB cells to repopulate the hematopoietic system of a recipient animal. Detection of cell surface antigens and transplantation protocols are extensively described

below in the section entitled "*Expansion and Differentiation of Genetically Modified Cells*".

5 V. Methods of the invention

The invention provides methods for inducing a specific biological activity in a tissue specific manner. In a preferred embodiment, the invention provides a method for modulating cell growth, differentiation and/or survival. According to the method of the invention, a cell is modified to express a modified form of a target protein which mediates  
10 the desired biological activity, said target protein interacting specifically with a modified form of a ligand of the target protein, which essentially does not interact with the wild-type target protein.

In a preferred embodiment of the invention, the target protein is a protein involved in the  $\text{Ca}^{2+}$ /calcineurin pathway, which is involved, in particular in activation of  
15 lymphocytes, e.g., T lymphocytes. In an even more preferred embodiment, the target protein is a protein which forms a ternary complex with calcineurin or FRB. Even more preferably, the target protein is cyclophilin, FKBP12, or FRB. Calcineurin is present in most tissues, with the highest level of expression being present in the brain. In lymphocytes, in particular in T cell, calcineurin is involved in activation of the T cells in  
20 the presence of  $\text{Ca}^{2+}$ . Thus, the invention provides a method for regulating T cell activation, e.g., inducing tolerance, without significantly affecting biological activities mediated by calcineurin in other cell types. For example, a population of cells can be engineered to express a modified cyclophilin selectively in T cells, such as by operably linking the gene encoding the modified cyclophilin molecule to a promoter that activates  
25 transcription specifically in T cells, e.g. CD4 promoter. Only the T cells will express the modified cyclophilin and therefore be responsive to the modified ligand. Thus, upon contact with the modified ligand, activation of the T cells expressing the modified cyclophilin will be inhibited, without inducing toxic effects in the cells which do not express the modified cyclophilin.

30 Furthermore, it has been observed that a reduction in calcineurin activity by only 50% significantly impairs signaling by the antigen receptor on T cells. Similarly, patients treated for transplant rejection have only a 50% reduction in calcineurin activity at the therapeutic concentration of the drug, though they do not usually reject the transplant. In addition, cyclosporin appears to induce tolerance to transplanted tissue even after the drug  
35 is withdrawn. For example, in the case of bone marrow populated largely by the



transplanted cells, while the lymphocyte population is derived largely or in part from the recipient. Thus, this indicates that blockage of calcineurin action by only 50% for long periods of time results in the development of tolerance to transplanted tissue. Parallel studies in mice have also suggested that these drugs are capable of inducing long term  
5 tolerance of transplanted tissues.

Accordingly, the invention is useful in any situation in which tolerance of T lymphocytes is desired. The invention can be applied in vitro or in vivo. In a preferred embodiment, the method is used on cells, e.g, cells obtained from a subject, the cells are modified in vitro and then administered to the subject. In another embodiment, the cells  
10 are modified in vivo to express a modified target protein. Conditions which can be treated according to the method of the invention include those involving an immune reaction and are further described below.

In one embodiment, this invention is directed to a method for preventing graft rejection or for treating host versus graft disease following blood marrow transplantation.  
15 In one embodiment, the invention, comprises the following steps: (a) inserting DNA encoding a modified cellular target protein, e.g, cyclophilin specific for a modified cyclosporin into a hematopoietic stem cell to produce a transformed hematopoietic stem cell; (b) introducing the transformed hematopoietic stem cell into a recipient mammal, such that the modified cellular target protein cyclophilin is expressed; and,  
20 (c) administering an effective amount of the modified cyclosporin to the recipient mammal. As used herein, the term "hematopoietic stem cell" refers to a cell that is capable of developing into mature myeloid and/or lymphoid cells. The method of this invention avoids the undesirable side effect of broad spectrum immune suppressants which are often used in transplantation. The genetic engineering techniques for cloning a protein,  
25 transfecting a cell, and introducing the transfected cell into a patient in gene therapy are known. One of skill in this art can determine through routine experimentation the preferred cloning techniques, transfection methods and gene delivery protocol to be used.

In a preferred embodiment, this invention is directed to the modified cyclosporin drug, CpSar11-CsA, which can be administered to the patient receiving the transformed  
30 hematopoietic stem cells that are capable of expressing the modified cellular target protein cyclophilin CypAgtm and directed to the modified target protein cyclophilin with the alterations in its amino acid sequence making it specific for the modified cyclosporin CpSar11-CsA.

In another embodiment, the invention is used for treating autoimmune disorders by  
35 inducing tolerance of autoimmune cells. Immunosuppressive drugs remain the cornerstone of therapy for autoimmune disorders, although their efficacy is limited and

their chronic use entails considerable risk. Immunosuppressive treatment is particularly indicated for progressive neurologic disability without remission when the patient is on a rapidly progressive course. The invention provides a method for treating autoimmune diseases without incurring such risks and toxic effects.

- 5           The method according to this invention includes (a) inserting DNA encoding a modified cellular target protein, for example a modified cyclophilin target protein, specific for a modified ligand, cyclosporin, into a T cell to produce a transformed T cell; (b) introducing the transformed T cell into a patient suffering from an autoimmune disorder, such that the modified target protein is expressed, and then, (c) administering to  
10 the patient an effective amount of a modified immune agent whose target protein is the modified target protein. In this type of application, specific populations of T cells are transfected and regulated by the modified drug, for example, cyclosporin A. It is preferable that a significant amount of cells are transformed. This can be achieved, by viral transformation, as further described herein. Alternatively, cells can be targeted and  
15 transformed in vivo with a construct encoding the modified target protein.

- One exemplary autoimmune disease which can be treated according to the method of the invention is multiple sclerosis. Multiple sclerosis (MS) is characterized by chronic inflammation, demyelination, and gliosis (scarring). MS affects 350,000 Americans and is, with the exception of trauma, the most frequent cause of neurologic disability in early  
20 to middle adulthood. Indirect evidence supports an autoimmune etiology for MS, perhaps triggered by a viral infection in a genetically susceptible host.

- T cells reactive against myelin proteins, either myelin basic protein (MBP) or myelin proteolipid protein (PLP), mediate CNS inflammation in experimental allergic encephalomyelitis (EAE), a laboratory model for demyelinating diseases. This has been  
25 proven by adoptive transfer experiments in which sensitized T cells from an animal with EAE can transfer disease to a healthy syngeneic recipient.

          It is possible that tissue damage in MS is mediated by cytokine products of activated T cells, macrophages, or astrocytes.

- According to this invention, one method of treating MS, particularly in those  
30 patients where MS has become life-threatening, is to administer a genetically engineered T cell that expresses a modified target protein for a modified immune agent, such as cyclosporin, FK506, and rapamycin and then administering the modified immunosuppressive drug.

- Another exemplary autoimmune disease which can be treated according to the  
35 method of the invention is Systemic Lupus Erythematosus (SLE). SLE is a disease of unknown cause in which tissues and cells are damaged by pathogenic autoantibodies and

immune complexes. In the United States, the prevalence of SLE in urban areas varies from 15 to 50 per 100,00 population.

SLE probably results from interactions between susceptibility genes and the environment. This interaction results in abnormal immune responses with T and B lymphocyte hyperactivity which is not suppressed by the usual immunoregulatory circuits.

Life threatening, severely disabling manifestations of SLE that are responsive to immunosuppression can be treated according to this invention by administering a genetically engineered T cell that expresses a modified target protein for a modified immune agent and then administering the modified immunosuppressive drug, such as cyclosporin, FK506, or rapamycin.

In addition to autoimmune diseases and graft versus host disease, undesired T cell activation may give rise to a variety of other diseases or conditions, e.g., allograft rejection, hypersensitivity, delayed-type hypersensitivity mediated conditions, and allergic reactions, e.g. drug allergies. Yet other diseases or disorders that can be treated according to the method of the invention include asthma, allergic diseases that have manifestations of inflammations such as dermatitis or rhinitis, for example, atopic dermatitis, symptoms such as bronchoconstriction accompanied by asthma, allergic diseases, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, other arthritic conditions, septic shock, sepsis, and endotoxic shock, atrophic gastritis, thyroiditis, allergic encephalomyelitis, gastric mucosa, thyrotoxicosis, autoimmune hemolytic anemia, thyroidosis, scleroderma, diabetes mellitus, Graves' disease, and sympathetic ophthalmia (Eisen, H. N., 1979, Immunology, Harper and Row, Hagerstown, Md., pp. 557-595).

Another application according to this invention is the selective activation of pathways in cells through receptor-ligand interactions. Thus, a therapeutic protein of choice can be selectively modified to bind with its mutant receptor, which will not bind with other unmodified receptors of "wild-type" or "normal" type, and thus activate the pathway.

For example, the following proteins have known structures and may be modified according to this invention to selectively activate a mutant target protein: human insulin, used in treating diabetes mellitus; human growth hormone, used in treating growth hormone deficiency in children; interferon-*alpha*, used to treat hairy cell leukaemia and chronic hepatitis A and C; tissue-type plasminogen activator (tPA), used to treat myocardial infarction; erythropoietin, used to treat anaemia in chronic renal failure; granulocyte colony-stimulating factor (G-CSF), used to treat neutropenia following cancer chemotherapy; granulocyte-macrophage colony-stimulating factor (GM-CSF), used for

myeloid reconstitution after bone marrow transplantation; and, Factor VIII used in treating haemophilia A.

In another embodiment, the invention can be used to treat neurologic diseases or conditions. For example, in certain conditions, e.g., degenerative diseases, it is desirable to regenerate neurons or other cells of the nervous system, e.g., by implantation of such cells. According to the method of the invention, the growth and/or differentiation of such cells could be controlled, by genetically engineering the cells to express a modified target protein involved in growth, differentiation of cell death control. Methods of genetically modifying donor cells by gene transfer for grafting into the central nervous system to treat defective, diseased or damaged cells are disclosed in U.S. Pat. No. 5650148 by Gage et al. The modified donor cells produce functional molecules that effect the recovery or improved function of cells in the CNS. Methods and vectors for carrying out gene transfer and grafting are also described in U.S. Pat. No. 5650148.

Alternatively, this invention can be used to engineer ligand-inducible cell death characteristics into cells. Such engineered cells can then be eliminated from a cell culture after they have served their intended purpose (e.g. production of a desired protein or other product) by adding the ligand to the medium. Engineered cells of this invention can also be used *in vivo*, to modify whole organisms, preferably animals, including humans, e.g. such that the cells produce a desired protein or other result within the animal containing such cells. Such uses include gene therapy.

In one embodiment of the invention, cells are modified *ex vivo* and introduced into a subject. Depending upon the nature of the cells, the cells may be introduced into a host organism, e.g. a mammal, in a wide variety of ways. Hematopoietic cells may be administered by injection into the vascular system, there being usually at least about  $10^4$  cells and generally not more than about  $10^{10}$ , more usually not more than about  $10^8$  cells. The number of cells which are employed will depend upon a number of circumstances, the purpose for the introduction, the lifetime of the cells, the protocol to be used, for example, the number of administrations, the ability of the cells to multiply, the stability of the therapeutic agent, the physiologic need for the therapeutic agent, and the like. Alternatively, with skin cells which may be used as a graft, the number of cells would depend upon the size of the layer to be applied to the burn or other lesion. Generally, for myoblasts or fibroblasts, the number of cells will be at least about  $10^4$  and not more than about  $10^8$  and may be applied as a dispersion, generally being injected at or near the site of interest. The cells will usually be in a physiologically-acceptable medium.

Instead of *ex vivo* modification of the cells, in many situations one may wish to modify cells *in vivo*. For this purpose, various techniques have been developed for

modification of target tissue and cells *in vivo*. A number of virus vectors have been developed, such as adenovirus and retroviruses, which allow for transfection and random integration of the virus into the host. See, for example, Dubensky et al. (1984) Proc. Natl. Acad. Sci. USA 81, 7529-7533; Kaneda et al., (1989) Science 243,375-378; Hiebert et al. 5 (1989) Proc. Natl. Acad. Sci. USA 86, 3594-3598; Hatzoglu et al. (1990) J. Biol. Chem. 265, 17285-17293 and Ferry, et al. (1991) Proc. Natl. Acad. Sci. USA 88, 8377-8381. The vector may be administered by injection, e.g. intravascularly or intramuscularly, inhalation, or other parenteral mode.

In accordance with *in vivo* genetic modification, the manner of the modification 10 will depend on the nature of the tissue, the efficiency of cellular modification required, the number of opportunities to modify the particular cells, the accessibility of the tissue to the DNA composition to be introduced, and the like. By employing an attenuated or modified retrovirus carrying a target transcriptional initiation region, if desired, one can activate the virus using one of the subject transcription factor constructs, so that the virus may be 15 produced and transfect adjacent cells.

The DNA introduction need not result in integration in every case. In some situations, transient maintenance of the DNA introduced may be sufficient. In this way, one could have a short term effect, where cells could be introduced into the host and then turned on after a predetermined time, for example, after the cells have been able to home 20 to a particular site.

Tissue specific expression of the modified target protein of the invention can also be achieved by selectively introducing a vector encoding the modified target protein in the desired cell type. This can be achieved by various methods. For example, one can choose a viral vector which specifically infects the desired cell type. Alternatively, one can use 25 liposomes, bacteria, or other form of delivery vehicle that can be targeted to the desired cell type by linking to the delivery vehicle a ligand that interacts specifically with the desired cell. The ligand can be a protein, e.g., a growth factor, which interacts with a growth factor target protein on the target cells. In a preferred embodiment, the ligand is altered such that it does not induce a biological activity, but only serves as a target 30 molecule for the construct of the invention. The ligand can be an antibody, specifically recognizing an epitope on the desired target cell. Numerous antibodies to surface molecules are available commercially. Alternatively, antibody molecules can also be prepared according to methods known in the art.

The modified ligand providing for activation of the modified target protein may be 35 administered as desired. Depending upon the binding affinity of the modified ligand, the response desired, the manner of administration, the half-life, the number of cells present,

various protocols may be employed. The modified ligand may be administered parenterally or orally. The number of administrations will depend upon the factors described above. The modified ligand may be taken orally as a pill, powder, or dispersion; buccally; sublingually; injected intravascularly, intraperitoneally, subcutaneously; by  
5 inhalation, or the like. The modified ligand (and monomeric compound) may be formulated using conventional methods and materials well known in the art for the various routes of administration. The precise dose and particular method of administration will depend upon the above factors and be determined by the attending physician or human or animal healthcare provider. For the most part, the manner of administration will be  
10 determined empirically.

The particular dosage of the modified ligand for any application may be determined in accordance with the procedures used for therapeutic dosage monitoring, where maintenance of a particular level of expression is desired over an extended period of times, for example, greater than about two weeks, or where there is repetitive therapy,  
15 with individual or repeated doses of ligand over short periods of time, with extended intervals, for example, two weeks or more. A dose of the modified ligand within a predetermined range would be given and monitored for response, so as to obtain a time-expression level relationship, as well as observing therapeutic response. Depending on the levels observed during the time period and the therapeutic response, one could provide a  
20 larger or smaller dose the next time, following the response. This process would be iteratively repeated until one obtained a dosage within the therapeutic range. Where the modified ligand is chronically administered, once the maintenance dosage of the ligand is determined, one could then do assays at extended intervals to be assured that the cellular system is providing the appropriate response and level of the expression product.

It should be appreciated that the system is subject to many variables, such as the cellular response to the ligand, the efficiency of expression and, as appropriate, the level of secretion, the activity of the expression product, the particular need of the patient, which may vary with time and circumstances, the rate of loss of the cellular activity as a result of loss of cells or expression activity of individual cells, and the like. Therefore, it is  
30 expected that for each individual patient, even if there were universal cells which could be administered to the population at large, each patient would be monitored for the proper dosage for the individual.

The subject methodology and compositions may be used for the treatment of a wide variety of conditions and indications. For example, B- and T-cells may be used in  
35 the treatment of cancer, infectious diseases, metabolic deficiencies, cardiovascular disease, hereditary coagulation deficiencies, autoimmune diseases, joint degenerative diseases, *e.g.* arthritis, pulmonary disease, kidney disease, endocrine abnormalities, *etc.* Various cells

APV007.25

- 45 -

involved with structure, such as fibroblasts and myoblasts, may be used in the treatment of genetic deficiencies, such as connective tissue deficiencies, arthritis, hepatic disease, *etc.*

VI Kits

This invention further provides kits useful for the foregoing applications. One such kit contains one or more nucleic acids encoding a modified target protein thereof. The kit preferably also contains a modified ligand for the target protein. Thus, in one embodiment, the kit comprises a vector containing a gene encoding a modified cyclophilin molecule operably linked to a promoter expressed specifically in T cells and a modified cyclophilin molecule.

The contents of all cited references including literature references, issued patents, published patent applications and co-pending patent applications, as cited throughout this application are hereby expressly incorporated by reference.




## EXAMPLES

**Example 1: Synthesis of a modified Cyclosporin A, CpSar11-CsA**

This Example describes the synthesis of a modified form of Cyclosporin A, termed CpSar11-CsA, which does not significantly interact with the wild-type receptor of cyclosporin A, cyclophilin.

As shown below in Scheme 1, the synthesis of CpSar11-CsA first required the asymmetric synthesis of  $\alpha$ -cyclopentyl sarcosine using a combination of the methods of Evans, et al. (*J. Am. Chem. Soc.* 112: 4011-4030 (1990)) and Dorow, et al. (*J. Org. Chem.* 60: 4986-7 (1995)) and the subsequent incorporation of this unnatural amino acid into the CsA macrocycle.

Scheme 1



In the synthesis, HZN-nonapeptid (H<sub>2</sub>N-Abu-Sar-MeLeu-Val-MeLeu-Ala-DAla-MeLeu-MeLeu-(Ac-N-MeValinol ester) was synthesized from CsA. The reagent abbreviations include the following: DCM, dichloromethane; DMF, dimethylformamide; KHMDS, potassium hexamethyldisilazide; Trisyl-N<sub>3</sub>, triisopropylbenzenesulfonylazide; THF, tetrahydrofuran; Fmoc-CL, 9-fluorenylmethylchloroformate; Boc, t-butyloxycarbonyl; TFA, trifluoroacetic acid; PyBrop, bromo-trispyrrolidinophosphonium hexafluorophosphate; DIEA, diisopropylethylamine; dimedone, 5,5-dimethyl-1,4-cyclohexanedione; PyAop, 7-azabenzotriazo-1-yl-oxy(trispyrrolidino)phosphonium hexafluorophosphate.

The details of the synthesis are set forth below.

### N- $\alpha$ -cyclopentylacetyl-4S-benzyloxazolidinone (1)

To a solution of cyclopentylacetic acid (4.94 g, 38.51 mmol) and DMF (one drop) in DCM (100 mL), oxalylchloride (23.1 mL, 2.0 M in DCM, 1.2 eq, 46.2 mmol) was added dropwise over one hour at room temperature. The reaction was stirred for another two hours, evaporated under reduced pressure and dried under vacuum to afford crude cyclopentylacetyl chloride. This residue was dissolved in THF (80 mL) and cooled to  $-78^{\circ}\text{C}$ . To a solution of 4S-benzyloxazolidinone (6.79 g, 38.5 mmol) in THF (50 mL) at  $-78^{\circ}\text{C}$ , nBuLi (26.2 mL, 1.45 M, 38 mmol) was added dropwise by syringe and stirred for an additional 15 minutes producing lithiated oxazolidinone. This solution was added over 30 minutes via cannula to the solution of cyclopentylacetyl chloride. The reaction mixture was stirred 30 minutes at  $-78^{\circ}\text{C}$  before quenching with 1 M  $\text{NaH}_2\text{SO}_4$  (75 mL). The THF was removed under reduced pressure and the aqueous layer was extracted with DCM (3 x 75 mL). The combined organics were washed with 10%  $\text{NaHCO}_3$  aq. (50 mL), brine (50 mL), dried over  $\text{Na}_2\text{SO}_4$ , filtered and evaporated onto silica (15 g). The product was purified by chromatography (silica gel, 5-20% EtOAc in hexanes) to give 7.97g (70 %) of a white solid:  $[\alpha]^{20}_{\text{D}} = +52.0^{\circ}$  (c 1,  $\text{CHCl}_3$ ); IR (film) 2948, 2835, 1779, 1696, 1455, 1383, 1352, 1210, 1099, 700  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.2-7.4 (m, 5H), 4.67 (m, 1H), 4.16, (M, 2H), 3.30 (dd,  $J = 3.3, 13.3$ , 1H), 3.02 (dd,  $J = 6.9, 16.6$ , 1H), 2.90 (dd,  $J = 7.4, 16.6$ , 1H), 2.77 (dd,  $J = 9.7, 13.3$ , 1H), 2.33 (m, 1H), 1.89 (m, 2H), 1.62 (m, 4H), 1.22 (m, 2H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  172.9, 153.4, 135.3, 127.2, 66.0, 55.1, 41.3, 37.9, 35.7, 32.44, 32.38, 24.9; HRMS ( $\text{CI}^+$ ,  $\text{NH}_3$ ) calc'd for  $\text{C}_{17}\text{H}_{21}\text{NO}_3$ : 305.1865, found 305.1870.

### 2S- $\alpha$ -azido- $\alpha$ -cyclopentylacetyl-4S-oxalolidinone (2)

To THF (40 mL) at  $-78^{\circ}\text{C}$ , potassium hexamethyldisilazide (16.6 mL, 0.91 M in toluene, 1.1 eq. 15.1 mmol) was added and stirred for 10 minutes. A pre-cooled ( $-78^{\circ}\text{C}$ ) solution of N- $\alpha$ -cyclopentylacetyl-4S-benzyloxazolidinone **1** (3.94 g, 13.7 mmol) in THF (40 mL) was added and stirred for 30 minutes and followed by a pre-cooled ( $-78^{\circ}\text{C}$ ) solution of Trisyl azide (5.09 g, 16.45 mmol, 1.2 eq) in THF (40 mL). After 5 minutes the reaction was quenched with glacial acetic acid (3.65 mL) and warmed to room temperature. The mixture was evaporated to  $\sim 20$  mL under reduced pressure, diluted with brine (300 mL) and extracted with DCM (3  $\times$  300 mL). The combined organics were washed with 10%  $\text{NaHCO}_3$  aq, dried over  $\text{MgSO}_4$ , filtered, evaporated and purified by chromatography (silica gel, 60-100% DCM in hexanes) to give 3.81 g (80 %) of a clear oil:  $[\alpha]_{\text{D}}^{20} = +84.0^{\circ}$  (c 1,  $\text{CDCl}_3$ ); IR (film) 2957, 2870, 2105, 1781, 1701, 1455, 1387, 1211, 1109, 702  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.2-7.4 (m, 5H), 4.99 (d,  $J = 8.7$ , 1H), 4.70 (m, 1H), 4.24, (M, 2H), 3.32 (dd,  $J = 3.3, 13.6$ , 1H), 2.87 (dd,  $J = 9.4, 13.5$ , 1H), 2.47 (m, 1H), 1.8-1.9 (m, 1H), 1.5-1.8 (m, 6H), 1.25-1.33 (m, 2H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  170.4, 152.9, 134.7, 129.4, 127.4, 66.4, 63.2, 55.4, 41.3, 37.5, 29.2, 28.8, 25.3, 25.1; HRMS ( $\text{CI}^+$ ,  $\text{NH}_3$ ) calc'd for  $\text{C}_{17}\text{H}_{20}\text{N}_4\text{O}_3$ : 346.1879, found 346.1879.

### 2S-azido- $\alpha$ -cyclopentylacetic acid (3)

To an ice cold solution of the oxazolidinone **2** (3.74 g, 11.4 mmol) in THF/ $\text{H}_2\text{O}$  (3/1, 120 mL) was added solid  $\text{LiOH}\cdot\text{H}_2\text{O}$  (0.955 g, 22.8 mmol, 2 eq). After stirring for 1 hour at  $0^{\circ}\text{C}$ ,  $\text{NaHCO}_3$  aq. (0.5 M, 120 mL) was added and the THF was evaporated under reduced pressure. The aqueous mixture was washed with DCM (4  $\times$  100 mL), acidified to pH 2 with 3M  $\text{HCl}$  and extracted with  $\text{EtOAc}$  (3  $\times$  150 mL). The combined  $\text{EtOAc}$  layers were dried over  $\text{Na}_2\text{SO}_4$ , filtered and

evaporated to give 1.85 g (87 %) of a clear oil:  $[\alpha]^{20}_D = -38.4^\circ$  (c 0.5,  $\text{CDCl}_3$ ); IR (film) 2300-3500 br, 2953, 2103, 1717, 1233, 646, 631, 619  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  10.1 (br s, 1H), 3.73 (d,  $J = 7.9$ , 1H), 2.39 (m, 1H), 1.74-1.9 (m, 2H), 1.54-1.73 (m, 4H), 1.4-1.5 (m, 2H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  176.5, 65.7, 41.3, 29.3, 28.8, 25.3, 25.1; HRMS ( $\text{CI}^+$ ,  $\text{NH}_3$ ) calc'd for  $\text{C}_7\text{H}_{11}\text{N}_3\text{O}_2$ : 187.1195, found 187.1189.

#### L- $\alpha$ -cyclopentylsarcosine (4)

To a solution of the azide 3 (1.29 g, 7.6 mmol) in 1,2-dichloroethane (20 mL) at room temperature was added a solution of bromodimethylborane (1.34 g, 11.1 mmol, 1.46 eq. in 35 mL 1,2 dichloroethane) dropwise over 1.5 hours. After stirring for 1 hour the reaction, EtOH (652  $\mu\text{L}$ , 11.1 mmol, 1.46 eq.) was added, stirred for an additional 20 minutes and concentrated to ~20 mL under reduced pressure. This suspension was triturated with DCM (100 mL) and filtered to give 1.66 g (92 %) of an off white solid after drying under vacuum:  $[\alpha]^{20}_D = +20.3^\circ$  (c 1, MeOH); IR (film) 2300-3250 br, 2955, 2350, 1736, 1557, 1460, 1208  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  3.93 (d,  $J = 6.4$ , 1H), 2.74 (s, 3H), 2.38 (m, 1H), 1.75-1.93 (m, 2H), 1.53-1.73 (m, 5H), 1.39-1.5 (m, 1H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  170.6, 66.1, 41.6, 33.2, 30.2, 29.2, 26, 25.9; HRMS ( $\text{CI}^+$ ,  $\text{NH}_3$ ) calc'd for  $\text{C}_8\text{H}_{15}\text{NO}_2$ : 158.1181, found 158.1185.

#### 9-fluorenylmethyloxycarbonyl-L- $\alpha$ -cyclopentylsarcosine (Fmoc-CpSar-OH) (5)

To a solution of the aminoacid 4 (184 mg, 773  $\mu\text{mol}$ ) in  $\text{H}_2\text{O}$ /dioxane (1/1, 20 mL), solid  $\text{Na}_2\text{CO}_3$  (287 mg, 2.7 mmol, 3.5 eq) and 9-fluorenylmethylchloroformate (300 mg, 1.16 mmol, 1.5 eq.) were added. After stirring overnight at room temperature, more  $\text{Na}_2\text{CO}_3$  (100 mg) was added and the reaction was complete after stirring for 1 hour. The reaction mixture was

diluted with H<sub>2</sub>O (30 mL), extracted with EtOAc (2 x 30 mL), acidified to pH 2 with 3M HCl and extracted with EtOAc (3 x 30 mL). The combined organics were washed with brine (30 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated to give 190 mg (95 %) of a white solid:  $[\alpha]^{20}_D = -45^\circ$  (c 1, CDCl<sub>3</sub>); IR (film) 2250-3400 br, 2953, 1740, 1701, 1451, 1402, 1319, 1138, 758, 741 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>), 2 rotamers,  $\delta$  7.77-7.73 (m, 4H), 7.5-7.65 (m, 4H), 7.24-7.43 (m, 8H), 4.41-4.59 (m, 6H), 4.2-4.3 (m, 2H), 4.11-4.17 (m, 1H), 2.91, 2.89 (2s, 6H), 2.39, 2.23 (2m, 2H), 1.94, 1.83 (2m, 2H), 1.35-1.74 (m, 12H), 1.25, 1.01 (2m, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>), 2 rotamers,  $\delta$  176.4, 176.3, 157.3, 156.2, 144.1, 144.0, 143.9, 143.9, 143.8, 141.5, 141.4, 141.4, 127.8, 127.7, 127.1, 125.0, 124.9, 120.0, 120.0, 67.9, 67.6, 63.4, 63.0, 47.4, 39.1, 39.0, 31.2, 31.0, 30.6, 29.8, 29.7, 25.6, 25.5, 24.9, 24.8; HRMS (CI+, NH<sub>3</sub>) calc'd for C<sub>23</sub>H<sub>25</sub>NO<sub>4</sub>: 380.1862, found 380.1866.

**N-tButyloxycarbonyl-(4R)-4-[(E)-2-butenyl]-4,N-dimethyl-L-threonine allyl ester (Boc-MeBmt-OAll) (6)**

To a solution of Boc-MeBmt-OH (97 mg, 322  $\mu$ mol) in EtOH/H<sub>2</sub>O (6/1, 3.5 mL), Cs<sub>2</sub>CO<sub>3</sub> (110 mg, 338  $\mu$ mol, 1.05 eq) was added, stirred for 30 minutes, evaporated and azeotroped with benzene (3 x 5 mL). The cesium salt was dissolved in DMF (1 mL) and allyl bromide (33.4  $\mu$ L, 386  $\mu$ mol, 1.2 eq) was added via syringe and the reaction was stirred overnight at room temperature. The reaction mixture was separated between H<sub>2</sub>O and diethyl ether (30 mL each), washed with H<sub>2</sub>O (30 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, evaporated and purified by chromatography (silica gel, 10-25% EtOAc in hexanes) to give 107 mg (97 %) of a clear oil:  $[\alpha]^{20}_D +0.7^\circ$  (c 1, CDCl<sub>3</sub>); IR (film) 3478 br, 2975, 2934, 1750, 1648, 1482, 1451, 1393, 1368, 1323, 1252, 1152, 968, 934, cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  5.93 (m, 1H), 5.4-5.53 (m, 2H), 5.35 (d, J = 17.2, 1H), 5.25 (d, J = 10.4, 1H), 4.5-4.85 (m, 3H), 3.75-4.0 (m, 2H), 2.99, 2.95 (2s, 3H), 2.28-2.46 (m, 1H), 1.88-2.03

(m, 1H), 1.67, (d,  $J = 5.0$ , 3H), 1.48, 1.45 (2s, 9H), 0.87 (d,  $J = 6.7$ , 3H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  170.3, 157.2, 131.7, 129.1, 126.9, 118.3, 80.5, 75.5, 65.7, 63.3, 36.1, 35.8, 28.2, 17.9, 15.6; HRMS ( $\text{CI}^+$ ,  $\text{NH}_3$ ) calc'd for  $\text{C}_{18}\text{H}_{31}\text{NO}_5$ : 342.2280, found 342.2264.

#### HNMeBmt-OAll (7)

To a solution of Boc-MeBmt-OAll 6 (76.6 mg, 0.22 mmol) in DCM (1 mL) at  $0^\circ\text{C}$ , trifluoroacetic acid (0.5 mL) was added dropwise. After stirring for 2 hours, the reaction was quenched into 10%  $\text{NaHCO}_3$  aq. (30 mL), diluted with  $\text{H}_2\text{O}$  (10 mL) and the pH was adjusted to 9.5 with 1N NaOH. This solution was extracted with EtOAc (4 x 40 mL) and the combined organics were dried over  $\text{Na}_2\text{SO}_4$ , filtered and evaporated to give 50.2 mg (90 %) of a crude oil.

#### Fmoc-CpSar-MeBmt-OAll (8)

To a solution of acid 5 (19 mg, 50  $\mu\text{mol}$ , 0.97 eq) and the crude amine 7 (12.5 mg, 52  $\mu\text{mol}$ ) in DCM (300  $\mu\text{L}$ ), diisopropylethylamine (30  $\mu\text{L}$ ) was added followed by PyBrop (29 mg, 62.2  $\mu\text{mol}$ , 1.2 eq) and the reaction was stirred overnight under nitrogen. The reaction mixture was purified by chromatography (silica, 10-20% EtOAc in hexanes) to give 10.5 mg (35 %) of an oil: IR (film)  $\nu$   $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ), multiple rotamers,  $\delta$  7.2-7.8 (m, 8H), 5.83-6 (m, 1H), 5.2-5.5 (m, 4H), 4.8-5.0 (m, 1H), 4.53-4.75 (m, 3H), 4.4-4.54 (m, 1H), 4.17-4.27 (m, 1H), 3.85-4.15 (m, 1.5H), 3.80 (d,  $J = 10.8$ , 0.5H), 3.15, 2.84, 2.67, 2.25 (4s, 6H), 2.57-2.67 (m, 0.5H), 2.26-2.4 (m, 1.5H), 1.73-2 (m, 2H), 1.4-1.7 (m, 7H), 1.15-1.35 (m, 3H), 0.72, 0.81, 0.96 (3d,  $J = 6.8$ , 3H), 0.5, 0.22 (m, 1H); LRMS ( $\text{FAB}^+$ , NaI) calc'd for  $\text{C}_{36}\text{H}_{46}\text{N}_2\text{O}_6$ : 602, found 603, 625 ( $\text{M}+\text{H}$ ,  $\text{M}+\text{Na}$ ).

**Fmoc-CpSar-MeBmt-OH (9)**

Allyl ester 8 (8.5 mg, 14.1  $\mu\text{mol}$ ) and 3,3-dimethyl-1,5-cyclohexanedione (13.9 mg, 99  $\mu\text{mol}$ , 5 eq) were dissolved in THF (1 mL). A crystal of tetrakis-triphenylphosphine palladium was added and the reaction was stirred under nitrogen at room temperature for 2 hours. The reaction mixture was evaporated under nitrogen and purified by repeated chromatography (silica gel, 0 to 1% HOAc in 50% EtOAc/Hexanes to 1%HOAc in EtOAc) to give 4.3 mg (54 %) of an oil:  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ), multiple rotamers,  $\delta$  7.27-7.8 (m, 8H), 5.3-5.55 (m, 2H), 3.8-4.9 (m, 6.5H), 3.79 (d,  $J = 10.8$ , 0.5H), 3.15, 2.84, 2.67, 2.25 (4s, 6H), 2.5-2.67 (m, 0.5H), 2.25-2.4 (m, 1.5H), 1.35-2 (m, 7.5H), 1-1.35 (m, 6.5H), 0.72, 0.81, 0.96 (3d,  $J=6.8$ , 3H); LRMS (FAB+, NaI) calc'd for  $\text{C}_{33}\text{H}_{42}\text{N}_2\text{O}_6$ : 562, found 585 (M+Na).

**Fmoc-CpSar-MeBmt-Abu-Sar-MeLeu-Val-MeLeu-Ala-D-Ala-MeLeu-Meleu-valinol ester (10)**

To a solution of acid 9 (4.2 mg, 7.5  $\mu\text{mol}$ ) and amine (from deprotection of 4, chapter 4 part 1) (8.42 mg,  $\mu\text{mol}$ , 1.0 eq.) and lutidine (10  $\mu\text{L}$ ) in DCM (200  $\mu\text{L}$ ), PyAop (5.7 mg,  $\mu\text{mol}$ , 1.46 eq) was added and the reaction was stirred overnight under nitrogen. The mixture was purified by chromatography (silica gel, 0-20% acetone in EtOAc) to give 12.0 mg (99 %) of an oil:  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ) many rotamers, possible mixture of diastereomers, fingerprint spectra in appendix 1. LRMS (FAB+, NaI) calc'd for  $\text{C}_{87}\text{H}_{140}\text{N}_{12}\text{O}_{16}$ : 1608, found 1609, 1631 (M+H, M+Na).

**HNMe-CpSar-MeBmt-Abu-Sar-MeLeu-Val-MeLeu-Ala-D-Ala-MeLeu-Meleu-OH (11)**

The protected undcapeptide 10 (12 mg, 7.45  $\mu\text{mol}$ ), DBU (12  $\mu\text{L}$ ) and LiBr (9 mg) were dissolved in THF/ $\text{H}_2\text{O}$  (10/1, 330  $\mu\text{L}$ ) and stirred for 6 hours at room



temperature. More DBU (12  $\mu$ L) and LiBr (9 mg) were added and the reaction was stirred overnight. After evaporation of the THF under nitrogen, MeOH (500  $\mu$ L) and a drop of HOAc were added and the solution was filtered through a LH-20 column (6 cm x 1 cm). Product containing fractions were evaporated, dissolved in phosphate buffer (pH 7) and extracted with DCM (4 x 15 mL). The combined organics were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated to give 5.5 mg (59 %) of a glassy solid: LRMS (FAB+) calc'd for C<sub>64</sub>H<sub>115</sub>N<sub>11</sub>O<sub>13</sub>: 1245, found 1246 (M+H).

### CpSar11-CsA (12)

A solution of the deprotected peptide 11 (5.5 mg, 4.4  $\mu$ mol), PyAop (23 mg, 44  $\mu$ mol, 10 eq) and 2,6-lutidine (23  $\mu$ l) in DCM (10 mL) was stirred for 48 h at RT. The reaction mixture was evaporated and the residue dissolved in MeCN and purified by reverse phase HPLC (Beckman ODS ultrasphere 5  $\mu$  10 mm x 25 cm, 0.1% TFA/MeCN 50:50  $\rightarrow$  10:90 in 25 min., 70°C) to afford the pure cyclic peptide (2.8 mg, 52 %) as a white solid: R<sub>f</sub> 0.3 (EtOAc); [ $\alpha$ ]<sub>D</sub><sup>20</sup> -205° (c 0.1, CHCl<sub>3</sub>); IR (film) 3050-3580 br, 3320, 2957, 2850, 1636, 1558, 1506, 1456, 1412, 1098 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  = 0.71 (d, J = 6.0 Hz, 3H, CH<sub>3</sub>-C(4<sup>1</sup>)), 0.80-1.10 (m, 33H, CH<sub>3</sub>-C(3<sup>2</sup>), 2CH<sub>3</sub>-C(4<sup>4</sup>), 2CH<sub>3</sub>-C(3<sup>5</sup>), 2CH<sub>3</sub>-C(4<sup>6</sup>), 2CH<sub>3</sub>-C(4<sup>9</sup>), 2CH<sub>3</sub>-C(4<sup>10</sup>)), 1.25 (d, J = 6.0 Hz, 3H, CH<sub>3</sub>-C(2<sup>8</sup>)), 1.35 (d, J = 7.2 Hz, 3H, CH<sub>3</sub>-C(2<sup>7</sup>)), 1.10-1.80, 1.90-2.20 (m, 25H, H-C(4<sup>1</sup>), H-C(5<sup>1</sup>), 2H-C(3<sup>2</sup>), 2H-C(3<sup>4</sup>), H-C(4<sup>4</sup>), 2H-C(3<sup>6</sup>), H-C(4<sup>6</sup>), 2H-C(3<sup>9</sup>), H-C(4<sup>9</sup>), 2H-C(3<sup>10</sup>), H-C(4<sup>10</sup>), H-C(3<sup>11</sup>), 4H-C(4<sup>11</sup>), 4H-C(5<sup>11</sup>), 1.62 (m, 3H, H-C(8<sup>1</sup>)), 2.42 (m, 2H, H-C(5<sup>1</sup>), H-C(3<sup>5</sup>)), 2.68 (s, 3H, CH<sub>3</sub>-N<sup>10</sup>), 2.70 (s, 3H, CH<sub>3</sub>-N<sup>11</sup>), 3.10 (s, 3H, CH<sub>3</sub>-N<sup>4</sup>), 3.11 (s, 3H, CH<sub>3</sub>-N<sup>9</sup>), 3.26 (s, 3H, CH<sub>3</sub>-N<sup>6</sup>), 3.40 (s, 3H, CH<sub>3</sub>-N<sup>3</sup>), 3.52 (s, 3H, CH<sub>3</sub>-N<sup>1</sup>), 3.20, 4.72 (d, J = 13.9 Hz, 2H, 2H-C(2<sup>3</sup>)), 3.80 (m, 1H, H-C(3<sup>1</sup>)), 4.52 (m, 1H, H-C(2<sup>7</sup>)), 4.65 (m, 1H, H-C(2<sup>5</sup>)), 4.82 (m, 1H, H-C(2<sup>8</sup>)), 4.95-5.1 (m, 3H, H-C(2<sup>2</sup>), H-C(2<sup>6</sup>), H-C(2<sup>10</sup>)), 5.17

(d, J = 11.2 Hz, 1H, H-C(2<sup>11</sup>)), 5.33 (m, 3H, H-C(6<sup>1</sup>), H-C(7<sup>1</sup>), H-C(2<sup>4</sup>)), 5.47 (d, J = 6.2 Hz, 1H, H-C(2<sup>1</sup>)), 5.69 (dd, J = 4.3, 10.9 Hz, 1H, H-C(2<sup>9</sup>)), 7.18 (d, J = 7.9 Hz, 1H, H-N<sup>8</sup>), 7.46 (d, J = 8.5 Hz, 1H, H-N<sup>5</sup>), 7.69 (d, J = 7.5 Hz, 1H, H-N<sup>7</sup>), 7.99 (d, J = 9.8 Hz, 1H, H-N<sup>2</sup>).; LRMS (FAB+) calc'd for C<sub>64</sub>H<sub>113</sub>N<sub>11</sub>O<sub>12</sub>: 1227, found 1228 (M+H).

### **Example 3: Interaction of a Modified Cyclosporin A with a Modified Cyclophilin Induces Gene Activation Selectively in Cells Expressing the Modified Cyclophilin**

This Example shows that the modified cyclosporin A, CpSar11-CsA, interacts specifically with a modified cyclophilin, CypAgtm, to induce cyclophilin-dependent gene activation.

A modified cyclophilin having the capability to interact with CpSar11-CsA was designed based on the crystal structure of cyclophilin, CypA, and CsA. The crystal structure of the CypA-CsA complex shows that residue 11 of CsA directly contacts Cyp, binding in a deep hydrophobic pocket in the active site of cyclophilin. (See Pflugl, G., et al, *Nature* 361:91-4 (1993) and Ke, H., et al, *Structure* 2:33-44 (1994).) It was reasoned that the addition of atoms at that site should significantly reduce the binding of CpSar11-CsA to CypA, presumably through steric interaction between the side chain of CpSar11 and CypA. To select possible receptors capable of binding CpSar11-CsA, computer models of complexes were generated between CpSar11-CsA and several CypA mutants. Based on these models, three mutations were selected in residues lining the binding pockets of CypA: one to remove the offending steric interaction (phenylalanine at amino acid position thirteen to glycine (F113G)), and two others (serine at amino acid position 99 to threonine (S99T) and cysteine at amino acid position 115 to methionine (C115M)) that improved the fit between the new receptor and ligand.

To determine CpSar11-CsA's binding characteristics, both the unmodified CypA and the modified CypA (S99T, F113G, C115M) (CypAgtm) was overexpressed in *E. coli* and purified according to standard techniques. The binding constants for CpSar11-CsA for each receptor was determined with a direct fluorescence binding assay according to the

procedure described in Belshaw, P.J., Schoepfer, J.G., Lui, K-Q., Morrison, K.L. & Schreiber, S.L., *Angew Chem. Int. Ed. Engl.* 34:2129-32 (1995).

As shown in Table 1, CpSar11-CsA has little affinity for wild type CypA, yet binds CypAgtm with high affinity. Kds were determined using a direct fluorescence  
5      bidding assay as previously described in Belshaw et al., supra.

**Table I**

**Cyclophilin binding constants and NFAT-signaling inhibition for CpSar11-CsA**

10

Assay	Binding Constant	IC50 in Cellular
	Kd	NFAT-Signalling
15      CypA wild type + NFAT-SEAP	>5 M	>400 nM
CypAgtm + NFAT-SEAP	9 nM	25 nM

20

Since it is the composite surface of Cyp-CsA that binds to and thereby inhibits the phosphatase activity of Cn and as the modifications to both the receptor and ligand were expected to be buried in the complex, it was expected that these new receptor-ligand combinations would have the ability to inhibit calcineurin (Cn) and thus NFAT mediated  
25      gene activation. This hypothesis was confirmed by using a cellular assay in which NFAT-signaling was measured on a reporter gene, as described below.

30

CypA and mutants were sub-cloned from pGEX based expression vectors into pBJ5, a eukaryotic expression vector containing an N-terminal FLAG epitope tag. The signaling assay was performed as previously described in Belshaw, P.J., Spencer, D.M., Crabtree, G.R. & Schreiber, S.L., *Chemistry & Biology*, submitted (1996). Briefly 10<sup>7</sup>

Jurkat cells were electroporated with NFAT-SEAP reporter plasmid (1  $\mu$ g) alone or in combination with a Cyp expression vector (5  $\mu$ g). After 20 hours, cells were stimulated in 96 well plates with phorbol ester (PMA)(50 ng/mL) and ionomycin (1  $\mu$ M), which mimics T cell activation and receptor signaling. Varying concentrations of CpSar11-CsA or of CsA were added to the cultures. Twenty-four hours later, cells were assayed for SEAP activity. The data for each transfection are presented as percent SEAP activity relative to the signal for [CpSar11-CsA]=0. Stimulation of these cells with phorbol ester (PMA) and ionomycin, which mimics the T cell receptor signaling, resulted in activation of NFAT via Cn.

The results of this assay, shown in Figure 1, indicate that CpSar11-CsA had little or no effect on reporter gene expression at concentrations up to 400 nM in cells expressing either endogenous cyclophilins alone or coexpressing a wild type cyclophilin. Yet, in cells expressing CypAgtm, CpSar11-CsA potently inhibited NFAT signaling as shown in Figure 1 and in Table 1, above. However, results were obtained with the following modified receptor-ligand pairs: a modified cyclophilin A, CypA (S99T, F113A), referred to herein as CypAat and the modified cyclosporin A, Melle11-CsA. In fact, in this NFAT-signaling assay, it was found that although Melle11-CsA potently inhibited NFAT signaling in cells expressing CypAat, Melle11-CsA still inhibited NFAT signaling in cells transfected with the NFAT reporter gene alone (data not shown). Presumably this was due to formation of endogenous Cyp-Melle11-CsA complexes that inhibited Cn. In this assay CsA has an IC50 of 15nM in cells transfected with NFAT-SEAP alone.

As can be seen from these results, the transfected cells were made conditionally sensitive to a drug, dependent on the expression of a dominant allele of its receptor protein.

**Example 3: Other Exemplary Modified Cyclophilins and FK506 Molecules which Mediate Gene Activation by Selective Interaction with Modified Receptors**

This Example describes additional modified cyclosporin and FK506 molecules which selectively interact with a modified cyclophilin and are capable of inducing NF-AT mediated gene transcription.

Altered cyclosporin molecules unable to bind to cyclophilins by virtue of a methyl group at the 11 position of the peptide ring or in another chemical strategy, a cyclopentyl CsA, were prepared. These molecules, generically referred to as CsA<sup>t</sup> after the fact that they are unable to combine with the wild-type cyclophilin to block the activity of calcineurin, are non-toxic and not immunosuppressive in normal cells or whole animals. An engineered cyclophilin molecule binding specifically to these modified cyclosporin and FK506 molecules was prepared. This modified cyclophilin contained mutations of F113G and S99T, which create a "hole" to accommodate the methyl or pentyl group of CsA<sup>t</sup>, thus permitting binding to the altered cyclosporins. We call the altered cyclophilins Cph<sup>t</sup> since they combine only with the non-toxic cyclosporin. A schematic of the binding of the CsA<sup>t</sup>/Cph<sup>t</sup> and the CsA/Cph complexes to the active site of calcineurin is shown in Figure 2.

In parallel studies altered FK506 molecules were made that have electrophilic additions "bumps" at the C9 position of FK506 generating 9-S-methoxy-FK506 (FK506<sup>t</sup>) that does not bind to endogenous FKBP, but does bind to FKBP12F36V (FKBP<sup>t</sup>).

The affinity of the interaction between cyclosporin and the mutant cyclophilin was measured by binding of labeled protein. These were found to be about 7 nM with no detectable binding to the wildtype Cph. The half time of association and dissociation were similar for the bumped combinations and the wild type combinations. These experiments indicate that the bumped CsA should only be immunosuppressive in cells expressing the compensatory mutant Cph<sup>t</sup>. In parallel studies the binding of the 9-S-methoxy-FK506 to FKBP12 F36V was found to be 5 nM by Scatchard analysis of the binding of radiolabeled protein to pure FKBP<sup>t</sup>. On the other hand, FK506 binds to FKBP with a K<sub>d</sub> of 0.3 nM in the same assay indicating that some loss of affinity is related to the "bump-hole" combination, which could be optimized by introducing specific mutations and selecting for FKBP molecules having a higher affinity for the bumped FK506.

As illustrated in Figure 3, the bumped cyclosporin does not effect signaling by the antigen receptor. This was shown by incubating human peripheral mononuclear cells from blood donors with anti CD3 and CD28 in the presence of CsA and CsAt- from 0 to 1000 nM. At 48 hours cells were assayed for DNA synthesis by  $^3\text{H}$  thymidine incorporation.

5

To determine if the Cph<sup>t-</sup> would confer selective sensitivity to CsAt- to cells expressing it, Jurkat cells were transfected with the cyclophilin containing the compensatory mutation and tested for NF-AT-dependent transcription. As shown in Figure 4, CsA<sup>t-</sup> produced a complete blockage of signaling in cells transfected with Cph<sup>t-</sup> but not Cph. Similarly, the bumped FK506 (9-methoxy FK506) has no effect on signaling unless cells are transfected with a FKBP containing the compensatory mutation that allows binding of the bumped FK506.

10

**Example 4: Transgenic Mice Sensitive to the Immunosuppressive and Tolerogenic Effects of Cyclosporin A and/or FK506, but Resistant to its Toxic Effects**

One prediction of the theory that calcineurin is the sole target of the immunosuppressive as well as the toxic side effects of both the cyclosporin A/CpH and FK506/FKBP complexes is that if the formation of these complexes could be directed solely to lymphoid tissue they would be non-toxic for other organs. To do this transgenic mice that express Cph<sup>t-</sup> only in  
5 T cells and B cells. For expression in T cells, the gene encoding the modified cyclophilin can be operably linked to the CD4 promoter/enhancer. This will result in expression in all T cells from the double positive stage in the thymus to mature peripheral lymphocytes. For expression in B cells, the gene encoding the cyclophilin molecule can be operably linked to the immunoglobulin Eu promoter/enhancer. Both of these promoters have been  
10 used frequently in the art to obtain T or B cell specific expression, respectively. The transgenic mice can be prepared according to methods known in the art.

To test the animals for sensitivity to CsA<sup>t-</sup>, peripheral leukocytes can be isolated from these animals and the ability of the transgenic lymphocytes to proliferate in response to irradiated murine fibroblasts from a strain of mouse having an MHC background that  
15 gives maximum stimulation with the FYB strain can be tested.

If, as predicted, lymphocyte proliferation is completely inhibited by CsA<sup>t-</sup>, it can be determined if CsA<sup>t-</sup> can suppress rejection of tissue grafts. This can be done, e.g., by comparing the ability of CsA and CsA<sup>t-</sup> to block the immune responses to transplanted skin graphs. Groups of 20 mice can be treated with doses of each drug ranging from those  
20 required to inhibit 25 to 99% of calcineurin activity assayed by NF-AT dephosphorylation assay using extracts from peripheral blood lymphocytes. This is probably be in the range of 1 mg/kg/day to 10 mg/kg/day. No other immunosuppressive agent should be given and graft rejection can be tested at intervals after initiation of treatment and grafting. Toxic side effects can be assessed by observation for the CNS toxicity which is manifested as  
25 ataxia and excessive activity. Renal toxic effects can be assessed by determining the concentration of BUN and creatinine. It is expected that this will show graft survival with fewer toxic side effects.

To test for the ability of CsA<sup>t-</sup> to prevent the development of self tolerance one can treat the pregnant Cph<sup>t-</sup> mice with doses of CsA<sup>t-</sup> that lead to complete suppression of  
30 graft rejection and determine if the newborn animals have undergone positive selection as judged by the development of single positive thymocytes and normal numbers of peripheral lymphocytes. Negative selection will be tested by several criteria. The most

stringent is the development of autoimmune phenomena after withdrawal of CsA<sup>t-</sup>. If, as predicted, complete suppression of negative selection occurs, it is expected that the animals respond to their own tissue when the signaling pathway is restored by the terminating treatment with the drug. This will be accessed by examination of tissues such as the kidney, pancreas and others for inflammatory infiltrates, by the development of clones of autoreactive T cells judged by the failure of super antigen reactive cells to be deleted, and by the development of auto antibodies to classic self antigens such as DNA, and ribonuclear proteins.

To show that CsA<sup>t-</sup> can suppress graft rejection, skin grafts from non-compatible mice can be implanted into Cph<sup>t-</sup> transgenic mice, which can then be treated with CsA<sup>t-</sup> and rejection of the graft will be assessed using well defined criteria. As previously shown for cyclosporin A, it is expected that CsA<sup>t-</sup> will suppress rejection. To determine if long term total blockage of the antigen receptor signaling pathway will lead to tolerance to the transplanted tissue the animals can be treated for various lengths of time after transplantation with CsA<sup>t-</sup>. It will then be tested if withdrawal of CsA<sup>t-</sup> will allow continued suppression of graft rejection implying that the animals were made tolerant to the transplanted tissue.

To show that CsA<sup>t-</sup> can prevent graft-vs-host disease, bone marrow can be taken from Cph<sup>t-</sup> mice and transferred to irradiated MHC-mismatched mice and the mice observed for the development of graft-vs-host disease. Animals can be treated with CsA<sup>t-</sup> for 1, 2, 4, or 8 weeks after transplantation with the dose necessary to inhibit: a) 50% or b) 99% of calcineurin activity in lymphocytes. In other experiment, purified stem cells from the Cph<sup>t-</sup> mice can be used to do the transplantation.

The transgenic Cph<sup>t-</sup> mice can also be used to confirm that complete blockage of the calcineurin/NF-AT pathway will prevent the development of autoimmune diabetes in NOD mice.

Cph<sup>t-</sup> transgenic mice can be made either directly in NOD mice or in the FYB strain to facilitate breeding to the NOD mice as described above. Transgenic mice can be crossed with the NOD mice and followed for the expression of Cph<sup>t-</sup> at levels approximating those of the endogenous Cph A gene. Once backcrossing is complete, the animals will be tested for the development of diabetes.



To test the effects of CsA<sup>t-</sup> on the development of diabetes in the NOD mice, these can be administered CsA<sup>t-</sup> at specific times during fetal life (p.c. day 14 to 21), after birth, 0- 3 weeks, 4-8 weeks, 4-12 weeks, and 4- 16 weeks. It is expected, based at least in part on previous results obtained, that CsA<sup>t-</sup> will suppress the development of autoimmune diabetes. Animals will be monitored for the symptoms of diabetes as known in the art and including: 1) determining the presence of auto antibodies to GAD, HSP70, CPH; 2) T cell activation and 3) islet inflammation and lymphoid infiltration.

The transgenic mice can also be used to show that long term suppression of the calcineurin/NF-AT pathway with CsA<sup>t-</sup> can lead to tolerance and the prevention of diabetes in the absence of continued CsA<sup>t-</sup> treatment. The ability of CsA<sup>t-</sup> to induce long term tolerance and prevention of inflammation in the islets of the NOD mice can be tested by withdrawing CsA<sup>t-</sup> at various times after the initiation of treatment. The times until the development of symptoms will be measured as defined above. In addition animals can be monitored for the development of auto antibodies to GAD, CPH, and HSP70. If the animals do not develop auto antibodies and do not develop disease after ceasing immunosuppression with CsA<sup>t-</sup>, this will be indicative that the suppression of the Ca<sup>2+</sup>/calcineurin pathway can lead to the development of tolerance and address the question of the underlying mechanism.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious to one skilled in the art that certain changes and modifications may be practiced within the scope of the appended claims.

## (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 348 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (ix) FEATURE:

- (A) NAME/KEY: CDS  
 (B) LOCATION: 14..325

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```

GGAATTCCTA ATA ATG TCC GTA CAA GTA GAA ACC ATC TCC CCA GGA GAC      49
  Met Ser Val Gln Val Glu Thr Ile Ser Pro Gly Asp
    1                      5                      10

GGG CGC ACC TTC CCC AAG CGC GGC CAG ACC TGC GTG GTG CAC TAC ACC      97
Gly Arg Thr Phe Pro Lys Arg Gly Gln Thr Cys Val Val His Tyr Thr
    15                      20                      25

GGG ATG CTT GAA GAT GGA AAG AAA TTT GAT TCC TCC CGT GAC CGT AAC     145
Gly Met Leu Glu Asp Gly Lys Lys Phe Asp Ser Ser Arg Asp Arg Asn
    30                      35                      40

AAG CCC TTT AAG TTT ATG CTA GGC AAG CAG GAG GTG ATC CGA GGC TGG     193
Lys Pro Phe Lys Phe Met Leu Gly Lys Gln Glu Val Ile Arg Gly Trp
    45                      50                      55

GAA GAA GGG GTT GCC CAG ATG AGT GTG GGT CAG CGT GCC AAA CTG ACT     241
Glu Glu Gly Val Ala Gln Met Ser Val Gly Gln Arg Ala Lys Leu Thr
    65                      70                      75

ATA TCT CCA GAT TAT GCC TAT GGT GCC ACT GGG CAC CCA GGC ATC ATC     289
Ile Ser Pro Asp Tyr Ala Tyr Gly Ala Thr Gly His Pro Gly Ile Ile
    80                      85                      90

CCA CCA CAT GCC ACT CTC GTC TTC GAT GTG GAG CTT CTAAACTGG          335
Pro Pro His Ala Thr Leu Val Phe Asp Val Glu Leu
    95                      100

AATGACGGGA TCC                                                    348

```

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7943 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: both  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (ix) FEATURE:

- (A) NAME/KEY: CDS  
 (B) LOCATION: 80..7726

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```

ACGGGGCCTG AAGCGGCGGT ACCGGTGCTG GCGGCGGCAG CTGAGGCCTT GGCCGAAGCC      60

```

APV007.25

- 65 -

	GCGCGAACCT CAGGGCAAG ATG CTT GGA ACC GGA CCT GCC GCC ACC ACC																112
	Met Leu Gly Thr Gly Pro Ala Ala Ala Thr Thr																
	1 5 10																
5	GCT	GCC	ACC	ACA	TCT	AGC	AAT	GTG	AGC	GTC	CTG	CAG	CAG	TTT	GCC	AGT	160
	Ala	Ala	Thr	Thr	Ser	Ser	Asn	Val	Ser	Val	Leu	Gln	Gln	Phe	Ala	Ser	
	15 20 25																
10	GGC	CTA	AAG	AGC	CGG	AAT	GAG	GAA	ACC	AGG	GCC	AAA	GCC	GCC	AAG	GAG	208
	Gly	Leu	Lys	Ser	Arg	Asn	Glu	Glu	Thr	Arg	Ala	Lys	Ala	Ala	Lys	Glu	
	30 35 40																
15	CTC	CAG	CAC	TAT	GTC	ACC	ATG	GAA	CTC	CGA	GAG	ATG	AGT	CAA	GAG	GAG	256
	Leu	Gln	His	Tyr	Val	Thr	Met	Glu	Leu	Arg	Glu	Met	Ser	Gln	Glu	Glu	
	45 50 55																
20	TCT	ACT	CGC	TTC	TAT	GAC	CAA	CTG	AAC	CAT	CAC	ATT	TTT	GAA	TTG	GTT	304
	Ser	Thr	Arg	Phe	Tyr	Asp	Gln	Leu	Asn	His	His	Ile	Phe	Glu	Leu	Val	
	60 65 70 75																
25	TCC	AGC	TCA	GAT	GCC	AAT	GAG	AGG	AAA	GGT	GGC	ATC	TTG	GCC	ATA	GCT	352
	Ser	Ser	Ser	Asp	Ala	Asn	Glu	Arg	Lys	Gly	Gly	Ile	Leu	Ala	Ile	Ala	
	80 85 90																
30	AGC	CTC	ATA	GGA	GTG	GAA	GGT	GGG	AAT	GCC	ACC	CGA	ATT	GGC	AGA	TTT	400
	Ser	Leu	Ile	Gly	Val	Glu	Gly	Gly	Asn	Ala	Thr	Arg	Ile	Gly	Arg	Phe	
	95 100 105																
35	GCC	AAC	TAT	CTT	CGG	AAC	CTC	CTC	CCC	TCC	AAT	GAC	CCA	GTT	GTC	ATG	448
	Ala	Asn	Tyr	Leu	Arg	Asn	Leu	Leu	Pro	Ser	Asn	Asp	Pro	Val	Val	Met	
	110 115 120																
40	GAA	ATG	GCA	TCC	AAG	GCC	ATT	GGC	CGT	CTT	GCC	ATG	GCA	GGG	GAC	ACT	496
	Glu	Met	Ala	Ser	Lys	Ala	Ile	Gly	Arg	Leu	Ala	Met	Ala	Gly	Asp	Thr	
	125 130 135																
45	TTT	ACC	GCT	GAG	TAC	GTG	GAA	TTT	GAG	GTG	AAG	CGA	GCC	CTG	GAA	TGG	544
	Phe	Thr	Ala	Glu	Tyr	Val	Glu	Phe	Glu	Val	Lys	Arg	Ala	Leu	Glu	Trp	
	140 145 150 155																
50	CTG	GGT	GCT	GAC	CGC	AAT	GAG	GGC	CGG	AGA	CAT	GCA	GCT	GTC	CTG	GTT	592
	Leu	Gly	Ala	Asp	Arg	Asn	Glu	Gly	Arg	Arg	His	Ala	Ala	Val	Leu	Val	
	160 165 170																
55	CTC	CGT	GAG	CTG	GCC	ATC	AGC	GTC	CCT	ACC	TTC	TTC	TTC	CAG	CAA	GTG	640
	Leu	Arg	Glu	Leu	Ala	Ile	Ser	Val	Pro	Thr	Phe	Phe	Phe	Gln	Gln	Val	
	175 180 185																
60	CAA	CCC	TTC	TTT	GAC	AAC	ATT	TTT	GTG	GCC	GTG	TGG	GAC	CCC	AAA	CAG	688
	Gln	Pro	Phe	Phe	Asp	Asn	Ile	Phe	Val	Ala	Val	Trp	Asp	Pro	Lys	Gln	
	190 195 200																
65	GCC	ATC	CGT	GAG	GGA	GCT	GTA	GCC	GCC	CTT	CGT	GCC	TGT	CTG	ATT	CTC	736
	Ala	Ile	Arg	Glu	Gly	Ala	Val	Ala	Ala	Leu	Arg	Ala	Cys	Leu	Ile	Leu	
	205 210 215																
70	ACA	ACC	CAG	CGT	GAG	CCG	AAG	GAG	ATG	CAG	AAG	CCT	CAG	TGG	TAC	AGG	784
	Thr	Thr	Gln	Arg	Glu	Pro	Lys	Glu	Met	Gln	Lys	Pro	Gln	Trp	Tyr	Arg	
	220 225 230 235																
75	CAC	ACA	TTT	GAA	GAA	GCA	GAG	AAG	GGA	TTT	GAT	GAG	ACC	TTG	GCC	AAA	832
	His	Thr	Phe	Glu	Glu	Ala	Glu	Lys	Gly	Phe	Asp	Glu	Thr	Leu	Ala	Lys	
	240 245 250																
80	GAG	AAG	GGC	ATG	AAT	CGG	GAT	GAT	CGG	ATC	CAT	GGA	GCC	TTG	TTG	ATC	880
	Glu	Lys	Gly	Met	Asn	Arg	Asp	Asp	Arg	Ile	His	Gly	Ala	Leu	Leu	Ile	
	255 260 265																
85	CTT	AAC	GAG	CTG	GTC	CGA	ATC	AGC	AGC	ATG	GAG	GGA	GAG	CGT	CTG	AGA	928
	Leu	Asn	Glu	Leu	Val	Arg	Ile	Ser	Ser	Met	Glu	Gly	Glu	Arg	Leu	Arg	
	270 275 280																

	GAA	GAA	ATG	GAA	GAA	ATC	ACA	CAG	CAG	CAG	CTG	GTA	CAC	GAC	AAG	TAC	976
	Glu	Glu	Met	Glu	Glu	Ile	Thr	Gln	Gln	Gln	Leu	Val	His	Asp	Lys	Tyr	
5		285					290					295					
	TGC	AAA	GAT	CTC	ATG	GGC	TTC	GGA	ACA	AAA	CCT	CGT	CAC	ATT	ACC	CCC	1024
	Cys	Lys	Asp	Leu	Met	Gly	Phe	Gly	Thr	Lys	Pro	Arg	His	Ile	Thr	Pro	
	300					305					310					315	
10	TTC	ACC	AGT	TTC	CAG	GCT	GTA	CAG	CCC	CAG	CAG	TCA	AAT	GCC	TTG	GTG	1072
	Phe	Thr	Ser	Phe	Gln	Ala	Val	Gln	Pro	Gln	Gln	Ser	Asn	Ala	Leu	Val	
					320					325					330		
15	GGG	CTG	CTG	GGG	TAC	AGC	TCT	CAC	CAA	GGC	CTC	ATG	GGA	TTT	GGG	ACC	1120
	Gly	Leu	Leu	Gly	Tyr	Ser	Ser	His	Gln	Gly	Leu	Met	Gly	Phe	Gly	Thr	
				335					340					345			
20	TCC	CCC	AGT	CCA	GCT	AAG	TCC	ACC	CTG	GTG	GAG	AGC	CGG	TGT	TGC	AGA	1168
	Ser	Pro	Ser	Pro	Ala	Lys	Ser	Thr	Leu	Val	Glu	Ser	Arg	Cys	Cys	Arg	
			350					355					360				
	GAC	TTG	ATG	GAG	GAG	AAA	TTT	GAT	CAG	GTG	TGC	CAG	TGG	GTG	CTG	AAA	1216
25	Asp	Leu	Met	Glu	Glu	Lys	Phe	Asp	Gln	Val	Cys	Gln	Trp	Val	Leu	Lys	
		365					370					375					
	TGC	AGG	AAT	AGC	AAG	AAC	TCG	CTG	ATC	CAA	ATG	ACA	ATC	CTT	AAT	TTG	1264
	Cys	Arg	Asn	Ser	Lys	Asn	Ser	Leu	Ile	Gln	Met	Thr	Ile	Leu	Asn	Leu	
	380					385					390					395	
30	TTG	CCC	CGC	TTG	GCT	GCA	TTC	CGA	CCT	TCT	GCC	TTC	ACA	GAT	ACC	CAG	1312
	Leu	Pro	Arg	Leu	Ala	Ala	Phe	Arg	Pro	Ser	Ala	Phe	Thr	Asp	Thr	Gln	
					400					405					410		
35	TAT	CTC	CAA	GAT	ACC	ATG	AAC	CAT	GTC	CTA	AGC	TGT	GTC	AAG	AAG	GAG	1360
	Tyr	Leu	Gln	Asp	Thr	Met	Asn	His	Val	Leu	Ser	Cys	Val	Lys	Lys	Glu	
				415					420					425			
40	AAG	GAA	CGT	ACA	GCG	GCC	TTC	CAA	GCC	CTG	GGG	CTA	CTT	TCT	GTG	GCT	1408
	Lys	Glu	Arg	Thr	Ala	Ala	Phe	Gln	Ala	Leu	Gly	Leu	Leu	Ser	Val	Ala	
			430					435					440				
45	GTG	AGG	TCT	GAG	TTT	AAG	GTC	TAT	TTG	CCT	CGC	GTG	CTG	GAC	ATC	ATC	1456
	Val	Arg	Ser	Glu	Phe	Lys	Val	Tyr	Leu	Pro	Arg	Val	Leu	Asp	Ile	Ile	
		445					450					455					
	CGA	GCG	GCC	CTG	CCC	CCA	AAG	GAC	TTC	GCC	CAT	AAG	AGG	CAG	AAG	GCA	1504
	Arg	Ala	Ala	Leu	Pro	Pro	Lys	Asp	Phe	Ala	His	Lys	Arg	Gln	Lys	Ala	
	460					465					470					475	
50	ATG	CAG	GTG	GAC	GCC	ACA	GTC	TTC	ACT	TGC	ATC	AGC	ATG	CTG	GCT	CGA	1552
	Met	Gln	Val	Asp	Ala	Thr	Val	Phe	Thr	Cys	Ile	Ser	Met	Leu	Ala	Arg	
					480					485					490		
55	GCA	ATG	GGG	CCA	GGC	ATC	CAG	CAG	GAT	ATC	AAG	GAG	CTG	CTG	GAG	CCC	1600
	Ala	Met	Gly	Pro	Gly	Ile	Gln	Gln	Asp	Ile	Lys	Glu	Leu	Leu	Glu	Pro	
				495					500					505			
60	ATG	CTG	GCA	GTG	GGA	CTA	AGC	CCT	GCC	CTC	ACT	GCA	GTG	CTC	TAC	GAC	1648
	Met	Leu	Ala	Val	Gly	Leu	Ser	Pro	Ala	Leu	Thr	Ala	Val	Leu	Tyr	Asp	
			510					515					520				
	CTG	AGC	CGT	CAG	ATT	CCA	CAG	CTA	AAG	AAG	GAC	ATT	CAA	GAT	GGG	CTA	1696
65	Leu	Ser	Arg	Gln	Ile	Pro	Gln	Leu	Lys	Lys	Asp	Ile	Gln	Asp	Gly	Leu	
		525					530					535					
	CTG	AAA	ATG	CTG	TCC	CTG	GTC	CTT	ATG	CAC	AAA	CCC	CTT	CGC	CAC	CCA	1744
	Leu	Lys	Met	Leu	Ser	Leu	Val	Leu	Met	His	Lys	Pro	Leu	Arg	His	Pro	
	540					545					550					555	
70	GGC	ATG	CCC	AAG	GGC	CTG	GCC	CAT	CAG	CTG	GCC	TCT	CCT	GGC	CTC	ACG	1792
	Gly	Met	Pro	Lys	Gly	Leu	Ala	His	Gln	Leu	Ala	Ser	Pro	Gly	Leu	Thr	

- 67 -

570

5	ACC Thr	CTC Leu	CCT Pro	GAG Glu 575	GCC Ala	AGC Ser	GAT Asp	GTG Val	GGC Gly 580	AGC Ser	ATC Ile	ACT Thr	CTT Leu	GCC Ala 585	CTC Leu	CGA Arg	1840
	ACG Thr	CTT Leu	GGC Gly 590	AGC Ser	TTT Phe	GAA Glu	TTT Phe	GAA Glu 595	GGC Gly	CAC His	TCT Ser	CTG Leu	ACC Thr 600	CAA Gln	TTT Phe	GTT Val	1888
10	CGC Arg	CAC His 605	TGT Cys	GCG Ala	GAT Asp	CAT His	TTC Phe 610	CTG Leu	AAC Asn	AGT Ser	GAG Glu	CAC His 615	AAG Lys	GAG Glu	ATC Ile	CGC Arg	1936
15	ATG Met 620	GAG Glu	GCT Ala	GCC Ala	CGC Arg	ACC Thr 625	TGC Cys	TCC Ser	CGC Arg	CTG Leu 630	CTC Leu	ACA Thr	CCC Pro	TCC Ser	ATC Ile	CAC His 635	1984
20	CTC Leu	ATC Ile	AGT Ser	GGC Gly	CAT His 640	GCT Ala	CAT His	GTG Val	GTT Val	AGC Ser 645	CAG Gln	ACC Thr	GCA Ala	GTG Val	CAA Gln 650	GTG Val	2032
25	GTG Val	GCA Ala	GAT Asp	GTG Val 655	CTT Leu	AGC Ser	AAA Lys	CTG Leu	CTC Leu 660	GTA Val	GTT Val	GGG Gly	ATA Ile	ACA Thr 665	GAT Asp	CCT Pro	2080
30	GAC Asp	CCT Pro	GAC Asp 670	ATT Ile	CGC Arg	TAC Tyr	TGT Cys	GTC Val 675	TTG Leu	GCG Ala	TCC Ser	CTG Leu	GAC Asp 680	GAG Glu	CGC Arg	TTT Phe	2128
	GAT Asp	GCA Ala 685	CAC His	CTG Leu	GCC Ala	CAG Gln	GCG Ala 690	GAG Glu	AAC Asn	TTG Leu	CAG Gln	GCC Ala 695	TTG Leu	TIT Phe	GTG Val	GCT Ala	2176
35	CTG Leu 700	AAT Asn	GAC Asp	CAG Gln	GTG Val	TTT Phe 705	GAG Glu	ATC Ile	CGG Arg	GAG Glu 710	CTG Leu	GCC Ala	ATC Ile	TGC Cys	ACT Thr	GTG Val 715	2224
40	GGC Gly	CGA Arg	CTC Leu	AGT Ser	AGC Ser 720	ATG Met	AAC Asn	CCT Pro	GCC Ala 725	TTT Phe	GTC Val	ATG Met	CCT Pro	TTC Phe 730	CTG Leu	CGC Arg	2272
45	AAG Lys	ATG Met	CTC Leu 735	ATC Ile	CAG Gln	ATT Ile	TTG Leu	ACA Thr 740	GAG Glu 740	TTG Leu	GAG Glu	CAC His	AGT Ser 745	GGG Gly 745	ATT Ile	GGA Gly	2320
	AGA Arg	ATC Ile	AAA Lys 750	GAG Glu	CAG Gln	AGT Ser	GCC Ala 755	CGC Arg 755	ATG Met	CTG Leu	GGG Gly	CAC His	CTG Leu 760	GTC Val	TCC Ser	AAT Asn	2368
50	GCC Ala 765	CCC Pro	CGA Arg	CTC Leu	ATC Ile	CGC Arg 770	CCC Pro	TAC Tyr	ATG Met	GAG Glu	CCT Pro	ATT Ile 775	CTG Leu	AAG Lys	GCA Ala	TTA Leu	2416
55	ATT Ile 780	TTG Leu	AAA Lys	CTG Leu	AAA Lys	GAT Asp 785	CCA Pro	GAC Asp	CCT Pro	GAT Asp 790	CCA Pro	AAC Asn	CCA Pro	GGT Gly	GTG Val	ATC Ile 795	2464
60	AAT Asn	AAT Asn	GTC Val	CTG Leu 800	GCA Ala	ACA Thr	ATA Ile	GGA Gly	GAA Glu 805	TTG Leu	GCA Ala	CAG Gln	GTT Val	AGT Ser	GGC Gly 810	CTG Leu	2512
65	GAA Glu	ATG Met	AGG Arg 815	AAA Lys	TGG Trp	GTT Val	GAT Asp	GAA Glu 820	CTT Leu	TTT Phe	ATT Ile	ATC Ile	ATC Ile 825	ATG Met	GAC Asp	ATG Met	2560
70	CTC Leu	CAG Gln 830	GAT Asp	TCC Ser	TCT Ser	TTG Leu	TTG Leu	GCC Ala 835	AAA Lys	AGG Arg	CAG Gln	GTG Val	GCT Ala 840	CTG Leu	TGG Trp	ACC Thr	2608
	CTG	GGA	CAG	TTG	GTG	GCC	AGC	ACT	GGC	TAT	GTA	GTA	GAG	CCC	TAC	AGG	2656

APV007.25

- 68 -

	Leu	Gly	Gln	Leu	Val	Ala	Ser	Thr	Gly	Tyr	Val	Val	Glu	Pro	Tyr	Arg	
	845						850					855					
5	AAG	TAC	CCT	ACT	TTG	CTT	GAG	GTG	CTA	CTG	AAT	TTT	CTG	AAG	ACT	GAG	2704
	Lys	Tyr	Pro	Thr	Leu	Leu	Glu	Val	Leu	Leu	Asn	Phe	Leu	Lys	Thr	Glu	
	860					865					870					875	
10	CAG	AAC	CAG	GGT	ACA	CGC	AGA	GAG	GCC	ATC	CGT	GTG	TTA	GGG	CTT	TTA	2752
	Gln	Asn	Gln	Gly	Thr	Arg	Arg	Glu	Ala	Ile	Arg	Val	Leu	Gly	Leu	Leu	
					880					885					890		
15	GGG	GCT	TTG	GAT	CCT	TAC	AAG	CAC	AAA	GTG	AAC	ATT	GGC	ATG	ATA	GAC	2800
	Gly	Ala	Leu	Asp	Pro	Tyr	Lys	His	Lys	Val	Asn	Ile	Gly	Met	Ile	Asp	
				895					900					905			
20	CAG	TCC	CGG	GAT	GCC	TCT	GCT	GTC	AGC	CTG	TCA	GAA	TCC	AAG	TCA	AGT	2848
	Gln	Ser	Arg	Asp	Ala	Ser	Ala	Val	Ser	Leu	Ser	Glu	Ser	Lys	Ser	Ser	
			910					915					920				
25	CAG	GAT	TCC	TCT	GAC	TAT	AGC	ACT	AGT	GAA	ATG	CTG	GTC	AAC	ATG	GGA	2896
	Gln	Asp	Ser	Ser	Asp	Tyr	Ser	Thr	Ser	Glu	Met	Leu	Val	Asn	Met	Gly	
		925					930					935					
30	AAC	TTG	CCT	CTG	GAT	GAG	TTC	TAC	CCA	GCT	GTG	TCC	ATG	GTG	GCC	CTG	2944
	Asn	Leu	Pro	Leu	Asp	Glu	Phe	Tyr	Pro	Ala	Val	Ser	Met	Val	Ala	Leu	
	940					945					950					955	
35	ATG	CGG	ATC	TTC	CGA	GAC	CAG	TCA	CTC	TCT	CAT	CAT	CAC	ACC	ATG	GTT	2992
	Met	Arg	Ile	Phe	Arg	Asp	Gln	Ser	Leu	Ser	His	His	His	Thr	Met	Val	
					960					965					970		
40	GTC	CAG	GCC	ATC	ACC	TTC	ATC	TTC	AAG	TCC	CTG	GGA	CTC	AAA	TGT	GTG	3040
	Val	Gln	Ala	Ile	Thr	Phe	Ile	Phe	Lys	Ser	Leu	Gly	Leu	Lys	Cys	Val	
				975					980					985			
45	CAG	TTC	CTG	CCC	CAG	GTC	ATG	CCC	ACG	TTC	CTT	AAT	GTC	ATT	CGA	GTC	3088
	Gln	Phe	Leu	Pro	Gln	Val	Met	Pro	Thr	Phe	Leu	Asn	Val	Ile	Arg	Val	
			990					995					1000				
50	TGT	GAT	GGG	GCC	ATC	CGG	GAA	TTT	TTG	TTC	CAG	CAG	CTG	GGA	ATG	TTG	3136
	Cys	Asp	Gly	Ala	Ile	Arg	Glu	Phe	Leu	Phe	Gln	Gln	Leu	Gly	Met	Leu	
		1005					1010					1015					
55	GTG	TCC	TTT	GTG	AAG	AGC	CAC	ATC	AGA	CCT	TAT	ATG	GAT	GAA	ATA	GTC	3184
	Val	Ser	Phe	Val	Lys	Ser	His	Ile	Arg	Pro	Tyr	Met	Asp	Glu	Ile	Val	
		1020				1025					1030					1035	
60	ACC	CTC	ATG	AGA	GAA	TTC	TGG	GTC	ATG	AAC	ACC	TCA	ATT	CAG	AGC	ACG	3232
	Thr	Leu	Met	Arg	Glu	Phe	Trp	Val	Met	Asn	Thr	Ser	Ile	Gln	Ser	Thr	
					1040					1045					1050		
65	ATC	ATT	CTT	CTC	ATT	GAG	CAA	ATT	GTG	GTA	GCT	CTT	GGG	GGT	GAA	TTT	3280
	Ile	Ile	Leu	Leu	Ile	Glu	Gln	Ile	Val	Val	Ala	Leu	Gly	Gly	Glu	Phe	
				1055					1060					1065			
70	AAG	CTC	TAC	CTG	CCC	CAG	CTG	ATC	CCA	CAC	ATG	CTG	CGT	GTC	TTC	ATG	3328
	Lys	Leu	Tyr	Leu	Pro	Gln	Leu	Ile	Pro	His	Met	Leu	Arg	Val	Phe	Met	
			1070					1075					1080				
75	CAT	GAC	AAC	AGC	CCA	GGC	CGC	ATT	GTC	TCT	ATC	AAG	TTA	CTG	GCT	GCA	3376
	His	Asp	Asn	Ser	Pro	Gly	Arg	Ile	Val	Ser	Ile	Lys	Leu	Leu	Ala	Ala	
		1085					1090					1095					
80	ATC	CAG	CTG	TTT	GGC	GCC	AAC	CTG	GAT	GAC	TAC	CTG	CAT	TTA	CTG	CTG	3424
	Ile	Gln	Leu	Phe	Gly	Ala	Asn	Leu	Asp	Asp	Tyr	Leu	His	Leu	Leu	Leu	
		1100				1105					1110					1115	
85	CCT	CCT	ATT	GTT	AAG	TTG	TTT	GAT	GCC	CCT	GAA	GCT	CCA	CTG	CCA	TCT	3472
	Pro	Pro	Ile	Val	Lys	Leu	Phe	Asp	Ala	Pro	Glu	Ala	Pro	Leu	Pro	Ser	
					1120					1125						1130	

APV007.25

- 69 -

	CGA AAG GCA GCG CTA GAG ACT GTG GAC CGC CTG ACG GAG TCC CTG GAT	3520
	Arg Lys Ala Ala Leu Glu Thr Val Asp Arg Leu Thr Glu Ser Leu Asp	
	1135 1140 1145	
5	TTC ACT GAC TAT GCC TCC CGG ATC ATT CAC CCT ATT GTT CGA ACA CTG	3568
	Phe Thr Asp Tyr Ala Ser Arg Ile Ile His Pro Ile Val Arg Thr Leu	
	1150 1155 1160	
10	GAC CAG AGC CCA GAA CTG CGC TCC ACA GCC ATG GAC ACG CTG TCT TCA	3616
	Asp Gln Ser Pro Glu Leu Arg Ser Thr Ala Met Asp Thr Leu Ser Ser	
	1165 1170 1175	
15	CTT GTT TTT CAG CTG GGG AAG AAG TAC CAA ATT TTC ATT CCA ATG GTG	3664
	Leu Val Phe Gln Leu Gly Lys Lys Tyr Gln Ile Phe Ile Pro Met Val	
	1180 1185 1190 1195	
20	AAT AAA GTT CTG GTG CGA CAC CGA ATC AAT CAT CAG CGC TAT GAT GTG	3712
	Asn Lys Val Leu Val Arg His Arg Ile Asn His Gln Arg Tyr Asp Val	
	1200 1205 1210	
25	CTC ATC TGC AGA ATT GTC AAG GGA TAC ACA CTT GCT GAT GAA GAG GAG	3760
	Leu Ile Cys Arg Ile Val Lys Gly Tyr Thr Leu Ala Asp Glu Glu Glu	
	1215 1220 1225	
30	GAT CCT TTG ATT TAC CAG CAT CGG ATG CTT AGG AGT GGC CAA GGG GAT	3808
	Asp Pro Leu Ile Tyr Gln His Arg Met Leu Arg Ser Gly Gln Gly Asp	
	1230 1235 1240	
35	GCA TTG GCT AGT GGA CCA GTG GAA ACA GGA CCC ATG AAG AAA CTG CAC	3856
	Ala Leu Ala Ser Gly Pro Val Glu Thr Gly Pro Met Lys Lys Leu His	
	1245 1250 1255	
40	GTC AGC ACC ATC AAC CTC CAA AAG GCC TGG GGC GCT GCC AGG AGG GTC	3904
	Val Ser Thr Ile Asn Leu Gln Lys Ala Trp Gly Ala Ala Arg Arg Val	
	1260 1265 1270 1275	
45	TCC AAA GAT GAC TGG CTG GAA TGG CTG AGA CGG CTG AGC CTG GAG CTG	3952
	Ser Lys Asp Asp Trp Leu Glu Trp Leu Arg Arg Leu Ser Leu Glu Leu	
	1280 1285 1290	
50	CTG AAG GAC TCA TCA TCG CCC TCC CTG CGC TCC TGC TGG GCC CTG GCA	4000
	Leu Lys Asp Ser Ser Ser Pro Ser Leu Arg Ser Cys Trp Ala Leu Ala	
	1295 1300 1305	
55	CAG GCC TAC AAC CCG ATG GCC AGG GAT CTC TTC AAT GCT GCA TTT GTG	4048
	Gln Ala Tyr Asn Pro Met Ala Arg Asp Leu Phe Asn Ala Ala Phe Val	
	1310 1315 1320	
60	TCC TGC TGG TCT GAA CTG AAT GAA GAT CAA CAG GAT GAG CTC ATC AGA	4096
	Ser Cys Trp Ser Glu Leu Asn Glu Asp Gln Gln Asp Glu Leu Ile Arg	
	1325 1330 1335	
65	AGC ATC GAG TTG GCC CTC ACC TCA CAA GAC ATC GCT GAA GTC ACA CAG	4144
	Ser Ile Glu Leu Ala Leu Thr Ser Gln Asp Ile Ala Glu Val Thr Gln	
	1340 1345 1350 1355	
70	ACC CTC TTA AAC TTG GCT GAA TTC ATG GAA CAC AGT GAC AAG GGC CCC	4192
	Thr Leu Leu Asn Leu Ala Glu Phe Met Glu His Ser Asp Lys Gly Pro	
	1360 1365 1370	
75	CTG CCA CTG AGA GAT GAC AAT GGC ATT GTT CTG CTG GGT GAG AGA GCT	4240
	Leu Pro Leu Arg Asp Asp Asn Gly Ile Val Leu Leu Gly Glu Arg Ala	
	1375 1380 1385	
80	GCC AAG TGC CGA GCA TAT GCC AAA GCA CTA CAC TAC AAA GAA CTG GAG	4288
	Ala Lys Cys Arg Ala Tyr Ala Lys Ala Leu His Tyr Lys Glu Leu Glu	
	1390 1395 1400	
85	TTC CAG AAA GGC CCC ACC CCT GCC ATT CTA GAA TCT CTC ATC AGC ATT	4336
	Phe Gln Lys Gly Pro Thr Pro Ala Ile Leu Glu Ser Leu Ile Ser Ile	
	1405 1410 1415	

5	AAT AAT AAG CTA CAG CAG CCG GAG GCA GCG GCC GGA GTG TTA GAA TAT Asn Asn Lys Leu Gln Gln Pro Glu Ala Ala Ala Gly Val Leu Glu Tyr 1420 1425 1430 1435	4384
10	GCC ATG AAA CAC TTT GGA GAG CTG GAG ATC CAG GCT ACC TGG TAT GAG Ala Met Lys His Phe Gly Glu Leu Glu Ile Gln Ala Thr Trp Tyr Glu 1440 1445 1450	4432
15	AAA CTG CAC GAG TGG GAG GAT GCC CTT GTG GCC TAT GAC AAG AAA ATG Lys Leu His Glu Trp Glu Asp Ala Leu Val Ala Tyr Asp Lys Lys Met 1455 1460 1465	4480
20	GAC ACC AAC AAG GAC GAC CCA GAG CTG ATG CTG GGC CGC ATG CGC TGC Asp Thr Asn Lys Asp Asp Pro Glu Leu Met Leu Gly Arg Met Arg Cys 1470 1475 1480	4528
25	CTC GAG GCC TTG GGG GAA TGG GGT CAA CTC CAC CAG CAG TGC TGT GAA Leu Glu Ala Leu Gly Glu Trp Gly Gln Leu His Gln Gln Cys Cys Glu 1485 1490 1495	4576
30	AAG TGG ACC CTG GTT AAT GAT GAG ACC CAA GCC AAG ATG GCC CGG ATG Lys Trp Thr Leu Val Asn Asp Glu Thr Gln Ala Lys Met Ala Arg Met 1500 1505 1510 1515	4624
35	GCT GCT GCA GCT GCA TGG GGT TTA GGT CAG TGG GAC AGC ATG GAA GAA Ala Ala Ala Ala Ala Trp Gly Leu Gly Gln Trp Asp Ser Met Glu Glu 1520 1525 1530	4672
40	TAC ACC TGT ATG ATC CCT CGG GAC ACC CAT GAT GGG GCA TTT TAT AGA Tyr Thr Cys Met Ile Pro Arg Asp Thr His Asp Gly Ala Phe Tyr Arg 1535 1540 1545	4720
45	GCT GTG CTG GCA CTG CAT CAG GAC CTC TTC TCC TTG GCA CAA CAG TGC Ala Val Leu Ala Leu His Gln Asp Leu Phe Ser Leu Ala Gln Gln Cys 1550 1555 1560	4768
50	ATT GAC AAG GCC AGG GAC CTG CTG GAT GCT GAA TTA ACT GCA ATG GCA Ile Asp Lys Ala Arg Asp Leu Leu Asp Ala Glu Leu Thr Ala Met Ala 1565 1570 1575	4816
55	GGA GAG AGT TAC AGT CGG GCA TAT GGG GCC ATG GTT TCT TGC CAC ATG Gly Glu Ser Tyr Ser Arg Ala Tyr Gly Ala Met Val Ser Cys His Met 1580 1585 1590 1595	4864
60	CTG TCC GAG CTG GAG GAG GTT ATC CAG TAC AAA CTT GTC CCC GAG CGA Leu Ser Glu Leu Glu Glu Val Ile Gln Tyr Lys Leu Val Pro Glu Arg 1600 1605 1610	4912
65	CGA GAG ATC ATC CGC CAG ATC TGG TGG GAG AGA CTG CAG GGC TGC CAG Arg Glu Ile Ile Arg Gln Ile Trp Trp Glu Arg Leu Gln Gly Cys Gln 1615 1620 1625	4960
70	CGT ATC GTA GAG GAC TGG CAG AAA ATC CTT ATG GTG CGG TCC CTT GTG Arg Ile Val Glu Asp Trp Gln Lys Ile Leu Met Val Arg Ser Leu Val 1630 1635 1640	5008
75	GTC AGC CCT CAT GAA GAC ATG AGA ACC TGG CTC AAG TAT GCA AGC CTG Val Ser Pro His Glu Asp Met Arg Thr Trp Leu Lys Tyr Ala Ser Leu 1645 1650 1655	5056
80	TGC GGC AAG AGT GGC AGG CTG GCT CTT GCT CAT AAA ACT TTA GTG TTG Cys Gly Lys Ser Gly Arg Leu Ala Leu Ala His Lys Thr Leu Val Leu 1660 1665 1670 1675	5104
85	CTC CTG GGA GTT GAT CCG TCT CGG CAA CTT GAC CAT CCT CTG CCA ACA Leu Leu Gly Val Asp Pro Ser Arg Gln Leu Asp His Pro Leu Pro Thr 1680 1685 1690	5152
90	GTT CAC CCT CAG GTG ACC TAT GCC TAC ATG AAA AAC ATG TGG AAG AGT Val His Pro Gln Val Thr Tyr Ala Tyr Met Lys Asn Met Trp Lys Ser 1700 1705 1710 1715	5200



APV007.25

- 71 -

	1695	1700	1705	
5	GCC CGC AAG ATC GAT GCC TTC CAG CAC ATG CAG CAT TTT GTC CAG ACC Ala Arg Lys Ile Asp Ala Phe Gln His Met Gln His Phe Val Gln Thr 1710 1715 1720			5248
10	ATG CAG CAA CAG GCC CAG CAT GCC ATC GCT ACT GAG GAC CAG CAG CAT Met Gln Gln Gln Ala Gln His Ala Ile Ala Thr Glu Asp Gln Gln His 1725 1730 1735			5296
15	AAG CAG GAA CTG CAC AAG CTC ATG GCC CGA TGC TTC CTG AAA CTT GGA Lys Gln Glu Leu His Lys Leu Met Ala Arg Cys Phe Leu Lys Leu Gly 1740 1745 1750 1755			5344
20	GAG TGG CAG CTG AAT CTA CAG GGC ATC AAT GAG AGC ACA ATC CCC AAA Glu Trp Gln Leu Asn Leu Gln Gly Ile Asn Glu Ser Thr Ile Pro Lys 1760 1765 1770			5392
25	GTG CTG CAG TAC TAC AGC GCC GCC ACA GAG CAC GAC CGC AGC TGG TAC Val Leu Gln Tyr Tyr Ser Ala Ala Thr Glu His Asp Arg Ser Trp Tyr 1775 1780 1785			5440
30	AAG GCC TGG CAT GCG TGG GCA GTG ATG AAC TTC GAA GCT GTG CTA CAC Lys Ala Trp His Ala Trp Ala Val Met Asn Phe Glu Ala Val Leu His 1790 1795 1800			5488
35	TAC AAA CAT CAG AAC CAA GCC CGC GAT GAG AAG AAG AAA CTG CGT CAT Tyr Lys His Gln Asn Gln Ala Arg Asp Glu Lys Lys Lys Leu Arg His 1805 1810 1815			5536
40	GCC AGC GGG GCC AAC ATC ACC AAC GCC ACC ACT GCC GCC ACC ACG GCC Ala Ser Gly Ala Asn Ile Thr Asn Ala Thr Thr Ala Ala Thr Thr Ala 1820 1825 1830 1835			5584
45	GCC ACT GCC ACC ACC ACT GCC AGC ACC GAG GGC AGC AAC AGT GAG AGC Ala Thr Ala Thr Thr Thr Ala Ser Thr Glu Gly Ser Asn Ser Glu Ser 1840 1845 1850			5632
50	GAG GCC GAG AGC ACC GAG AAC AGC CCC ACC CCA TCG CCG CTG CAG AAG Glu Ala Glu Ser Thr Glu Asn Ser Pro Thr Pro Ser Pro Leu Gln Lys 1855 1860 1865			5680
55	AAG GTC ACT GAG GAT CTG TCC AAA ACC CTC CTG ATG TAC ACG GTG CCT Lys Val Thr Glu Asp Leu Ser Lys Thr Leu Leu Met Tyr Thr Val Pro 1870 1875 1880			5728
60	GCC GTC CAG GGC TTC TTC CGT TCC ATC TCC TTG TCA CGA GGC AAC AAC Ala Val Gln Gly Phe Phe Arg Ser Ile Ser Leu Ser Arg Gly Asn Asn 1885 1890 1895			5776
65	CTC CAG GAT ACA CTC AGA GTT CTC ACC TTA TGG TTT GAT TAT GGT CAC Leu Gln Asp Thr Leu Arg Val Leu Thr Leu Trp Phe Asp Tyr Gly His 1900 1905 1910 1915			5824
70	TGG CCA GAT GTC AAT GAG GCC TTA GTG GAG GGG GTG AAA GCC ATC CAG Trp Pro Asp Val Asn Glu Ala Leu Val Glu Gly Val Lys Ala Ile Gln 1920 1925 1930			5872
	ATT GAT ACC TGG CTA CAG GTT ATA CCT CAG CTC ATT GCA AGA ATT GAT Ile Asp Thr Trp Leu Gln Val Ile Pro Gln Leu Ile Ala Arg Ile Asp 1935 1940 1945			5920
	ACG CCC AGA CCC TTG GTG GGA CGT CTC ATT CAC CAG CTT CTC ACA GAC Thr Pro Arg Pro Leu Val Gly Arg Leu Ile His Gln Leu Leu Thr Asp 1950 1955 1960			5968
	ATT GGT CGG TAC CAC CCC CAG GCC CTC ATC TAC CCA CTG ACA GTG GCT Ile Gly Arg Tyr His Pro Gln Ala Leu Ile Tyr Pro Leu Thr Val Ala 1965 1970 1975			6016
	TCT AAG TCT ACC ACG ACA GCC CGG CAC AAT GCA GCC AAC AAG ATT CTG			6064

## APV007.25

- 72 -

	Ser 1980	Lys	Ser	Thr	Thr	Thr 1985	Ala	Arg	His	Asn	Ala	Ala 1990	Asn	Lys	Ile	Leu 1995	
5	AAG	AAC	ATG	TGT	GAG	CAC	AGC	AAC	ACC	CTG	GTC	CAG	CAG	GCC	ATG	ATG	6112
	Lys	Asn	Met	Cys	Glu	His	Ser	Asn	Thr	Leu	Val	Gln	Gln	Ala	Met	Met	
					2000					2005					2010		
10	GTG	AGC	GAG	GAG	CTG	ATC	CGA	GTG	GCC	ATC	CTC	TGG	CAT	GAG	ATG	TGG	6160
	Val	Ser	Glu	Glu	Leu	Ile	Arg	Val	Ala	Ile	Leu	Trp	His	Glu	Met	Trp	
					2015				2020					2025			
15	CAT	GAA	GGC	CTG	GAA	GAG	GCA	TCT	CGT	TTG	TAC	TTT	GGG	GAA	AGG	AAC	6208
	His	Glu	Gly	Leu	Glu	Glu	Ala	Ser	Arg	Leu	Tyr	Phe	Gly	Glu	Arg	Asn	
				2030					2035					2040			
20	GTG	AAA	GGC	ATG	TTT	GAG	GTG	CTG	GAG	CCC	TTG	CAT	GCT	ATG	ATG	GAA	6256
	Val	Lys	Gly	Met	Phe	Glu	Val	Leu	Glu	Pro	Leu	His	Ala	Met	Met	Glu	
				2045				2050					2055				
25	CGG	GGC	CCC	CAG	ACT	CTG	AAG	GAA	ACA	TCC	TTT	AAT	CAG	GCC	TAT	GGT	6304
	Arg	Gly	Pro	Gln	Thr	Leu	Lys	Glu	Thr	Ser	Phe	Asn	Gln	Ala	Tyr	Gly	
						2060					2070					2075	
30	CGA	GAT	TTA	ATG	GAG	GCC	CAA	GAG	TGG	TGC	AGG	AAG	TAC	ATG	AAA	TCA	6352
	Arg	Asp	Leu	Met	Glu	Ala	Gln	Glu	Trp	Cys	Arg	Lys	Tyr	Met	Lys	Ser	
					2080					2085					2090		
35	GGG	AAT	GTC	AAG	GAC	CTC	ACC	CAA	GCC	TGG	GAC	CTC	TAT	TAT	CAT	GTG	6400
	Gly	Asn	Val	Lys	Asp	Leu	Thr	Gln	Ala	Trp	Asp	Leu	Tyr	Tyr	His	Val	
					2095				2100					2105			
40	TTC	CGA	CGA	ATC	TCA	AAG	CAG	CTG	CCT	CAG	CTC	ACA	TCC	TTA	GAG	CTG	6448
	Phe	Arg	Arg	Ile	Ser	Lys	Gln	Leu	Pro	Gln	Leu	Thr	Ser	Leu	Glu	Leu	
					2110				2115					2120			
45	CAA	TAT	GTT	TCC	CCA	AAA	CTT	CTG	ATG	TGC	CGG	GAC	CTT	GAA	TTG	GCT	6496
	Gln	Tyr	Val	Ser	Pro	Lys	Leu	Leu	Met	Cys	Arg	Asp	Leu	Glu	Leu	Ala	
					2125				2130				2135				
50	GTG	CCA	GGA	ACA	TAT	GAC	CCC	AAC	CAG	CCA	ATC	ATT	CGC	ATT	CAG	TCC	6544
	Val	Pro	Gly	Thr	Tyr	Asp	Pro	Asn	Gln	Pro	Ile	Ile	Arg	Ile	Gln	Ser	
						2140					2150					2155	
55	ATA	GCA	CCG	TCT	TTG	CAA	GTC	ATC	ACA	TCC	AAG	CAG	AGG	CCC	CGG	AAA	6592
	Ile	Ala	Pro	Ser	Leu	Gln	Val	Ile	Thr	Ser	Lys	Gln	Arg	Pro	Arg	Lys	
					2160						2165				2170		
60	TTG	ACA	CTT	ATG	GGC	AGC	AAC	GGA	CAT	GAG	TTT	GTT	TTC	CTT	CTA	AAA	6640
	Leu	Thr	Leu	Met	Gly	Ser	Asn	Gly	His	Glu	Phe	Val	Phe	Leu	Leu	Lys	
					2175					2180				2185			
65	GGC	CAT	GAA	GAT	CTG	CGC	CAG	GAT	GAG	CGT	GTG	ATG	CAG	CTC	TTC	GGC	6688
	Gly	His	Glu	Asp	Leu	Arg	Gln	Asp	Glu	Arg	Val	Met	Gln	Leu	Phe	Gly	
					2190				2195				2200				
70	CTG	GTT	AAC	ACC	CTT	CTG	GCC	AAT	GAC	CCA	ACA	TCT	CTT	CGG	AAA	AAC	6736
	Leu	Val	Asn	Thr	Leu	Leu	Ala	Asn	Asp	Pro	Thr	Ser	Leu	Arg	Lys	Asn	
					2205				2210				2215				
75	CTC	AGC	ATC	CAG	AGA	TAC	GCT	GTC	ATC	CCT	TTA	TCG	ACC	AAC	TCG	GGC	6784
	Leu	Ser	Ile	Gln	Arg	Tyr	Ala	Val	Ile	Pro	Leu	Ser	Thr	Asn	Ser	Gly	
						2220					2230					2235	
80	CTC	ATT	GGC	TGG	GTT	CCC	CAC	TGT	GAC	ACA	CTG	CAC	GCC	CTC	ATC	CGG	6832
	Leu	Ile	Gly	Trp	Val	Pro	His	Cys	Asp	Thr	Leu	His	Ala	Leu	Ile	Arg	
					2240					2245					2250		
85	GAC	TAC	AGG	GAG	AAG	AAG	AAG	ATC	CTT	CTC	AAC	ATC	GAG	CAT	CGC	ATC	6880
	Asp	Tyr	Arg	Glu	Lys	Lys	Lys	Ile	Leu	Leu	Asn	Ile	Glu	His	Arg	Ile	
					2255					2260					2265		

- 73 -

	ATG	TTG	CGG	ATG	GCT	CCG	GAC	TAT	GAC	CAC	TTG	ACT	CTG	ATG	CAG	AAG	6928
	Met	Leu	Arg	Met	Ala	Pro	Asp	Tyr	Asp	His	Leu	Thr	Leu	Met	Gln	Lys	
			2270					2275					2280				
5	GTG	GAG	GTG	TTT	GAG	CAT	GCC	GTC	AAT	AAT	ACA	GCT	GGG	GAC	GAC	CTG	6976
	Val	Glu	Val	Phe	Glu	His	Ala	Val	Asn	Asn	Thr	Ala	Gly	Asp	Asp	Leu	
			2285				2290					2295					
10	GCC	AAG	CTG	CTG	TGG	CTG	AAA	AGC	CCC	AGC	TCC	GAG	GTG	TGG	TTT	GAC	7024
	Ala	Lys	Leu	Leu	Trp	Leu	Lys	Ser	Pro	Ser	Ser	Glu	Val	Trp	Phe	Asp	
			2300				2305				2310					2315	
15	CGA	AGA	ACC	AAT	TAT	ACC	CGT	TCT	TTA	GCG	GTC	ATG	TCA	ATG	GTT	GGG	7072
	Arg	Arg	Thr	Asn	Tyr	Thr	Arg	Ser	Leu	Ala	Val	Met	Ser	Met	Val	Gly	
					2320					2325					2330		
20	TAT	ATT	TTA	GGC	CTG	GGA	GAT	AGA	CAC	CCA	TCC	AAC	CTG	ATG	CTG	GAC	7120
	Tyr	Ile	Leu	Gly	Leu	Gly	Asp	Arg	His	Pro	Ser	Asn	Leu	Met	Leu	Asp	
				2335					2340					2345			
25	CGT	CTG	AGT	GGG	AAG	ATC	CTG	CAC	ATT	GAC	TTT	GGG	GAC	TGC	TTT	GAG	7168
	Arg	Leu	Ser	Gly	Lys	Ile	Leu	His	Ile	Asp	Phe	Gly	Asp	Cys	Phe	Glu	
				2350				2355					2360				
30	GTT	GCT	ATG	ACC	CGA	GAG	AAG	TTT	CCA	GAG	AAG	ATT	CCA	TTT	AGA	CTA	7216
	Val	Ala	Met	Thr	Arg	Glu	Lys	Phe	Pro	Glu	Lys	Ile	Pro	Phe	Arg	Leu	
				2365			2370					2375					
35	ACA	AGA	ATG	TTG	ACC	AAT	GCT	ATG	GAG	GTT	ACA	GGC	CTG	GAT	GGC	AAC	7264
	Thr	Arg	Met	Leu	Thr	Asn	Ala	Met	Glu	Val	Thr	Gly	Leu	Asp	Gly	Asn	
						2385					2390					2395	
40	TAC	AGA	ATC	ACA	TGC	CAC	ACA	GTG	ATG	GAG	GTG	CTG	CGA	GAG	CAC	AAG	7312
	Tyr	Arg	Ile	Thr	Cys	His	Thr	Val	Met	Glu	Val	Leu	Arg	Glu	His	Lys	
					2400					2405					2410		
45	GAC	AGT	GTC	ATG	GCC	GTG	CTG	GAA	GCC	TTT	GTC	TAT	GAC	CCC	TTG	CTG	7360
	Asp	Ser	Val	Met	Ala	Val	Leu	Glu	Ala	Phe	Val	Tyr	Asp	Pro	Leu	Leu	
				2415					2420					2425			
50	AAC	TGG	AGG	CTG	ATG	GAC	ACA	AAT	ACC	AAA	GGC	AAC	AAG	CGA	TCC	CGA	7408
	Asn	Trp	Arg	Leu	Met	Asp	Thr	Asn	Thr	Lys	Gly	Asn	Lys	Arg	Ser	Arg	
				2430				2435					2440				
55	ACG	AGG	ACG	GAT	TCC	TAC	TCT	GCT	GGC	CAG	TCA	GTC	GAA	ATT	TTG	GAC	7456
	Thr	Arg	Thr	Asp	Ser	Tyr	Ser	Ala	Gly	Gln	Ser	Val	Glu	Ile	Leu	Asp	
				2445			2450					2455					
60	GGT	GTG	GAA	CTT	GGA	GAG	CCA	GCC	CAT	AAG	AAA	ACG	GGG	ACC			

CCCATCACGT TTTTCTGAG GCTTTGTAC TTTAGTAAAT GCTTCCACTA AACTGAAACC 7806  
 5 ATGGTGAGAA AGTTTGACTT TGTAAATAT TTTGAAATGT AAATGAAAAG AAGTACTGTA 7866  
 TATTAAGAAGT TGGTTTGAAC CAACCTTCTA GCTGCTGTTG AAGAATATAT TGTCAGAAAC 7926  
 ACAAGGCTTG ATTTGGT 7943

## (2) INFORMATION FOR SEQ ID NO:3:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 723 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: both  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (ix) FEATURE:

- (A) NAME/KEY: CDS  
 (B) LOCATION: 15..509

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GTGTACTATT AGCC ATG GTC AAC CCC ACC GTG TTC TTC GAC ATT GCC GTC 50  
                   Met Val Asn Pro Thr Val Phe Phe Asp Ile Ala Val  
                   1                  5                  10

GAC GGC GAG CCC TTG GGC CGC GTC TCC TTT GAG CTG TTT GCA GAC AAG 98  
 Asp Gly Glu Pro Leu Gly Arg Val Ser Phe Glu Leu Phe Ala Asp Lys  
                   15                  20                  25

GTC CCA AAG ACA GCA GAA AAT TTT CGT GCT CTG AGC ACT GGA GAG AAA 146  
 Val Pro Lys Thr Ala Glu Asn Phe Arg Ala Leu Ser Thr Gly Glu Lys  
                   30                  35                  40

GGA TTT GGT TAT AAG GGT TCC TGC TTT CAC AGA ATT ATT CCA GGG TTT 194  
 Gly Phe Gly Tyr Lys Gly Ser Cys Phe His Arg Ile Ile Pro Gly Phe  
                   45                  50                  55                  60

ATG TGT CAG GGT GGT GAC TTC ACA CGC CAT AAT GGC ACT GGT GGC AAG 242  
 Met Cys Gln Gly Gly Asp Phe Thr Arg His Asn Gly Thr Gly Gly Lys  
                   65                  70                  75

TCC ATC TAT GGG GAG AAA TTT GAA GAT GAG AAC TTC ATC CTA AAG CAT 290  
 Ser Ile Tyr Gly Glu Lys Phe Glu Asp Glu Asn Phe Ile Leu Lys His  
                   80                  85                  90

ACG GGT CCT GGC ATC TTG TCC ATG GCA AAT GCT GGA CCC AAC ACA AAT 338  
 Thr Gly Pro Gly Ile Leu Ser Met Ala Asn Ala Gly Pro Asn Thr Asn  
                   95                  100                  105

GGT TCC CAG TTT TTC ATC TGC ACT GCC AAG ACT GAG TGG TTG GAT GGC 386  
 Gly Ser Gln Phe Phe Ile Cys Thr Ala Lys Thr Glu Trp Leu Asp Gly  
                   110                  115                  120

AAG CAT GTG GTG TTT GGC AAA GTG AAA GAA GGC ATG AAT ATT GTG GAG 434  
 Lys His Val Val Phe Gly Lys Val Lys Glu Met Asn Ile Val Glu  
                   125                  130                  135                  140

GCC ATG GAG CGC TTT GGG TCC AGG AAT GGC AAG ACC AGC AAG AAG ATC 482  
 Ala Met Glu Arg Phe Gly Ser Arg Asn Gly Lys Thr Ser Lys Lys Ile  
                   145                  150                  155

ACC ATT GCT GAC TGT GGA CAA CTC GAA TAAGTTTGAC TTGTGTTTTA 529  
 Thr Ile Ala Asp Cys Gly Gln Leu Glu  
                   160                  165

APV007.25

- 75 -

	TCTTAACCAC CAGATCATTC CTTCTGTAGC TCAGGAGAGC ACCCCTCCAC CCCATTGCT	589
5	CGCAGTATCC TAGAATCTTT GTGCTCTCGC TGCAGTTCCC TTTGGGTTCC ATGTTTTCTT	649
	TGTTCCCTCC CATGCCTAGC TGGATTGCAG AGTTAAGTTT ATGATTATGA AATAAAAACT	709
10	AAATAACAAT TGTC	723

**WHAT IS CLAIMED IS:**

1. A method for selectively inhibiting proliferation of a hematopoietic cell comprising contacting a hematopoietic cell which ectopically expresses a gene encoding a mutated macrolide binding protein (MBP) with a macrolide which selectively induces macrolide-dependent inhibition of proliferation of cells expressing the mutated MBP compared to cells expressing a wild-type form of the MBP, the mutated MBP having an altered macrolide-binding specificity relative to the wild-type form MBP.
2. A method for selectively inhibiting proliferation of a hematopoietic cell comprising
  - (i) causing, in the cell, the ectopic expression of an MBP gene encoding a mutated macrolide binding protein (MBP) having an altered macrolide-binding specificity relative to a wild-type form of the MBP, which mutated MBP retains the ability to cause macrolide-dependent inhibition of proliferation; and
  - (ii) contacting the cell with a macrolide which selectively binds to the altered MBP relative to the wild-type MBP and selectively induces macrolide-dependent inhibition of proliferation of cells expressing the mutated MBP relative to cells not expressing only the wild-type MBP.
3. The method of claim 2, wherein the MBP is selected from the group consisting of a FRAP, an FK506-binding protein, a cyclophilin and a calcineurin.
4. The method of claim 2, wherein the mutated MBP has a dissociation constant,  $K_d$ , at least one order of magnitude less than the  $K_d$  of the wild-type MBP.
5. The method of claim 2, wherein the mutated MBP has a dissociation constant,  $K_d$ , at least three orders of magnitude less than the  $K_d$  of the wild-type MBP.
6. The method of claim 2, wherein the MBP gene is present on an expression vector in the cell.
7. The method of claim 2, wherein the MBP gene is present in the cell as part of a viral expression construct.
8. The method of claim 2, wherein the MBP gene is a homologous recombinant in the cells genomic DNA.
9. The method of claim 2, wherein the macrolide is an analog of rapamycin, FK506 or cyclosporin.

10. The method of claim 2, wherein the MBP gene encodes a FRAP protein, and the macrolide is an analog of rapamycin.
11. The method of claim 2, wherein the MBP gene encodes an FK506 binding protein, and the macrolide is an analog of FK506 or rapamycin.
- 5 12. The method of claim 2, wherein the MBP gene encodes a calcineurin protein, and the macrolide is an analog of FK506 or cyclosporin.
13. The method of claim 2, wherein the MBP gene encodes a cyclophilin protein, and the macrolide is an analog of cyclosporin.
14. The method of claim 2, wherein the cell is a mammalian cell.
- 10 15. The method of claim 2, wherein the cell is a human cell.
16. A method for selectively inhibiting proliferation of a transplanted hematopoietic cell comprising
  - 15 (i) transplanting, into an animal, hematopoietic cells which ectopically expresses a MBP gene encoding a mutated macrolide binding protein (MBP), the mutated MBP having an altered macrolide-binding specificity relative to the wild-type form MBP
  - (ii) administering to the animal an amount of a macrolide sufficient to inhibit proliferation of the transplanted cells, which macrolide selectively induces macrolide-dependent inhibition of proliferation of cells expressing the mutated MBP compared to cells expressing a wild-type form of the MBP.
- 20 17. The method of claim 16, wherein the MBP is selected from the group consisting of a FRAP, an FK506-binding protein, a cyclophilin and a calcineurin.
18. The method of claim 16, wherein the mutated MBP has a dissociation constant,  $K_d$ , at least one order of magnitude less than the  $K_d$  of the wild-type MBP.
- 25 19. The method of claim 16, wherein the mutated MBP has a dissociation constant,  $K_d$ , at least three orders of magnitude less than the  $K_d$  of the wild-type MBP.
20. The method of claim 16, wherein the MBP gene is present on an expression vector in the cell.
21. The method of claim 16, wherein the MBP gene is present in the cell as part of a viral expression construct.
- 30 22. The method of claim 16, wherein the MBP gene is a homologous recombinant in the cells genomic DNA.

23. The method of claim 16, wherein the macrolide is an analog of rapamycin, FK506 or cyclosporin.
24. The method of claim 16, wherein the animal is a mammal.
25. The method of claim 24, wherein the animal is a human.
- 5 26. The method of claim 16, wherein the transplanted cells are autologous to the animal.
27. The method of claim 16 or 26, wherein the transplanted cells comprise transplanted bone marrow.
28. The method of claim 16 or 26, wherein the transplanted cells comprise hematopoietic stem cells.
- 10 29. The method of claim 16, wherein the ectopic expression of the MBP gene is transcriptionally regulated by a T-cell specific transcriptional regulatory sequence.
30. The method of claim 16, wherein the animal is in an immunosuppressed state.
31. A method for treating graft-versus-host disease in an animal by selectively inhibiting proliferation of transplanted hematopoietic cells, comprising
  - 15 (i) prior to transplanting tissue containing hematopoietic cells, transducing at least a sub-population of hematopoietic cells of the tissue with a gene for ectopic expression of a mutated macrolide binding protein (MBP), the mutated MBP having an altered macrolide-binding specificity relative to the wild-type form MBP; and
  - 20 (ii) subsequent to transplanting the hematopoietic cells, administering to the animal an amount of a macrolide sufficient to inhibit proliferation of the hematopoietic transplanted cells, which macrolide selectively induces macrolide-dependent inhibition of proliferation of the transplanted cells expressing the mutated MBP compared to endogenous cells of the animal.
- 25 32. An expression construct encoding a mutated macrolide binding protein (MBP) selected from the group consisting of FRAP, FKBP, cyclophilin and calcineurin, wherein the mutated MBP has an altered macrolide-binding specificity relative to the wild-type form MBP and, in the presence of a macrolide which binds the mutated MBP, induces macrolide-dependent inhibition of proliferation of a cell expressing
- 30 the mutated MBP.
33. A kit for for selectively inhibiting proliferation of a hematopoietic cell, comprising
  - (i) an expression construct for ectopically expressing an MBP gene encoding a mutated macrolide binding protein (MBP) having an altered macrolide-binding



specificity relative to a wild-type form of the MBP, which mutated MBP retains the ability to cause macrolide-dependent inhibition of proliferation; and

- (ii) a macrolide which selectively binds to the altered MBP relative to the wild-type MBP and selectively induces macrolide-dependent inhibition of proliferation of cells expressing the mutated MBP relative to cells not expressing only the wild-type MBP.

34. A method of promoting engraftment and hematopoietic activity of a hematopoietic stem cell from a donor, comprising:

(a) inserting nucleic acid encoding a modified macrolide binding protein specific for a modified macrolide into a hematopoietic stem cell to produce a transformed hematopoietic stem cell;

(b) introducing the transformed hematopoietic stem cell into a recipient mammal, such that the modified cellular receptor cyclophilin is expressed; and,

(c) administering an effective amount of the modified cyclosporin to said recipient mammal.

35. Hematopoietic stem cells transfected with the expression construct of claim 32.

36. A T cell transfected with an expression construct of claim 32.

**ABSTRACT OF THE INVENTION**

5 This invention is directed to a modified cyclosporin A and to a modified, genetically engineered version of its receptor, cyclophilin. This invention is further directed to a method for treating host versus graft disease following blood marrow transplantation by transfecting stem cells so that after introduction into a patient the stem cells will express the modified cyclophilin, and, as necessary, administer the modified cyclosporin A to the patient.

10

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199  
2200  
2201  
2202  
2203  
2204  
2205

FIGURE 1




Figure 2




Figure 3




Figure 4

